Functional characterisation of ANKRD1 and its regulation by RASSF1A and YAP1 signalling by Jimenez Carrera, Adriana Patricia
	  	  	  
 
 
 
 
 
Functional characterisation of ANKRD1 and its 
regulation by RASSF1A and YAP1 signalling 
 
 
 
 
 
 
 
DISSERTATION 
Zur Erlangung des Doktorgrades der Naturwissenschaften 
(Doctor rerum naturalium Dr. rer. nat.)  
 
 
 
Angefertigt am Institut für Genetik 
Fachbereich Biologie und Chemie 
 der Justus-Liebig-Universität Giessen  
 
 
 
 
 
Vorgelegt von 
Adriana Patricia Jiménez Carrera 
 
Giessen, Januar 2017 
 
 
	  	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Gutachter: Prof. Dr. Reinhard Dammann 
Institut für Genetik 
Fachbereich Biologie und Chemie 
der Justus-Liebig-Universität Giessen 
 
2. Gutachter: Prof. Dr. M. Lienhard Schmitz 
Institut für Biochemie 
Fachbereich Medizin 
der Justus-Liebig-Universität Giessen 
 
 
	  	  	  
ERKLÄRUNG 
 
Hiermit erkläre ich, dass ich die vorliegende Doktorarbeit selbständig und ohne unzulässige 
fremde Hilfe oder Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe. 
Alle Textstellen, die wörtlich oder sinngemäß aus veröffentlichten Schriften entnommen 
sind, und alle Angaben, die auf mündlichen Auskünfte beruhen, sind als solche kenntlich 
gemacht. Bei den von mir durchgeführten und in der Dissertation erwähnten 
Untersuchungen habe ich die Grundsätze guter wissenschaftlicher Praxis, wie sie in der 
“Satzung der Justus-Liebig-Universität Gießen zur Sicherung guter wissenschaftlicher 
Praxis” niedergelegt sind, eingehalten. 
 
 
Giessen, den 31.01.2017               …………………………………………………………. 
 
                                                         Adriana Patricia Jiménez Carrera 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  	  
 
 
Während dieser Arbeit ist eine Publikation mit dem Titel “The tumor suppressor RASSF1A 
induces the YAP1 target gene ANKRD1 that is epigenetically inactivated in human cancers 
and inhibits tumor growth” entstanden. Die Publikation ist in der Revisionsphase bei der 
Zeitschrift “Oncotarget”. 
 
Eine weitere Publikation als Ko-Autorin wurde 2016 veröffentlicht mit dem Titel “The dual 
specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by 
epigenetic mechanisms”. T. Haag, A.M. Richter, M.B. Schneider, A.P. Jiménez, and R.H. 
Dammann. BMC Cancer 2016. Die Ergebnisse dieser Publikation wurden bei dieser Arbeit 
nicht mit einbezogen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For Claude 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  	  
Index 
ABBREVIATIONS ........................................................................................................ 1	  
SUMMARY ................................................................................................................... 4	  
ZUSAMMENFASSUNG ............................................................................................... 5	  
1. INTRODUCTION ...................................................................................................... 7	  
1.1 Cancer ....................................................................................................................... 7	  
1.2 The Hippo pathway .................................................................................................. 8	  
1.3 Deregulation of the Hippo pathway in cancer ........................................................ 11	  
1.4 Yes-associated protein 1 (YAP1) ........................................................................... 13	  
1.5 RAS association domain family (RASSF) ............................................................. 15	  
1.6 Ankyrin repeat domain protein 1 (ANKRD1) ........................................................ 17	  
Aims of this study ........................................................................................................ 19	  
2. MATERIALS AND METHODS ............................................................................. 20	  
2.1 MATERIALS ......................................................................................................... 20	  
2.1.1 List of Materials .................................................................................................. 20	  
2.1.1.1 Chemicals ......................................................................................................... 20	  
2.1.1.2 Size and molecular weight standards ............................................................... 22	  
2.1.1.3 Antibiotics ........................................................................................................ 22	  
2.1.1.4 Transfection reagents ....................................................................................... 22	  
2.1.1.5 Enzymes ........................................................................................................... 22	  
2.1.1.6 Kits and microarrays ........................................................................................ 23	  
2.1.1.7 Antibodies for western blots ............................................................................ 24	  
2.1.1.8 Vectors ............................................................................................................. 24	  
2.1.1.9 Chemically- competent E. coli strains .............................................................. 27	  
2.1.1.10 Human cell lines ............................................................................................. 27	  
2.1.1.11 Hepatic primary tumors and normal liver tissues ........................................... 28	  
2.1.2 Primers ................................................................................................................ 28	  
2.1.3 Media ................................................................................................................... 30	  
2.1.4 General buffers and solutions .............................................................................. 31	  
2.1.5 Buffers for SDS-PAGE and western blot ............................................................ 32	  
2.1.6 Basic commodities .............................................................................................. 33	  
2.1.6.1 Consumables .................................................................................................... 33	  
2.1.6.2 Equipment ........................................................................................................ 33	  
2.1.6.3 Centrifuges ....................................................................................................... 34	  
2.1.6.4 Incubators ......................................................................................................... 34	  
2.1.6.5 Microscopes and camera .................................................................................. 34	  
2.1.6.6 Shakers ............................................................................................................. 34	  
2.1.6.7 PCR Thermocyclers ......................................................................................... 35	  
2.1.6.8 Water baths ....................................................................................................... 35	  
2.1.7 Software .............................................................................................................. 35	  
2.2. METHODS ............................................................................................................ 36	  
2.2.1 Molecular cloning ............................................................................................... 36	  
2.2.1.1 Restriction digestion ......................................................................................... 36	  
2.2.1.2 Ligation and transformation ............................................................................. 36	  
2.2.1.3 Plasmid preparation and glycerol stock cultures .............................................. 37	  
2.2.2 Mutagenesis ......................................................................................................... 37	  
2.2.3 Cell culture .......................................................................................................... 38	  
2.2.3.1 Cell lines and transfections .............................................................................. 38	  
2.2.3.2 Promoter assays ................................................................................................ 38	  
2.2.3.3 Colony formation and growth curves ............................................................... 39	  
	  	  	  
2.2.3.4 Generation of stable cell line ............................................................................ 40	  
2.2.3.5 Knockdown assays by small interfering RNA ................................................. 41	  
2.2.4 DNA isolation ..................................................................................................... 42	  
2.2.5 RNA isolation ...................................................................................................... 42	  
2.2.6 Methylation analysis ........................................................................................... 43	  
2.2.6.1 In vitro methylation (ivm) ................................................................................ 43	  
2.2.6.2 DNA bisulfite conversion ................................................................................. 43	  
2.2.6.3 Combined bisulfite restriction analysis (CoBRA) ........................................... 44	  
2.2.7 Agarose gel electrophoresis (AGE) ..................................................................... 44	  
2.2.8 Polymerase chain reaction (PCR) ....................................................................... 44	  
2.2.8.1 Reverse transcriptase PCR (RT-PCR) .............................................................. 45	  
2.2.8.2 Semiquantitative PCR ...................................................................................... 46	  
2.2.8.3 Quantitative real time PCR (qRT-PCR) ........................................................... 47	  
2.2.8.4 PCR for CoBRA ............................................................................................... 48	  
2.2.8.5 Mutagenesis PCR ............................................................................................. 48	  
2.2.9 Protein extraction ................................................................................................ 49	  
2.2.10 Co-Immunoprecipitation (Co-IP) ...................................................................... 50	  
2.2.11 SDS-Polyacrylamide-Gel-Electrophoresis (SDS-PAGE) ................................. 51	  
2.2.12 Western blot ...................................................................................................... 51	  
2.2.13 Fluorescence-activated cell sorting (FACS) ..................................................... 52	  
2.2.13.1 Flow cytometry .............................................................................................. 53	  
2.2.13.2 Fluorescence-activated cell sorting ................................................................ 54	  
2.2.14 Microarrays ....................................................................................................... 55	  
2.2.15 Fluorescence microscopy .................................................................................. 56	  
2.2.16 Statistical analysis ............................................................................................. 57	  
3. RESULTS ................................................................................................................. 58	  
3.1 Role of RASSF1A in the Hippo pathway .............................................................. 58	  
3.1.1 RASSF1A regulates the expression of YAP1 target genes ................................. 58	  
3.1.2 Characterisation of the YAP1-inducible cell line ............................................... 60	  
3.1.3 YAP1 downregulates the expression of tumor suppressor genes ....................... 63	  
3.1.4 RASSF1A neutralizes the oncogenic potential of YAP1 and induces cell cycle 
arrest ............................................................................................................................. 64	  
3.1.5 RASSF1A triggers the translocation of YAP1 into the nucleus ......................... 67	  
3.1.6 Microarray data confirm the upregulation of ANKRD1 by YAP1 and RASSF1A 
and reveal novel target genes ....................................................................................... 70	  
3.1.7 The Hippo pathway regulates the expression of ANKRD1 ................................. 74	  
3.1.8 ANKRD1 is epigenetically silenced in human cancer and represents a potential 
tumor suppressor gene .................................................................................................. 75	  
3.1.9 ANKRD1 activates the expression of CDKN1A, BAX and TP53 ....................... 79	  
3.1.10 RASSF1A-YAP1-ANKRD1 regulates TP53 via MDM2 ................................. 81	  
3.1.11 ANKRD1 interacts with TP53 and MDM2 ....................................................... 83	  
3.1.12 ANKRD1 knockdown results in a decreased TP53, BAX, CDKN1A and MDM2 
expression ..................................................................................................................... 84	  
3.2 Role of the C-terminal members of the RASSF in the Hippo pathway ................. 86	  
3.2.1 Aberrant promoter methylation of C-terminal RASSFs in liver tumors ............. 86	  
3.2.2 C-terminal RASSFs affect the cell cycle ............................................................. 87	  
3.2.3 Effect of RASSFs on YAP1 target genes ............................................................ 88	  
3.2.4 Effects of RASSFs on MDM2 level .................................................................... 92	  
4. DISCUSSION .......................................................................................................... 94	  
4.1 The Hippo pathway and cancer .............................................................................. 94	  
	  	  	  
4.2 The oncogenic function of YAP1 ........................................................................... 95	  
4.3 RASSF1A regulates the expression of the YAP1 target genes and counteracts the 
oncogenic function of YAP1 ........................................................................................ 99	  
4.3 RASSF1A triggers the nuclear localization of YAP1 .......................................... 102	  
4.4 ANKRD1 is a potential tumor suppressor gene ................................................... 103	  
4.5 Effect of the other C-terminal RASSFs on the Hippo pathway ........................... 107	  
APPENDIX 1 ............................................................................................................. 110	  
APPENDIX 2 ............................................................................................................. 110	  
APPENDIX 3 ............................................................................................................. 111	  
APPENDIX 4 ............................................................................................................. 111	  
APPENDIX 5 ............................................................................................................. 112	  
APPENDIX 6 ............................................................................................................. 113	  
APPENDIX 7 ............................................................................................................. 115	  
APPENDIX 8 ............................................................................................................. 116	  
APPENDIX 9 ............................................................................................................. 117	  
APPENDIX 10 ........................................................................................................... 118	  
APPENDIX 11 ........................................................................................................... 120	  
APPENDIX 12 ........................................................................................................... 120	  
REFERENCES ........................................................................................................... 122	  
ACKNOWLEGMENTS ............................................................................................. 135	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  1	  	  
ABBREVIATIONS 
 
β Beta 
Δ Delta 
∆Np63 N-terminus truncated p63 isoform 
ΔNp73 N-terminus truncated p73 isoform 
µ Micro 
AJUBA LIM protein AJUBA 
AMOT Angiomotin 
ANKRD1 Ankyrin Repeat Domain 1/CARP 
APS Ammonium persulfate 
ATM Ataxia telangiectasia mutated 
Aza 5’-Aza-2’-desoxycytidine 
BAX BCL2-associated X protein 
BBC3 BCL2 binding component 3/PUMA 
bp Base pair 
CDKN1A Cyclin-dependent Kinase Inhibitor 1A/p21 
cDNA Complementary DNA 
CoBRA Combined bisulfite restriction analysis 
Co-IP Co-immunoprecipitation 
CpG Cytosine and guanine dinucleotides 
CDK6 Cyclin dependent kinase 6 
CYR61 Cysteine-rich angiogenic inducer 61 
CTGF Connective tissue growth factor 
C-terminal Carboxyl-terminal 
Ctrl Control 
d Day 
D. melanogaster Drosophila melanogaster 
ddH2O Water 
DMEM Dulbecco’s modified Eagle Medium 
DNA Deoxyribonucleic acid 
DNAse Deoxyribonuclease 
dNTP Nucleoside triphosphate 
Dox Doxycycline 
	  2	  	  
ECL Enhanced chemiluminescence 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
e.g. Example given 
et al. and others 
EtOH Ethanol 
FACS Fluorescence-activated cell sorting 
FCS Fetal calf serum 
Fig. Figure 
FSC Forward light scatter 
g Acceleration of gravity 
g Gram 
G418 Geneticin 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GFP Green fluorescent protein 
h Hour(s) 
HCC Hepatocellular carcinoma 
HRP Horsera dish peroxidase 
ind. Induction 
Ivm In vitro methylated 
JNK c-Jun N-terminal kinase 
kDa kilo Dalton 
l Liter 
LATS Large Tumor Suppressor 
M Molar 
m Milli 
MAPK Mitogen-activated protein kinase 
MDM2 Human homologue of mouse double minute 2 
MgCl2 Magnesium chloride 
min Minutes 
MST Mammalian STE20 like Kinase 
NF2 Neurofibromatosis type II 
ON Over night 
p16 Tumor suppressor protein p16, CDKN2A 
PBS Phosphate buffered saline 
	  3	  	  
PCR Polymerase chain reaction 
PEI Polyethylenimine 
pH Negative of the logarithm to base 10 of the activity of hydrogen 
PS Penicillin and streptomycin 
PVDF Polyvinylidene difluoride 
RA Ras-association domain 
RASSF Ras Association Domain Family 
RNA Ribonucleic acid 
RNAse Ribonuclease 
rpm Revolutions per minute 
RT Room temperature 
RT-PCR Reverse transcriptase PCR 
qRT-PCR Quantitative real time PCR 
s Seconds 
SAM S-adenosylmethionine 
SARAH Sav/Rassf/Hpo domain 
SDS Sodium dodecyl sulphate 
S Serine 
siRNA Small interfering RNA 
T Threonine 
TBE Tris borate EDTA buffer 
TBS Tris buffered saline 
TE Tris EDTA buffer 
TEAD TEA domain family 
TEMED N,N,N′,N′-Tetramethylethane 
TET ON Tetracycline-controlled gene expression 
TGF- β Transforming growth factor beta 
TP53 Tumor suppressor protein p53 
TP73 Tumor suppressor protein p73 
U Enzyme unit 
WNT Wnt signaling 
Y Tyrosine 
YAP1 Yes-Associated Protein 1 
YFP Yellow fluorescent protein 
	  4	  	  
SUMMARY 
 
The Hippo pathway controls organ size and is involved in both cell proliferation as well as in 
apoptosis. In cancer, the signalling via Hippo is deregulated and promotes tumor growth. The 
proto-oncogene YAP1 is the downstream transcriptional co-activator of this pathway with its 
function depending on the binding to several transcription factors such as TEAD, SMAD and 
TP73. The tumor suppressor gene RASSF1A is one of the main regulators of the Hippo 
signalling; however, RASSF1A is epigenetically silenced in cancer. In the literature, there are 
indications for the role of RASSF1A in the regulation of the pro-apoptotic function of the 
Hippo pathway. The aim of this study was to analyse the regulatory role of RASSF1A on 
YAP1 target genes. Therefore, a YAP1-inducible cell line was generated and further 
characterised after induction of YAP1 and co-expression with RASSF1A.  
 
An important observation in this study was the oncogenic potential of YAP1. The induction of 
YAP1 promotes cell proliferation by activation of pro-proliferative genes and by the 
transcriptional repression of tumor suppressor genes such as TP53, RASSF1A, BAX, CDKN1A 
and BBC3. Expression screenings by microarray revealed novel potential YAP1 target genes 
that are regulated by RASSF1A. In addition, microscopy and flow cytometry data showed that 
the expression of RASSF1A triggers the nuclear translocation of YAP1 inducing nuclear 
deformation, cell cycle arrest and apoptosis. In addition, it was observed that RASSF1A and 
YAP1 repress the expression of growth-associated genes and growth factors such as MDM2. 
Further analysis indicated that RASSF1A neutralizes the oncogenic function of YAP1 by 
activation of the YAP1 target genes ANKRD1, AJUBA, BAX and CDKN1A. RASSF1A 
activates Hippo signalling via the SARAH (Sav/Rassf/Hpo) domain and, together with YAP1, 
regulates the expression of the target gene ANKRD1. The further characterisation of ANKRD1 
indicated its potential function as tumor suppressor gene. ANKRD1 inhibits cell growth and is 
silenced by promoter methylation in lung and in prostate cancer cell lines. At the protein level, 
ANKRD1 stabilises TP53 via reduction of the level of MDM2, which results in the 
transcriptional activation of CDKN1A and BAX. Previous reports suggested ANKRD1 as co-
activator of TP53. In this study, the knockdown of ANKRD1 by siRNA and promoter assays 
corroborated the obtained findings and the data from the literature. The data from this work 
suggest a novel mechanism of RASSF1A and YAP1 interaction, namely to regulate TP53 and 
the G1/S cell cycle transition via the Hippo pathway and ANKRD1. The inactivation of 
RASSF1A by aberrant promoter methylation results in the deregulation of the signalling, which 
promotes cell proliferation by the action of the oncogene YAP1. 
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ZUSAMMENFASSUNG 
 
Der Hippo Signalweg kontrolliert die Organgröße bei der Regulation der Zellproliferation und 
Apoptose. Bei Krebs ist der Hippo Signalweg dereguliert und fördert das Tumorwachstum. Das 
Proto-Onkogen YAP1 ist der transkriptionale Co-Aktivator dieses Signalwegs, und seine 
Funktion hängt von der Bindung an unterschiedliche Transkriptionsfaktoren wie TEAD, 
SMAD und TP73 ab. Das Tumorsuppressor-Gen RASSF1A ist einer der Hauptregulatoren des 
Hippo Signalwegs, jedoch ist RASSF1A in Krebszellen epigenetisch inaktiviert. In der Literatur 
gibt es Hinweise auf die Rolle von RASSF1A bei der Regulation der pro-apoptotischen 
Funktion des Hippo Signalwegs. Das Ziel dieser Arbeit war die Analyse der regulatorischen 
Rolle von RASSF1A auf die YAP1-Zielgene. Daher wurde eine YAP1-induzierbare Zelllinie 
generiert und charakterisiert sowohl nach der Induktion von YAP1 als auch nach Expression 
von RASSF1A. 
 
Eine wichtige Beobachtung dieser Studie war die potentielle onkogene Funktion von YAP1. 
Die Induktion von YAP1 fördert die Zellproliferation durch Aktivierung von pro-proliferativen 
Genen sowie durch die Transkriptionsrepression von Tumorsuppressor-Genen wie TP53, 
RASSF1A, BAX, CDKN1A und BBC3. Transkriptom-Analysen mittels Microarrays zeigten 
neue potentielle YAP1-Zielgene, die durch RASSF1A reguliert werden. Darüber hinaus zeigten 
Mikroskopie- und Durchflusszytometrie- Daten, dass die Expression von RASSF1A die 
nukleare Translokation von YAP1, Zellkernveränderung, Zellzyklus-Arrest und Apoptose 
induziert. Zusätzlich wurde beobachtet, dass RASSF1A und YAP1 die Expression von 
Wachstums-assoziierten Genen und Wachstumsfaktoren wie MDM2 unterdrücken. Weitere 
Analysen zeigten, dass RASSF1A die pro-proliferative Funktion von YAP1 durch Aktivierung 
der YAP1-Zielgene ANKRD1, AJUBA, BAX und CDKN1A neutralisiert. RASSF1A aktiviert 
den Hippo Signalweg über die SARAH-Domäne (Sav/Rassf/Hpo) und reguliert zusammen mit 
YAP1 die Expression des Zielgens ANKRD1. Die weitere Charakterisierung von ANKRD1 
zeigte seine potentielle Funktion als Tumorsuppressor-Gen. ANKRD1 hemmt das 
Zellwachstum und ist durch Promoter-Methylierung in Lunge und in Prostatakrebs-Zelllinien 
inaktiviert. Auf Proteinebene stabilisiert ANKRD1 die Expression von TP53 durch 
Verringerung von MDM2, was zu einer transkriptionellen Aktivierung von CDKN1A und BAX 
führt. Die Literatur berichtet, dass ANKRD1 ein möglicher Co-Aktivator von TP53 sei. Die 
Ergebnisse dieser Studie bestätigten die erhaltenen Befunde und die Angaben aus der Literatur.  
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Diese Ergebnisse deuten auf einen neuen Mechanismus von RASSF1A und YAP1 hin, um 
TP53 und den G1/S Zellzyklus-Übergang über den Hippo Signalweg und ANKRD1 zu 
regulieren. Die epigenetische Inaktivierung von RASSF1A führt zu der Deregulierung des 
Signalwegs, was widerum die Zellproliferation durch die Wirkung des Onkogens YAP1 
fördert. 
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1. INTRODUCTION 
 
1.1 Cancer   
 
Cancer is a result from the progressive acquisition and accumulation of genetic and 
epigenetic alterations in cells and tissues (Hanahan and Weinberg, 2011). In normal cells or 
quiescent cells, the balance of growth-suppressing tumor suppressor genes and growth-
promoting oncogenes is essential for maintaining the genomic integrity. During cancer 
initiation genomic and epigenetic aberrations ocurr, which cause genomic instability (Risch 
and Plass, 2008). These alterations include the amplification of proto-oncogenes, deletions 
or translocation of genomic loci, changes in the epigenetic methylation pattern and loss of 
heterozygosity of tumor suppressor genes (Hanahan and Weinberg, 2011; Risch and Plass, 
2008). 
 
Genomic amplification and hypomethylation of promoter regions is associated with the 
activation of proto-oncogenes, which contributes to carcinogenesis (Feinberg et al., 2016). 
The depletion of genomic loci and the hypermethylation of CpG islands in the promoter 
region or at the first exon of tumor suppressor genes can lead to transcriptional gene 
silencing and the subsequent loss of gene expression (Feinberg et al., 2016; Risch and 
Plass, 2008). Alterations in DNA methylation affect genes that encode e.g. for DNA repair 
proteins, non-coding RNAs or for proteins involved in cell adhesion. The expression of 
these methylated genes changes and therefore, diverse cellular signalling pathways and the 
cell cycle are altered (Feinberg et al., 2016; Risch and Plass, 2008). The cell cycle is a 
critical process, which is strictly regulated to avoid hyperproliferation and genetic 
instability. In cancer cells, the cell cycle progression is deregulated. The silencing or 
inactivation of the principal regulators of the cell cycle checkpoints and apoptosis plays an 
essential role in promoting tumor progression (Hanahan and Weinberg, 2011). 
 
The imbalance in the expression between tumor suppressor genes and oncogenes disturbs 
the genomic integrity of the cells, which results in uncontrolled cell growth and the 
resistance to cell death. 
 
 
Introduction	  
8	  	  
1.2 The Hippo pathway 
 
The Hippo pathway is a kinase cascade that regulates organ size and plays an important 
role in cell differentiation, proliferation and apoptosis (Saucedo and Edgar, 2007); thus its 
deregulation is a key factor for tumorigenesis, tumor growth and metastasis (Saucedo and 
Edgar, 2007). According to recent reports, there is a crosstalk between the Hippo signalling 
and other cellular pathways such as MAPK, TGF-β and WNT signalling (Reddy and Irvine, 
2013; Sun and Irvine, 2013; Varelas et al., 2010; Varelas et al., 2008).  
 
The components of the Hippo pathway were first discovered in Drosophila melanogaster 
by genetic mosaic screens for mutated genes that produce cellular proliferation (Xu and 
Rubin, 1993). Among the discovered genes, novel tumor suppressor genes were found with 
homologues in humans such as PTEN, Salvador (Sav), large tumor suppressor gene 
Warts/LATS and Hippo (hpo/MST) (Justice et al., 1995; Tapon et al., 2002; Xu and Rubin, 
1993). Years later, the components of the signalling were further described to promote 
apoptosis and to control cell proliferation in D. melanogaster (Justice et al., 1995; Tapon et 
al., 2002; Xu and Rubin, 1993). This signalling pathway received the name from the Hippo 
(hpo) Ste-20 family protein kinase (Tapon et al., 2002). In D. melanogaster, loss-of-
function mutants of Hpo promoted tissue overgrowth in eyes and wings (Wu et al., 2003). 
The Hpo kinase was also described to phosphorylate Salvador and to interact with the 
tumor suppressor Warts (Wu et al., 2003). 
 
To date, the components of the Hippo pathway are described in three categories: the 
upstream regulatory elements, the core components and the downstream transcriptional 
effectors (Fig. 1). The principal components of the Hippo pathway in D. melanogaster are: 
Fat, Merlin/NF2 (Mer/NF2), Expanded (Ex), Kibra, Mats, Warts (Wts), Salvador (Sav), 
Hippo (Hpo) and the transcriptional regulator Yorki (Yki) (Fig. 1). Both in D. 
melanogaster and in mammals, the upstream regulatory components are a transmembrane 
protein (e.g. Fat) and the membrane-associated cytoplasmic tumor suppressor protein 
Merlin/NF2 (Lallemand et al., 2003; Zhang et al., 2010). The activation of the pathway is 
still under investigation. Some reports suggest the activation of the Hippo pathway by high 
cell density, since the upstream component Merlin/NF2 regulates the function of Yki/YAP1 
in association with cell-cell adhesion, cell polarity, cell junctions and mechanotransduction 
(Elbediwy et al., 2016; Kim et al., 2011; Lallemand et al., 2003; Zhao et al., 2007). As 
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indicated in figure 1, the pathway is initiated by the transmembrane protein Fat, by 
regulation of the membrane-associated proteins Mer, Ex and the scaffold protein Kibra that 
activate the phosphorylation of Hpo, Sav and Wts. Wts in turn regulates the transcriptional 
function of Yki (Fig.1). In D. melanogaster, the transcriptional activator Yki interacts with 
the transcription factors Scalloped (Sc) and Homothorax (Hth) to promote cell survival and 
cell proliferation e.g. in eye development (Peng et al., 2009; Wu et al., 2008; Zhang et al., 
2008). Some of the target genes of Yki in D. melanogaster are bantam, e2f1 and 
Drosophila Myc (dMyc) (Fausti et al., 2012; Neto-Silva et al., 2010; Peng et al., 2009). 
 
 
Figure 1: Components of the Hippo pathway in D. melanogaster and mammals. An extracellular stimulus 
activates a transmembrane protein (Fat in D. Melanogaster. G-protein coupled receptor and E-cadherin in 
mammals), which regulates the membrane-associated proteins Mer/NF2, Expanded (Ex) and Kibra/KIBRA 
that in turn activate the Hippo kinase cascade (Hpo/MSTs; Wts/LATSs). The kinase cascade is also activated 
by the members of the RAS association domain family (Rassf/RASSF1A) via the SARAH (Sav/Rassf/Hpo) 
domain. The active Hpo/MSTs kinases together with the scaffold protein Sav/SAV phosphorylate the 
Wts/LATSs kinases. Subsequently, the Wts/LATSs kinases together with the scaffold protein Mats/MOB1 
phosphorylate Yki/YAP1. The phosphorylation of the transcriptional activator Yki/YAP1 plays different roles 
such as cytoplasmic retention and degradation (via 14-3-3) or nuclear translocation. To regulate the 
expression of the specific target genes, Yki/YAP1 binds to several transcription factors, such as Scalloped 
(Sc) and Homothorax (Hth) in D. melanogaster and TEAD or TP73 in mammals. In blue: the upstream 
components. In green: the core proteins. In red: the transcriptional activator Yki/YAP1, which binds to the 
transcription factors (in orange).   
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The homologue Hippo components in mammals are very conserved (Saucedo and Edgar, 
2007). The large tumor suppressor proteins 1 and 2 (LATS1 and LATS2) are the 
homologues of Wts; the STE20-like kinases (MST1 and MST2) are the homologues of 
Hpo; SALVADOR (WW45 or SAV) is the homologue of Sav and MOBKL1A and 
MOBKL1B (MOB1) are the homologues of Mats. The transcription effectors in mammals 
are the Yes-associated protein 1 (YAP1) and its paralogue TAZ (Yki homologue) (Lei et 
al., 2008) (Fig. 1). The induction or activation of this pathway in mammals are still not 
clear, but recent reports suggest the upstream activation by G-protein coupled receptor 
signalling, which depending of the extracellular stimuli, represses or activates the Hippo 
pathway (Yu et al., 2012). For example, serum-borne lysophosphatidic acid and 
sphingosine 1-phosphophate inhibit LATSs (LATS1/2) phosphorylation by binding the 
G12/13-coupled receptors, while glucagon or epinephrine activate the LATS1/2 kinases 
(Yu et al., 2012). Another mechanism of regulation of the Hippo kinase cascade in 
mammals is via Angiomotin (AMOT), which is an upstream component of the Hippo 
pathway that binds to Mer/NF2 activating the kinase cascade (Li et al., 2015b). Also, E-
cadherin and β-catenin regulate the Hippo pathway by activation of Mer/NF2 (Kim et al., 
2011). 
 
The members of the RAS association domain family (RASSFs) represent further important 
regulatory proteins of the Hippo kinases (Schagdarsurengin et al., 2010). The RASSF 
members that contain a SARAH (Sav/Rassf/Hpo) interaction domain at the C-terminus, 
such as RASSF1A, activate the autophosphorylation of the MSTs kinases (MST1/2) 
(Dittfeld et al., 2012; Hwang et al., 2007). MSTs and SAV also present a SARAH 
interaction domain, which is essential for the interaction with regulatory factors such as 
RASSF1A and Raf1 (O'Neill et al., 2004; Schagdarsurengin et al., 2010). As indicated in 
figure 1, the activated MSTs/SAV complex phosphorylates the LATSs kinases (Chan et al., 
2005). LATSs activate the scaffold protein MOB1 and both together, phosphorylate YAP1 
that is a transcriptional regulator (Fig. 1). Active YAP1 translocates into the nucleus 
(Matallanas et al., 2007; Wang et al., 2016) and acts as co-activator with several 
transcription factors, such as TEAD (Zhao et al., 2008), SMAD (Grannas et al., 2015) or 
TP73 (Fig. 1) (Matallanas et al., 2007; Strano et al., 2001). Depending on the cellular 
context, YAP1 regulates the expression of target genes involved either in cell proliferation 
or apoptosis by binding to the corresponding transcription factors (Matallanas et al., 2007; 
Zhao et al., 2008). The pro-apoptotic function of the Hippo pathway is described in 
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association with RASSF1A and with the interaction of YAP1 with TP73 by regulating the 
expression of BAX and BBC3, also known as PUMA (see Fig. 1) (Basu et al., 2003; 
Matallanas et al., 2007). 
 
The roles of the phosphorylation and the nuclear translocation of YAP1 are still 
controversial in the literature. LATSs phosphorylate YAP1 at five serine sites within a 
HXRXXS consensus motif (Zhao et al., 2010a; Zhao et al., 2007). Several reports suggest 
that the phosphorylation in YAP1S127 is responsible for the nuclear translocation of 
YAP1(Matallanas et al., 2007; Zhao et al., 2007). In contrast, other reports have 
demonstrated that this phosphorylation site of YAP1 by LATSs is essential for the 
cytoplasmic retention of YAP1 for further cleavage by 14-3-3 and proteosomal degradation 
(see Fig. 1) (Basu et al., 2003).  
 
1.3 Deregulation of the Hippo pathway in cancer 
 
The Hippo signalling was first described as a tumor suppressor pathway in D. melanogaster 
(Justice et al., 1995; Tapon et al., 2002; Wu et al., 2003). In mammals, some of the 
components of the Hippo signalling (e.g. NF2, MSTs, LATSs and RASSF1A) are 
described as tumor suppressor genes, which are deregulated in cancer. For example, the 
inherited heterozygous mutation of the NF2 tumor suppressor gene is a risk factor for 
familial Neurofibromatosis type 2 (Gutmann, 1997; Lallemand et al., 2003). The loss of the 
wild-type allele of NF2 promotes tumor development in the nervous system and metastasis 
(Gutmann, 1997; Lallemand et al., 2003). In addition, the loss of NF2 is associated with the 
destabilisation of adherens junctions, hyperplasia of hepatocytes and the formation of 
hepatocellular carcinoma (HCC) (Lallemand et al., 2003; Zhang et al., 2010). The human 
Hippo kinases MST1/2 are hypermethylated in soft tissue sarcoma (Seidel et al., 2007). 
LATS1/2 are associated with MDM2 and the phosphorylation of TP53S15 (Aylon et al., 
2006; Furth et al., 2015). However, LATS1/2 are downregulated by hypermethylation in 
lung cancer (Sasaki et al., 2010). LATS1/2 are also silenced by tumor-specific mutations in 
non-small cell lung cancer and in esophageal squamous cell carcinoma (Ishizaki et al., 
2002; Strazisar et al., 2009).  
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The deregulation of the tumor suppressor gene RASSF1A and of the proto-oncogene YAP1 
in cancer is well characterised in the literature. RASSF1A regulates the cell cycle 
progression and induces apoptosis by several mechanisms. For example, RASSF1A 
regulates the cell cycle by stabilisation of the microtubule network (Dallol et al., 2004; 
Dallol et al., 2009; Rong et al., 2004) and by inhibiting Cyclin D1 (Agathanggelou et al., 
2003). RASSF1A regulates cell death by destabilising MDM2 via the interaction with the 
death-domain-associated protein (Song et al., 2008) and by stimulation of modulator of 
apoptosis (MOAP-1) in response to the presence of active KRAS (Foley et al., 2008). 
Moreover, RASSF1A activates the Hippo signalling by promoting the gene expression of 
pro-apoptotic genes (Dittfeld et al., 2012; Matallanas et al., 2007). Thereby the silencing of 
RASSF1A affects cellular stability and diverse pathways. Extensive studies have 
demonstrated that RASSF1A is epigenetically inactivated in several types of cancer 
including lung (Dammann et al., 2000), in pancreatic carcinoma (Dammann et al., 2003), 
prostate (Liu et al., 2002), HCC (Schagdarsurengin et al., 2003) and Merkel cell carcinoma 
(Dammann et al., 2001; Helmbold et al., 2009). RASSF1A methylation was suggested as a 
potential epigenetic biomarker for breast cancer (Shukla et al., 2006). In addition, the 
hypermethylation of RASSF1A is associated with poor prognosis in hepatoblastoma and 
neuroblastoma (Sugawara et al., 2007; Yang et al., 2004) as well as in metastasis (Liu et 
al., 2005). In contrast to the tumor suppressor RASSF1A, YAP1 is described as a proto-
oncogene in HCC and in gastric cancer (Kang et al., 2011; Xu et al., 2013). Furthermore, 
tumor tissues have shown an elevated YAP1 expression compared to normal tissue due to 
amplification of the YAP gene locus (Chr. 11q22) in oral squamous cell carcinoma, primary 
intracranial ependymomas and glioblastoma (Modena et al., 2006; Orr et al., 2011; Snijders 
et al., 2005). In lung and in gastric cancer, the amplification of YAP1 correlates with poor 
prognosis (Kang et al., 2011; Wang et al., 2010). The overexpression of YAP1 is associated 
with chemoresistance in HCC (Huo et al., 2013), in ovarian cancer (Xia et al., 2014) and in 
pancreatic cancer cells (Yuan et al., 2016). In addition, YAP1 is involved in tumorigenesis, 
proliferation and metastasis by interacting as co-factor with TEADs, SMADs and ß-catenin 
(Grannas et al., 2015; Rosenbluh et al., 2012; Varelas et al., 2010; Zhao et al., 2008), 
inducing among others the expression of pro-proliferative genes such as the connective 
tissue growth factor (CTGF), cyclin dependent kinase 6 (CDK6), cysteine-rich angiogenic 
inducer 61 (CYR61), and c-Myc (Schutte et al., 2014; Xie et al., 2013; Zhao et al., 2008). 
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These data suggest that the oncogenic function of YAP1 and the silencing of RASSF1A by 
promoter hypermethylation contribute to the deregulation of the Hippo signalling and 
hereby promoting cellular instability and tumorigenesis. 
 
1.4 Yes-associated protein 1 (YAP1) 
 
The Yes-associated protein (YAP) gene is located at the chromosome 11q22. This gene 
encodes for nine YAP isoforms by differential splicing (Gaffney et al., 2012). The major 
and best-characterised isoform is YAP1, which is the transcriptional activator of the Hippo 
pathway (Sudol et al., 2012). As mentioned before, the function of YAP1 differs depending 
of the binding to the transcription factors, which either promote or restrict proliferation. 
YAP1 interacts and binds to several factors such as TEAD (Sudol et al., 1995), SMADs 
(Grannas et al., 2015), different isoforms of TP63 and TP73 (Levy et al., 2008a; Matallanas 
et al., 2007; Tomlinson et al., 2010), ErbB4 (Komuro et al., 2003), RUNX (Basu et al., 
2003) and β-catenin (Rosenbluh et al., 2012).  
 
 
Figure 2: Protein structure of YAP1 with corresponding binding motifs. YAP1 has a length of 504 
aminoacids (aa) and a molecular weight of 65 kDa. YAP1 contains a TEAD binding domain (TEAD), a WW 
motif (WW), a SH3 binding motif (SH3), a transactivation domain (TAD) and PDZ motif (PDZ) with the 
FLTWL consensus sequence, which is essential for the nuclear translocation of YAP1. 
 
As indicated in figure 2, YAP1 contains a TEAD binding domain between amino acids 47 
and 154 at the N-terminus. Between amino acid 74 and 204, YAP1 contains a WW domain 
to bind PPxY consensus sequences (Sudol et al., 1995; Sudol et al., 2012). At the carboxyl 
terminus, YAP1 contains a SH3-binding motif, a transcriptional activation domain (TAD) 
and a PDZ binding motif (Fig. 2) (Oka et al., 2010; Sudol et al., 1995; Sudol et al., 2012). 
The PDZ domain contains a FLTWL motif that is essential for the nuclear translocation of 
YAP1 (Oka et al., 2010). The binding of YAP1 to the different transcription factors is 
essential for the expression of pro-proliferative or of pro-apoptotic genes. Both the TEAD 
binding domains and the PDZ binding motif are necessary for the interaction between 
YAP1 and TEAD (Li et al., 2010; Sudol et al., 2012). The YAP1/TEAD complex regulates 
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the expression of CTGF, AJUBA and ankyrin repeat domain protein 1 (ANKRD1) 
(Zanconato et al., 2015). YAP1 is also involved in the regulation of the target genes of the 
ErbB4 tyrosin kinase (Komuro et al., 2003). The ErbB4 receptor is a membrane associated 
tyrosine kinase. After activation of the tyrosine kinase, the C-terminus of ErbB4 is 
cleavaged and interacts with the WW domain of YAP1 (Komuro et al., 2003). The complex 
consisting of YAP1 and the fragment of ErbB4 translocate into the nucleus to regulate the 
gene expression of the target genes (Komuro et al., 2003). The WW domain is also 
important for the interaction of YAP1 with TP73 and with RUNX (Basu et al., 2003; 
Strano et al., 2001). 
 
The stability, cellular localization and function of YAP1 are modulated by phosphorylation. 
LATS1/2 are the main regulators of YAP1. LATS1/2 interact with YAP1 through PPxY 
consensus sequence in the WW domain (Hao et al., 2008; Macias et al., 2002). LATS1/2 
phosphorylate YAP1 in a HXRXXS context in S61, S109, S127, S164 and S381 (Zhao et 
al., 2010a; Zhao et al., 2007). Three of the LATSs phosphorylation sites are located in the 
TEAD domain of YAP1. In addition, other components of the Hippo pathway such as 
AMOT and the LIM protein AJUBA also indirectly regulate YAP1 by regulation of 
LATS1/2 (Das Thakur et al., 2010; Paramasivam et al., 2011; Zhao et al., 2011). In 
addition, YAP1 is phosphorylated by c-Abl on Y357 in response to DNA damage, thereby 
increasing the affinity of YAP1 to TP73 (Keshet et al., 2015; Levy et al., 2008a). In 
contrast, the protein kinase B (Akt) phosphorylates YAPS127 to induce the interaction with 
14-3-3 and the further degradation of YAP1 (Basu et al., 2003). In recent years, a crosstalk 
between YAP1 and the MAPK signalling has been described. For example, MAPK8 
(JNK1) and MAPK9 (JNK2) phosphorylate YAP1 at T119, S138, T154, S317 and T362 
(Tomlinson et al., 2010). The phosphorylation of YAP1 by the MAPKs stabilises the 
interaction of YAP1 to ΔNp63, regulating the UV-induced apoptosis (Tomlinson et al., 
2010). The regulation of YAP1 by MAPKs has also been associated with the oncogenic 
function of YAP1 in gastric cancer, in cholangiocellular tumors, gallbladder tumors (Kang 
et al., 2011; Li et al., 2014; Li et al., 2015a), and in association with the oncogenic KRAS 
in pancreatic ductal adenocarcinoma (Kapoor et al., 2014; Zhang et al., 2014). Other 
kinases that phosphorylate YAP1 are ERK2, PKCα, MAPK (p38) and CK1 (Muranen et 
al., 2016; Tomlinson et al., 2010; Zhao et al., 2010b).  
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1.5 RAS association domain family (RASSF) 
 
The RAS association domain family is composed of ten members, also known as RASSF1 
to RASSF10. The RASSFs are described as a family of tumor suppressor genes, which are 
frequently silenced in cancer (Richter et al., 2009). The RASSFs are involved in 
microtubule stabilisation, apoptosis and in the regulation of the cell cycle (Richter et al., 
2009; Rong et al., 2004; Song et al., 2009b). This gene family is distributed in two 
subgroups, according to the localization of the Ras-association domain (RA). RASSF1, 
RASSF2, RASSF3, RASSF4, RASSF5 and RASSF6 contain the RA domain at the 
carboxyl terminus (C-terminal RASSFs), wheras RASSF7, RASSF8, RASSF9 and 
RASSF10 present the RA domain at the amino terminus (N-terminal RASSFs). The RA, or 
RalGDS/AF-6, domain is characteristic for the Ras effectors and Ras-related GTPases 
(Dammann et al., 2000). Another feature that differs between the subgroups is the presence 
of the SARAH domain, which is only found in the C-terminal RASSFs (Schagdarsurengin 
et al., 2010). The SARAH domain is a protein-protein interaction domain, which allows 
e.g. the interaction between the members of the C-terminal RASSFs and the SARAH 
domain of MSTs and SALVADOR (Dittfeld et al., 2012; Schagdarsurengin et al., 2010). 
The RASSF members also contain a protein kinase C conserved region, or C1 domain, and 
the ATM domain with putative phosphorylation sites for ATM kinase (ataxia telangiectasia 
mutated) (Richter et al., 2009). As example, the protein structure of RAS association 
domain family 1 (RASSF1A) is indicated in figure 3.  
 
 
Figure 3: Protein structure of RASSF1A with corresponding binding motifs. RASSF1A has a length of 
340 amino acids (aa) and a molecular weight of 40 kDa. RASSF1A contains a protein kinase C motif (C1), an 
ATM domain (ATM) with putative phosphorylation sites for ATM kinase, a RA domain (RA) and the 
SARAH (Sav/Rassf/Hpo) domain at the carboxyl terminus, which mediates the interaction between 
RASSF1A and the MSTs. 
 
In the year 2000, Dammann et al. identified RASSF1 by yeast-two-hybrid screens through 
its interaction with XPA, a DNA excision repair protein (Dammann et al., 2000). The 
RASSF1 gene is located on chromosome 3p21.3 and contains eight exons. The RASSF1 
gene encodes for seven isoforms, which are transcribed by splicing using two alternative 
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promoters (1α and 2γ) (Dammann et al., 2000; Richter et al., 2009). The main isoforms 
with a biological relevance are RASSF1A and RASSF1C. Both isoforms have opposing 
functions in cancer. The isoform RASSF1A is the best-investigated RASSF member and, 
as previously described, it is frequently inactivated in cancer cells by promoter 
hypermethylation (CpG island of promoter 1α). In contrast, in the literature the RASSF1C 
isoform has been described to promote proliferation and metastasis in cancer (Amaar et al., 
2006; Reeves et al., 2013). 
 
RASSF1A co-localizes with tubulin and among its principal functions are microtubule 
stabilisation (Dallol et al., 2004; Rong et al., 2004), inhibition of cell cycle progression 
(Rong et al., 2007) and activation of the Hippo pathway (Dittfeld et al., 2012). RASSF1A 
regulates the cell cycle by several mechanisms, for example by repression of Cyclin A2 and 
Cyclin D1 (Ahmed-Choudhury et al., 2005; Shivakumar et al., 2002). RASSF1A, together 
with Aurora A, modulates the CDC20/anaphase-promoting complex (Liu et al., 2008; Song 
et al., 2009b). In this study, the function of the RASSF1A isoform in the regulation of the 
Hippo signalling was analysed. RASSF1A activates the Hippo signalling through the 
SARAH domain (Dittfeld et al., 2012). The proto-oncogene Raf1 inhibits the activation of 
MST2 by sequestering and binding to the SARAH domain of MST2 (O'Neill et al., 2004).  
The Raf1-MST2 complex is dissociated by RASSF1A, which allows the binding of 
RASSF1A to MST2 and the activation of the Hippo kinase cascade (Matallanas et al., 
2007). Moreover, other reports have suggested that RASSF1A triggers the translocation of 
YAP1 into the nucleus, stabilises the interaction of YAP1 with TP73 and regulates the 
expression of the pro-apoptotic genes BBC3 and BAX (Levy et al., 2008a; Matallanas et al., 
2007; Strano et al., 2001). 
 
In contrast to RASSF1A, the other C-terminal RASSFs are poorly investigated. To date 
RASSF1A, RASSF2 and RASSF5 are directly associated with the activation of both MSTs 
(Cooper et al., 2009; Ni et al., 2013; Praskova et al., 2004; Schagdarsurengin et al., 2010; 
Song et al., 2010). RASSF2 is silenced for example in thyroid cancer (Schagdarsurengin et 
al., 2010), in gastric cancer (Maruyama et al., 2008) and in pheochromocytoma (Richter et 
al., 2015). RASSF5 has been identified as a tumor suppressor e.g. in osteosarcoma cells in 
association with the Hippo pathway (Zhou et al., 2014) and in association with TP53 
(Calvisi et al., 2009; Donninger et al., 2015). 
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1.6 Ankyrin repeat domain protein 1 (ANKRD1) 
 
The ankyrin repeat domain protein 1 (ANKRD1) was first described as a nuclear protein in 
cardiomyocytes and to be important for heart development, transcriptional regulation and 
stretch sensing (Cinquetti et al., 2008; Ishiguro et al., 2002; Jeyaseelan et al., 1997; 
Mikhailov and Torrado, 2008). The ANKRD1 gene, also known as CARP (cardiac ankyrin 
repeat protein), is a target gene of YAP1 (Li et al., 2013; Zanconato et al., 2015). Other 
factors that regulated the gene expression of ankrd1 in mice are Nkx2, Gata-4 and Sp3 
(Chen et al., 2012; van Loo et al., 2007; Zou et al., 1997).  
 
 
 
Figure 4: Protein structure of ANKRD1 with corresponding binding motifs. ANKRD1 has a length of 
319 amino acids (aa) and a molecular weight of 40 kDa. ANKRD1 contains a coil-coil domain (CC), a PEST 
domain for the proteasomal degradation and four ankyrin interaction motifs (ANK). 
 
ANKRD1 is located both in the nucleus as well as at the Z-disc complexes in skeletal and 
heart muscle cells (Ishiguro et al., 2002). As indicated in figure 4, ANKRD1 contains a 
coil-coil domain and a PEST motif, which is important for the proteasomal degradation and 
four ankyrin motifs of 33 amino acids each (Fig. 4) (Badi et al., 2009; Mikhailov and 
Torrado, 2008; Mosavi et al., 2004). In silico prediction analyses suggest that ANKRD1 
also contains a caspase-3 cleavage site, a nuclear localization signal, a nuclear export signal 
and several putative phosphorylation and glycosylation sites (Mikhailov and Torrado, 
2008). The ankyrin motifs are protein-protein interaction domains, which are observed in 
several proteins such as in the members of the INK4 family of tumor suppressor genes and 
in the tumor suppressor 53 binding protein 2 (Mosavi et al., 2004). ANKRD1 is a key 
player for the stress response in cardiomyocytes by interaction with TITIN, DESMIN, 
YB1, MYPN and CASQ2 (Mikhailov and Torrado, 2008; Miller et al., 2003; Torrado et 
al., 2005). Other interaction partners of ANKRD1 are p50 (subunit of NF-kappa β) (Liu et 
al., 2015; Mohamed and Boriek, 2012), nucleolin (Almodovar-Garcia et al., 2014), 
myopalladin (Ishiguro et al., 2002) and TP53 (Kojic et al., 2010).   
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The function of ANKRD1 is still under investigation and there are few reports in the 
literature about its role in cancer. In mice, ankrd1 knockout resulted in a complete lack of 
phenotype (Barash et al., 2007). ANKRD1 is a transcriptional co-factor that negatively 
regulates the expression of cardiac genes (Jeyaseelan et al., 1997). Mutations and the 
deregulation in the expression of ANKRD1 are associated with cardiomyopathies and heart 
anomalies (Arimura et al., 2009; Bogomolovas et al., 2015; Crocini et al., 2013; Duboscq-
Bidot et al., 2009; Torrado et al., 2006). ANKRD1 is the transcriptional regulator of 
MMP13 and MMP10 (Almodovar-Garcia et al., 2014). In cancer, ANKRD1 has been 
described as possible proto-oncogene in intestinal tumorigenesis in association with the 
WNT pathway and with TGF-β signalling (Labbe et al., 2007). In ovarian cancer, 
ANKRD1 negatively regulates the cellular response to cisplatin and chemotherapy (Lei et 
al., 2015; Scurr et al., 2008). In contrast, ANKRD1 acts a potential tumor suppressor gene 
in HCC by fenretinide-induced apoptosis (Park et al., 2005) and in rhabdomyosarcomas 
(Ishiguro et al., 2002). In 2005, Han et al. observed that ANKRD1 together with 
GADD153, is involved in hypoxia-induced apoptosis (Han et al., 2005). Recently 
ANKRD1 is related with the TP53 and with the JNK-mediated apoptosis in mice 
cardiomyocytes (Mazelin et al., 2016; Shen et al., 2015). Other reports suggest ANKRD1 
to be a co-activator of TP53 and thereby induce the expression of CDKN1A and BAX (Kojic 
et al., 2010; Shen et al., 2015). 
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Aims of this study  
 
The Hippo pathway has been described as a pro-apoptotic kinase cascade that is activated 
by the tumor suppressor gene RASSF1A for regulation the transcriptional function of 
YAP1. The function of the transcriptional regulator YAP1 depends on the binding to 
specific transcription factors. There is evidence suggesting that RASSF1A regulates the 
apoptotic function of the Hippo pathway by promoting and stabilising the binding of YAP1 
to the tumor suppressor gene TP73 and the subsequent transcriptional regulation of the pro-
apoptotic genes. However, the mechanism behind the apoptotic function of the Hippo 
pathway needs to be elucidated in more detail. Therefore, the main purpose of this study 
was the identification and the functional characterisation of YAP1 target genes that are co-
regulated by the tumor suppressor gene RASSF1A.  
 
In order to analyse the regulatory function of RASSF1A on the YAP1 target genes, the 
following secondary aims were proposed for this study: 
 
• Create and characterise a YAP1-inducible cell system. 
• Conduct a comparative whole transcriptome study using the YAP1-inducible 
system after expression of RASSF1A. 
• Identify novel candidate target genes for validation, which are regulated by 
RASSF1A and YAP1, taking into account the fold expression change and the 
biological function. 
• Validate the expression level of the principal candidate genes by qRT-PCR. 
• Confirm these results with another method such as promoter assays and western 
blotting. 
• Perform functional analyses of the best candidate gene such as colony formation 
assays, overexpression and promoter assays. 
• Clarify the transcriptional function of the other C-terminal RASSFs in the 
regulation of the novel target genes compared to the RASSF1A mediated 
regulation.
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2. MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 List of Materials 
2.1.1.1 Chemicals  
 
5’-Aza-2’-desoxycytidine Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Acrylamide Merck KGaA. Darmstadt, Germany 
Agar agar Merck KGaA. Darmstadt, Germany 
Agarose beads with FLAG Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Ammonium persulfate (APS) Serva electrophoresis GmbH, Heidelberg, Germany 
Agarose Biozym Scientific GmbH, Oldendorf, Germany 
Bacto trypton Becton Dickinson and company, France 
Boric acid Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Bovine serum albumin (BSA) Thermo Scientific, Schwerte, Germany 
Bromphenol blue Carl Roth GmbH, Karlsruhe, Germany 
β-Mercaptoethanol Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Chloroform Carl Roth GmbH, Karlsruhe, Germany 
Complete protease inhibitor mix Roche GmbH, Mannheim, Germany 
DAPI Serva electrophoresis GmbH, Heidelberg, Germany 
DEPC water Carl Roth GmbH, Karlsruhe, Germany 
Dulbecco’s modified Eagle 
Medium (DMEM) 
GIBCO®, Life Technologies GmbH, Darmstadt, 
Germany 
Dimethylsulfoxide (DMSO) Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Disodium hydrogen phosphate Carl Roth GmbH, Karlsruhe, Germany 
dNTPs Thermo Scientific, Schwerte. Germany 
EDTA Carl Roth GmbH, Karlsruhe, Germany 
Ethanol Merck KGaA. Darmstadt, Germany 
Ethidium bromide  Carl Roth GmbH, Karlsruhe, Germany 
Fetal calf serum (FCS) PAA Laboratories GmbH, Cölbe, Germany 
Fetal calf serum tetracycline free  
(FCS for Tet-On cells) 
Biochrom GmbH, Merck KGaA. Darmstadt, 
Germany 
Formaldehyde Carl Roth GmbH, Karlsruhe, Germany 
Formamide Carl Roth GmbH, Karlsruhe, Germany 
Giemsa Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Glucose Carl Roth GmbH, Karlsruhe, Germany 
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Glycerol Carl Roth GmbH, Karlsruhe, Germany 
Glycine Carl Roth GmbH, Karlsruhe, Germany 
Glycogen Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
HEPES Carl Roth GmbH, Karlsruhe, Germany 
Immobilon Western 
Chemiluminescent 
HRP substrate 
Millipore GmbH, Schwalheim, Germany 
Hydrochloric acid Carl Roth GmbH, Karlsruhe, Germany 
Hydroquinone Merck KGaA. Darmstadt, Germany 
Isopropyl alcohol Merck KGaA. Darmstadt, Germany 
Magnesium chloride Merck KGaA. Darmstadt, Germany 
Methanol Merck KGaA. Darmstadt, Germany 
Milk powder Carl Roth GmbH, Karlsruhe, Germany 
NP40 AppliChem GmbH, Darmstadt, Germany 
Opti-MEM® GIBCO®, Invitrogen GmbH, Karlsruhe, Germany 
OrangeG Carl Roth GmbH, Karlsruhe, Germany 
Phosphate buffered saline (PBS) GIBCO®, Invitrogen GmbH, Karlsruhe, Germany 
Phenol Carl Roth GmbH, Karlsruhe, Germany 
Phenol/Chloroform/Isoamyl 
alcohol 
Carl Roth GmbH, Karlsruhe, Germany 
Propidium iodide Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Protein A agarose beads Calbiochem, Merck, Darmstadt, Germany 
RPMI GIBCO®, Life Technologies GmbH, Darmstadt 
Sodium acetate Merck KGaA. Darmstadt, Germany 
Sodium chloride Carl Roth GmbH, Karlsruhe, Germany 
Sodium dodecylsulfate (SDS) Carl Roth GmbH, Karlsruhe, Germany 
Sodium deoxycholate Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Sodium dihydrogen phosphate Carl Roth GmbH, Karlsruhe, Germany 
Sodium metabisulfite Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
SYBR® Select Master Mix Life Technologies GmbH, Darmstadt, Germany 
TEMED Carl Roth GmbH, Karlsruhe, Germany 
Tris base Carl Roth GmbH, Karlsruhe, Germany 
Triton X100 Carl Roth GmbH, Karlsruhe, Germany 
TRIzol® GIBCO®, Invitrogen GmbH, Karlsruhe, Germany 
Tween20 Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Yeast extract Carl Roth GmbH, Karlsruhe, Germany 
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2.1.1.2 Size and molecular weight standards 
 
100 bp DNA ladder Thermo Scientific, Schwerte, Germany 
1 kb DNA ladder Thermo Scientific, Schwerte, Germany 
PageRuler Prestained protein 
ladder 
Thermo Scientific, Schwerte, Germany 
 
2.1.1.3 Antibiotics 
 
Ampicillin Sigma-Aldrich Chemie GmbH, Steinheim 
Blasticidin Invitrogen Life technologies GmbH, Darmstadt 
Chloramphenicol Sigma-Aldrich Chemie GmbH, Steinheim 
Doxycycline Invitrogen Life technologies GmbH, Darmstadt 
Kanamycin Applichem GmbH, Darmstadt 
Geneticin (G418) Biochrom, Berlin 
Penicillin (10 U/µl)/ Streptomycin 
(10 µg/µl) solution  
GIBCO®, Invitrogen GmbH, Karlsruhe 
Zeocin Invitrogen Life technologies GmbH, Darmstadt 
 
2.1.1.4 Transfection reagents 
 
JetPei Polyplus-Transfection SA, Illkrich, France 
LipofectamineTM Invitrogen Life technologies GmbH, Darmstadt, 
Germany 
Lipofectamine® RNAiMAX Invitrogen Life technologies GmbH, Darmstadt, 
Germany 
Polyethylenimine (PEI) Polyplus-Transfection SA, Illkrich, France 
Turbofect Thermo Scientific, Schwerte, Germany 
X-tremeGENE HP Roche Applied Science, Mannheim, Germany 
X-tremeGENE 9 Roche Applied Science, Mannheim, Germany 
 
2.1.1.5 Enzymes 
 
DNaseI (1U/µl) Thermo Scientific, Schwerte, Germany 
FastAP, thermosensitive (1 U/µl) Thermo Scientific, Schwerte, Germany 
Methyltransferase SssI (20 U/µl) New England BioLabs, Schwalbach 
MMLV Reverse Transcriptase 
(200 U/µl) 
Promega GmbH, Mannheim, Germany 
Proteinase K (20 µg/µl) Thermo Scientific, Schwerte, Germany 
Ribolock  (40U/µl) Thermo Scientific, Schwerte, Germany 
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RNaseA (10 µg/µl) Thermo Scientific, Schwerte, Germany 
SAM New England BioLabs, Schwalbach, Germany 
T4 DNA Ligase (3 U/µl) Thermo Scientific, Schwerte, Germany 
Taq-DNA-Polymerase AG Dammann. Isolated from an E. coli strain 
expressing Taq- polymerase 
TrypLE TM Express (Trypsin) GIBCO®, Invitrogen GmbH, Karlsruhe, Germany 
 
 
 Restriction endonucleases 
 
BglII Thermo Scientific, Schwerte, Germany 
BamHI Thermo Scientific, Schwerte, Germany 
HindIII Thermo Scientific, Schwerte, Germany 
SalI Thermo Scientific, Schwerte, Germany 
TaqI Thermo Scientific, Schwerte, Germany 
XhoI Thermo Scientific, Schwerte, Germany 
XmaI Thermo Scientific, Schwerte, Germany 
 
 
2.1.1.6 Kits and microarrays 
 
CloneJET PCR cloning kit Thermo Scientific, Schwerte, Germany 
Dual Luciferase® Reporter Assay 
System 
Promega, Heidelberg, Germany 
EZ DNA Methylation kit  Zymo Research, USA  
GFP-Trap® ChromoTek GmbH, Planegg-Martinsried, 
Germany 
MSB®Spin PCRapace Invitek GmbH, Berlin, Germany 
NucleoSpin® Extract II Macherey-Nagel GmbH, Düren, Germany 
NucleoSpin® Plasmid QuickPure Macherey-Nagel GmbH, Düren, Germany 
NucleoBond® Xtra Midi Macherey-Nagel GmbH, Düren, Germany 
QIAquickChange Lightning Agilent, USA 
Gene Chip® human gene 2.0 ST 
arrays 
Affymetrix, UK 
GeneChip WT terminal labeling 
and controls reagent kit 
Affymetrix, UK 
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2.1.1.7 Antibodies for western blots 
 
Table 1.  List of antibodies and the corresponding dilution. 
Name Dilution Company 
ANKRD1 (H-120)  
rabbit polyclonal IgG 
1:500 
Santa Cruz Biotechnology, Santa Cruz, Inc., CA, 
USA 
BAX (06-499) 
rabbit polyclonal IgG 
1:1000 EMD Millipore, Massachusetts, USA 
GAPDH (FL-335)  
rabbit polyclonal IgG 
1:2000 
Santa Cruz Biotechnology, Santa Cruz, Inc., CA, 
USA 
GFP  
rabbit polyclonal IgG 
1:2000 
AG Renkawitz (University of Giessen, Institute for 
Genetic) 
Flag (M2) 
mouse monoclonal IgG 
1:1000 
Santa Cruz Biotechnology, Santa Cruz, Inc., CA, 
USA 
MDM2 (Ab-2) 
mouse monoclonal IgG 
1:1000 Calbiochem® Merck KGaA. Darmstadt, Germany 
mp53 (1C12) 
mouse polyclonal IgG 
1:1000 New England BioLabs, Schwalbach, Germany 
HRP (goat anti-rabbit/ 
mouse, IgG HRP-
conjugated) 
1:2000 
Santa Cruz Biotechnology, Santa Cruz, Inc., CA, 
USA 
YAP1 (H-125)  
rabbit polyclonal IgG 
1:200 
Santa Cruz Biotechnology, Santa Cruz, Inc., CA, 
USA 
 
2.1.1.8 Vectors 
 
The expression and luciferase reporter vectors used in this project were verified by 
restriction digestion and sequencing. 
 
Table 2. List of vectors used in this study. 
Vector name Resistance Manufacturer Remark 
pCMV-Flag-Tag1 Kanamycin Addgene, England empty vector 
pCMV-Flag-RASSF1A Kanamycin 
AG Dammann (University 
of Giessen. Institute for 
Genetic) 
 
pCMV-RASSF1A-
ΔSARAH Kanamycin 
AG Dammann  
depletion of SARAH 
domain 
pCMV-Flag-RASSF2A Kanamycin AG Dammann  
pCMV-Flag-RASSF3 Kanamycin AG Dammann  
pCMV-Flag-RASSF4A Kanamycin AG Dammann  
pCMV-Flag-RASSF5A Kanamycin AG Dammann  
pCMV-Flag-RASSF6A Kanamycin AG Dammann  
pCMV-Flag-YAP1 Kanamycin AG Dammann  
Materials	  and	  Methods	  
25	  	  
pCMV-YAP1-T119A Kanamycin Jiménez. AG Dammann Pointmutation 
pCMV-YAP1-S127A Kanamycin Jiménez. AG Dammann Pointmutation 
pCMV-YAP1-S138A Kanamycin Jiménez. AG Dammann Pointmutation 
pCMV-YAP1-S127E Kanamycin Goetze. AG Dammann Pointmutation 
 
pDNR-LIB-ANKRD1 
 
Chloramphen
icol 
 
Biocat BC018667 
cloning vector 
ANKRD1 cloned via 
SfiI (introduction of 
BglII site 9 bp before 
the TSS) 
pCMV-Flag-ANKRD1 Kanamycin Jiménez. AG Dammann 
Cloned from pDNR-
LIB-ANKRD1  via 
BglII/XhoI 
pcDNA3 
 
Ampicillin 
 
AG Dammann empty vector 
pcDNA3-p73 
 Ampicillin 
AG Stiewe (University of 
Marburg. IMT) 
 
pcDNA3-deltap73 
 Ampicillin 
AG Stiewe   
pcDNA3.1-mCherry 
 Ampicillin 
AG Dammann empty vector 
mCherry-YAP1 Ampicillin Jiménez. AG Dammann 
cloned from pCMV-
Flag-YAP1 via 
BglII/BamHI 
mCherry-YAP1-T119A Ampicillin Jiménez. AG Dammann pointmutation 
mCherry-YAP1-S127A Ampicillin Jiménez. AG Dammann pointmutation 
mCherry-YAP1-S138A Ampicillin Jiménez. AG Dammann pointmutation 
mCherry-YAP1-S127E Ampicillin Goetze. AG Dammann pointmutation 
pcDNA-Myc Ampicillin AG Dammann  
pcDNA-Max Ampicillin AG Dammann  
pcDNA4TO-Myc Zeocin 
Thermo Fisher Scientific, 
Germany 
empty vector 
pcDNA4TO-Flag-
ANKRD1 
Zeocin Jiménez. AG Dammann 
Cloned from pCMV-
Flag-ANKRD1 via 
BamHI/XhoI and 
BglII/XhoI 
pcDNA4TO-YAP1 Zeocin Jiménez. AG Dammann cloned via BglII 
pEGFP-C2 Kanamycin Clontech Inc., France empty vector 
pEYFP-C2 Kanamycin Clontech Inc., France empty vector 
pEGFP-RASSF1A Kanamycin AG Dammann  
pEYFP-RASSF1A Kanamycin AG Dammann  
pEYFP-RASSF2A Kanamycin AG Dammann  
pEYFP-RASSF3 Kanamycin AG Dammann  
pEYFP-RASSF4A Kanamycin AG Dammann  
pEYFP-RASSF5A Kanamycin AG Dammann  
pEYFP-RASSF6A Kanamycin AG Dammann  
pEYFP-MST1 Kanamycin AG Dammann  
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pEYFP-MST2 Kanamycin AG Dammann  
pEGFP-ANKRD1 Kanamycin Traum. AG Dammann 
cloned from pCMV-
Flag-ANKRD1 via 
BglII/XhoI 
BglII/SalI 
pEYFP-ANKRD1 Kanamycin Traum. AG Dammann 
cloned pCMV-Flag-
ANKRD1 via 
BglII/XhoI 
BglII/SalI 
pEGFP-p53 Kanamycin 
AG Schmitz (University of 
Giessen. Department of 
Biochemistry) 
 
pEGFP-lamin B1 Kanamycin 
AG Dobreva (MPI Bad 
Nauheim) 
 
pEYFP-YAP1 Kanamycin Jiménez. AG Dammann 
cloned from pCMV-
Flag-YAP1 via 
BglII/BamHI 
pEYFP-YAP1-T119A Kanamycin Jiménez. AG Dammann pointmutation 
pEYFP-YAP1-S127A Kanamycin Jiménez. AG Dammann pointmutation 
pEYFP-YAP1-S138A Kanamycin Jiménez. AG Dammann pointmutation 
pEYFP-YAP1-S127E Kanamycin Goetze. AG Dammann pointmutation 
pJET1.2/blunt Ampicillin 
Thermo Scientific,  
Germany 
cloning vector 
pJet-ANKRD1promoter Ampicillin Jiménez. AG Dammann cloning vector 
pRL-null 
(renilla luciferase) Ampicillin 
Promega, Germany luciferase vector 
pRL-ANKRD1 
(renilla luciferase) Ampicillin 
Traum. AG Dammann 
luciferase vector 
cloned from pJet-
ANKRD1promoter  
via HindIII/XmaI 
pRL-RASSF1A 0.5 kb 
(renilla luciferase) Ampicillin AG Dammann 
luciferase reporter 
vector 
pRL-RASSF1A 2.3 kb 
(renilla luciferase) Ampicillin AG Dammann 
luciferase vector 
pGL2-basic 
(firefly luciferase) Ampicillin 
AG Schmitz luciferase vector 
pGL3 
(firefly luciferase) Ampicillin 
AG Dammann luciferase vector 
pGL-BAX 
(firefly luciferase) Ampicillin 
AG Schmitz luciferase vector 
pGL-MDM2 
(firefly luciferase) Ampicillin 
AG Schmitz luciferase vector 
pGL-p21 
(firefly luciferase) Ampicillin 
AG Schmitz luciferase vector 
pGL-p53 synthetic TP53 
target sites (13x) 
(firefly luciferase) 
Ampicillin AG Schmitz 
luciferase vector 
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2.1.1.9 Chemically- competent E. coli strains 
 
The following E. coli strains were used for plasmid amplification. 
 
Table 3. List of E. coli strains. 
Strain Genotype Company 
DH5α supE44 lacU (80lacZM15) hsdR17 recA endA1 gyrA96 thi-1 relA1 ATCC53868 
TAM I mcrA D(mrr-hsdRMS-mcrBC) F80lacZDM15 DlacX74 recA1 araD139 (ara-leu)7697 galU galK rpsL endA1 nupG 
Active Motif, 
Rixensart, Belgien 
XL10-Gold 
TetrD(mcrA)183 D (mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte, F ́ proAB 
lacIqZDM15 Tn10 (Tetr) Amy Camr 
Stratagene, Agilent 
Technologies, 
Germany 
 
2.1.1.10 Human cell lines 
 
During this study, the following cell lines were used for transfections, colony formation, 
DNA and RNA isolation (see Table 4). The cells were cultivated at 37°C under 5% CO2 
concentration with the appropriate media containing 10% FCS and 1% penicillin and 
streptomycin (PS). The TREx293 cells were cultivated in DMEM with 1% PS and 10% 
FCS tetracycline free serum. The cells were stored in DMEM or RPMI media with 10% 
DMSO in liquid nitrogen.  
 
Table 4. Human cell lines. 
Cell line Origin Medium 
A427 non-small cell lung cancer RPMI 
A549 lung adenomacarcinoma DMEM 
Buf1280 Melanoma DMEM 
C8161 malignant melanoma DMEM 
H322 bronchioalveolar carcinoma RPMI 
H358 bronchioalveolar carcinoma RPMI 
HEK293T human embryonic kidney cells DMEM 
HeLa cervical carcinoma DMEM 
IGR-1 metastasis from malignant melanoma DMEM 
LNCaP prostate carcinoma RPMI 
MCF-7 breast adenocarcinoma RPMI 
MeWo Melanoma DMEM 
Sk-Mel13 Melanoma DMEM 
Sk-Mel28 Melanoma DMEM 
T47D breast cancer DMEM 
TREx293 embryonic kidney cells expressing Tet repressor, YAP1 
or ANKRD1 in tetracycline dependent manner 
DMEM 
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2.1.1.11 Hepatic primary tumors and normal liver tissues 
 
Primary human liver cancer and matching normal tissue samples used for methylation 
analysis were obtained from patients of the City of Hope Medical Center (Duarte, CA, 
USA.) or from the University of Halle-Wittenberg (Steinmann et al., 2011). The local 
committee of medical ethics and the patients approved the use. Samples names: 2800 (T/ 
N), 2844 (T/N), 974 (T/N), 1117 (T/N), 3084 (T/N). T=Tumor. N=Normal liver tissue. 
 
2.1.2 Primers 
 
During this study, the following primers were used (Table 5 - Table 9). All primers were 
provided desalted by Life Technologies GmbH. They were dissolved in DEPC water to a 
stock concentration of 100 µM, after that they were diluted and mixed to primer mix 
solutions with the forward and reverse primers each at 10 µM concentration for CoBRA 
and semiquantitative PCRs and at 2 µM concentration for quantitative real time PCR. The 
primer pairs for CoBRA and semiquantitative PCRs were optimized with respect to the 
annealing temperature during PCR (55°C to 62°C).  
 
 
 
Table 5.  Sequencing primers.  
Primer name Sequence (5 -́3 ́) 
EGFPSeqU GCCGCCGGGATCACTCTCG 
PCMV GCGGTAGGCGTGTACGG 
T7 TAATACGACTCACTATAGGG 
Mcherryseq1 GAACGCGCCGAGGGCCG 
 
 
Table 6.  Primers for ANKRD1 promoter region. 
Primer name Sequence (5 -́3 ́) Product size 
ANKRD1UHD3 AAGCTTCATGTCATGTGCTAATTATGGCCAG 606 bp 
 ANKRD1LXma TCCAACCCGGGAACCGAAGTAACACTCC 
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Table 7. Primers for CoBRA. 
Primer name Sequence (5 -́3 ́) 
Product size 
(annealing 
temperature) 
ANKRD1BSU1 AAGGAATTTTTGGAGTTGGTTTTGT 139 bp 
(56°C)   ANKRD1BSL1 CACCTACCTCTAAATTAACTCCTAATAAAAA 
MU379 
(for RASSF1A) 
GTTTTGGTAGTTTAATGAGTTTAGGTTTTTT  
ML730 
(for RASSF1A.  
1st PCR) 
ACCCTCTTCCTCTAACACAATAAAACTAACC (55 °C) 
ML561 
(for RASSF1A 
2nd PCR) 
CCCCACAATCCCTACACCCAAAT 
205 bp 
(54 °C)   
 
Table 8.  Primers for semi- and quantitative real-time PCR. 
Primer name Sequence (5 ́-3 ́) 
Product size 
(annealing 
temperature) 
ANKRD1RTF1 AGCGCCCGAGATAAGTTGCT 240 bp 
(60°C) ANKRD1RTR1 CACCAGATCCATCGGCGTCT 
BaxRTF AACTGGGGCCGGGTTGTCGC 196 bp 
(62°C) BaxRTRew CGCGGTGGTGGGGGTGAGG 
CTGFRTF1 CATCTTCGGTGGTACGGTGT 295 bp 
(62°C) CTGFRTR1 GACCAGGCAGTTGGCTCTAA 
UGAP389 TGGAGAAGGCTGGGGCTCAT 176 bp 
(60°C) LGAP545 GACCTTGGCCAGGGGTGCTA 
PUMARTFW GCGGCGGATGGCGGACGA 188 bp 
(60°C) PUMARTRW CTGACGTCCACCGGGCGGGT 
p21RTF CCTTGTGCCTCGGTCAGGGGAG 183 bp 
(62°C) p21RTR GGCCCTCGCGCTTCCAGGAC 
P53RTU1 TCAGATCCGTGGGCGTGAGCG 235 bp 
(62°C) P53RTL1 GGGGGTGGGAGGCTGTCAGTGG 
UHE2ab GGCTGGGAACCCGCGGTG 239 bp 
(60°C) L27111 TCCTGCAAGGAGGGTGGCTTCT 
YAP1RTFW1 TGTCTTCTCCCGGGATGTCTCAGG 215 bp 
(62°C) YAP1RTRW1 TGAGGGCAGGGTGCTTTGGTTG 
MDM2RTF1 ATCAGGCAGGGGAGAGTGAT 288 bp 
(62°C) MDM2RTR1 CCTCAACACATGACTCTCTGGA 
AJUBARTF1 GGATGGCATCCCCTTCACAGTGG 196 bp 
(60°C) AJUBARTR1 CATCCGGCAGTCCTCACAGTGGT 
U148P16 GCTGCCCAACGCACCGAATAGT 157 bp 
(60°C) L287P16 CTCCCGGGCAGCGTCGTG 
P73RTFW CAGCAGCCACAGCGCCCAGTC 191 bp 
(60°C) P73RTRW GGGCCCCCAGGTCCTCAATGG 
RSF2ARTF TCCTCCAGGGCCCATGTGAGC 237 bp 
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RSF2RTR TTGCTGGGGTCTCGGCTATCTCC (60°C) 
RSF3RTF AGCAGGGCCCAGAACAGACACAC 215 bp 
(60°C) RSF3RTR CCCCGCTTTAATCAGGCTTCCAC 
RSF4ARTF CCAGAATCCTGCATGGGCCATG 203 bp 
(60°C) RSF4ARTR CGTCAGACGCAGGGCTTGGAA 
RASF5CRTF TGCAGCCTGGACGAGGAACTGG 252 bp 
191 bp 
(60°C) 
RASF5ACRTR CCGCCGGAGTTTCAGATGCACTT 
RSF5ARTF GCACCCTCACCGTGACCTTCAGC 
RSF6ARTR GCCACATCACTGCTAATTTCTTCTGCA 166 bp 
(60°C) RSF6ARTF GTCCCCAGGATTTTGCTCTTCACATT 
 
Table 9. Mutagenesis primers. 
Primer name Sequence (5 -́3 ́) 
ANKRD1_Bgl
IIF1 
CAGTACCATCATGTTGGCTGAAGAGATCTTGTATGTTTTTCTGTCGTG 
ANKRD1_Bgl
IIR1 
CCACGACAGAAAAACATACAAGATCTCTTCAGCCAACATGATGGTACTG 
YapT119AU1 GAACATGCTGTGGAGCCAGGGCTCCTGCAG 
YapT119AL1 CTGCAGGAGCCCTGGCTCCACAGCATGTTC 
YapS127AU1 GAGAAGCTGGAGAGGCATGAGCTCGAACATGCT 
YapS127AL1 AGCATGTTCGAGCTCATGCCTCTCCAGCTTCTC 
YapS138AU1 GTCCCAGGAGCAACAGCTCCCAACTGCAG 
YapS138AL1 CTGCAGTTGGGAGCTGTTGCTCCTGGGAC 
YapS127EU1 ACTGCAGAGAAGCTGGAGATTCATGAGCTCGAACATGCTGTGG 
YapS127EL1 CCACAGCATGTTCGAGCTCATGAATCTCCAGCTTCTCTGCAGT 
YapS138EU1 GGGTCAGTGTCCCAGGTTCAACAGCTCCCAACTGCAG 
YapS138EL1 CTGCAGTTGGGAGCTGTTGAACCTGGGACACTGACCC 
mCherrydelgF GGGTAAGCCATAGAGATCTTGTACAGCTCGTCCA 
mCherrydelgR TGGACGAGCTGTACAAGATCTCTATGGCTTACCC 
 
 
2.1.3 Media 
 
All media were prepared in the Institute for Genetic from the University of Giessen and 
autoclaved before use. 
 
DMEM for 10 l 
pH 7.25 adjusted with HCl DMEM                    133 g 
 NaHCO3                    3.7 g 
 HEPES                     59.6 g 
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RPMI for 10 l 
pH 7.25 adjusted with HCl RPMI                      133 g 
 NaHCO3                     2 g 
 HEPES                      50 mM 
 
LB medium for 1 l 
pH 7.5 adjusted with HCl Bacto trypton           10 g 
 Yeast extract              5 g 
 NaCl                        10 g 
 
 
Sorting medium for FACS PBS (1X) 
 HEPES                    25 mM 
 
 
2.1.4 General buffers and solutions 
 
 
Loading Dye (6X) for 50 ml Saccharose               22.5 g 
 TBE buffer (10X)      6 ml 
 OrangeG                    0.5 g 
 
 
Mowiol  for slides Glycerol                      6 g 
 MOWIOL                2.4 g 
 Tris  (pH 8.5)          0.2 M 
 DABCO                   0.1% 
 
Proteinase K buffer  
Adjusted pH to 7.6 Tris                           50 mM 
 EDTA                       25 mM 
 NP40                        0.5% 
 SDS                          0.5% 
 
TBE buffer (10X) Tris                              1 M 
 EDTA                        10 mM 
 Boric acid                  0.8 M 
 
TE buffer (1X) 
pH adjusted to 7.6 with HCl Tris                            10 mM 
 EDTA                          1 mM 
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2.1.5 Buffers for SDS-PAGE and western blot 
 
Separation gel buffer Tris/HCl pH 8.8            1.5 M 
Stacking gel buffer Tris-HCl pH 6.8            0.5 M 
 
 
Blotting buffer  
For 1 l NaH2PO4                         1 M  (20 ml) 
 Na2HPO4                       0.5 M  (14 ml) 
 
 
Flag lysis buffer 
pH adjusted to 7.4 with HCl Tris                              50 mM 
 NaCl                          150 mM 
 EDTA                            1 mM 
 Triton X100                   0.5% 
 1x Complete proteinase inhibitor/ 50 ml buffer 
 
 
Laemmli buffer 
pH adjusted to 6.8 with HCl Tris                             140 mM 
 Glycerol                       20 % 
 SDS                               4 % 
 β-Mercaptoethanol        1 M 
 Bromphenol blue           0.01 % 
 
 
SDS-PAGE running buffer 
(10X) Tris                            250 mM 
 Glycine                      1.92 M 
 SDS                               0.1 % 
 
TBS buffer (10X) 
pH adjusted to 7.6 with HCl Tris                                200 mM 
 NaCl                             1.4 M 
 0.02 % Tween20 for TBS-T 
 
 
FACS sorting media PBS                              1x 
 EDTA                           1 mM 
 HEPES                         25 mM 
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2.1.6 Basic commodities 
2.1.6.1 Consumables 
 
Amersham Hybond-P PVDF 
membrane 
GE Healthcare, Munich, Germany 
Cryotubes (2 ml) Sarstedt AG & Co., Nümbrecht, Germany 
Cell culture dishes Sarstedt AG & Co., Nümbrecht, Germany 
Cell scraper Sarstedt AG & Co., Nümbrecht, Germany 
Reaction tubes (1.5 ml, 2 ml) Sarstedt AG & Co., Nümbrecht, Germany 
Falcon tubes (50 and 15 ml) Sarstedt AG & Co., Nümbrecht, Germany 
FACS tubes  
Gloves (rotiprotect nitril) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
PCR tubes and 8-well strip Techno Plastic Products AG, Trasadingen, 
Switzerland 
Plates  96 well plates for 
luminometer 
Greiner bio-one GmbH, Hampshire, UK 
Petri dishes Sarstedt AG & Co., Nümbrecht, Germany 
Techno Plastic Products AG, Trasadingen, Schweiz 
Pipet tips  
(10, 20, 100, 200, 1000 µl) 
Greiner bio-one GmbH, Hampshire, UK 
Scalpel B. Braun Melsungen AG, Melsungen, Germany 
Sterile filters Sartorius AG, Göttingen, Germany 
Tubes for qRT-PCR Biozym Scientific GmbH, Hessisch Oldendorf, 
Germany 
Whatman paper Carl Roth GmbH & Co., Karlsruhe, Germany 
 
2.1.6.2 Equipment  
 
Autoclav Technoclav Technomara AG, Wallisellen, Switzerland 
Acculab precision scale VIC-123 Sartorius AG, Göttingen, Germany 
Acculab precision scale VIC-5101 Sartorius AG, Göttingen, Germany 
Blotting chambers BioRad, Munich, Germany 
Block heater QBD2 Grant Instruments Ltd. Cambridge, UK 
Electrophoresis chambers PEQlab Biotechnologie GmbH, Erlangen, Germany 
FACS CANTO II BD Biosciences, Heidelberg, Germany 
FACS Aria III BD Biosciences, Heidelberg, Germany 
Freezer -80°C DF8517 Labotec GmbH, Göttingen, Germany 
Gel documentation transilluminator Decon Science Tec GmbH, Hohengandern, Germany 
Microplate luminometer ORION L, Berthold Detection Systems, Pforzheim, 
Germany 
Magnetic mixer (VMS-C7) VWR International GmbH, Darmstadt, Germany 
MALDI-TOF-MS AG Lochnit.  Amersham Bioscience Group 
Materials	  and	  Methods	  
34	  	  
Microwave Cinex Electronic GmbH, Aschenberg 
Molecular Imager VersaDoc Bio-Rad, Hercules, CA, USA 
Neubauer chamber LO - Laboroptik Ltd, Lancing, UK 
pH meter, pH 211 Microprocessor Hanna Instruments, Kiel, Germany 
Pipetting aid PZ HTL S.A.,Warszawa, Poland 
Power supply Bio-Rad Laboratories Inc., Hercules, CA, USA 
Rotor-Gene3000 Corbett Research, Germany 
Tecan Infinite M200 PRO Tecan GmbH, Grödig, Austria 
Versadoc BioRad, Munich, Germany 
Vortexer VWR International GmbH, Darmstadt, Germany 
 
2.1.6.3 Centrifuges 
 
Centrifuge 5418 Eppendorf GmbH, Hamburg, Germany 
Fresco 17 Centrifuge Heraeus, Hanau, Germany 
Multifuge 1S/1S-R Heraeus, Hanau, Germany 
Pico 17 Centrifuge Heraeus, Hanau, Germany 
 
2.1.6.4 Incubators 
 
HERAcell 150 Thermo Electron LED GmbH, Langenselbold, 
Germany 
Incubator shaker TH30 Edmund Bühler GmbH, Hechingen 
Laboratory incubator Type B6 Thermo Electron LED GmbH, Langenselbold, 
Germany 
2.1.6.5 Microscopes and camera 
 
Axio Observer.Z1  
(inverse microscope) 
Zeiss, Wetzlar, Germany 
Camara Orca-ER, HAMAMATSU Zeiss, Wetzlar, Germany 
Fluorescence microscope  Zeiss, Wetzlar, Germany 
 
2.1.6.6 Shakers 
 
Shaker Rotamax 120 Heidolph Instruments GmbH & Co. KG, Schwabach, 
Germany 
Shaker Roto-Shake Genie Scientific Industries Inc., Bohemia, N.Y., USA 
Thermomixer compact Eppendorf-Netheler-Hinz GmbH, Germany 
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2.1.6.7 PCR Thermocyclers 
 
Mastercycler Eppendorf-Netheler-Hinz GmbH, Hamburg, 
Germany 
Mastercycler Gradient Eppendorf-Netheler-Hinz GmbH, Hamburg, 
Germany 
 
2.1.6.8 Water baths 
 
WB10 P-D Industriegesellschaft  GmbH, Dresden Germany 
AL-5 Lauda Dr. R. Wobser GmbH &Co. KG, Lauda- 
Königshofen, Germany 
 
2.1.7 Software 
 
BioEdit Sequence Alignment 
Editor Version 7.1.3.0 
 
Ibis biosciences, Carlsbad, USA 
Image J National Institutes of Health, Bethesda, USA 
Mascot Server Matrix science 
Python vs. CoBRA 
 
https://launchpad.net/python.vs.cobra, Frederick 
Turczek 
R project version 3.1.3 R Foundation 
Rotor-Gene6 Corbett Research, Qiagen, Hilden, Germany 
UCSC Genome Browser University of California, Santa Cruz, USA 
Motic Images Plus 2.0 Motic Deutschland GmbH, Wetzlar, Germany 
Simplicity software ORION L, Berthold Detection Systems, 
Pforzheim, Germany 
BDFacsDivaTM Version 6.1.3. BD Biosciences 
Volocity version 6.3 PerkinElmer 
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2.2. METHODS 
2.2.1 Molecular cloning 
2.2.1.1 Restriction digestion 
 
Molecular cloning describes the insertion of a DNA fragment into a specific expression 
vector. In this work, the cDNA of ANKRD1 and YAP1 were cloned into different 
expression vectors. Furthermore, the promoter region of ANKRD1 was cloned into a 
luciferase reporter vector. To avoid a religation of the target vector, most of the cloning 
vectors were treated by double digestion as indicated in Table 2. By the digestion with one 
enzyme, an extra dephosphorylation step was performed using 5 units of FastAP, 1x of the 
corresponding buffer, ddH2O, and an incubation at 37°C for 30 min. To obtain the inserts 
from the original vectors, 15 µg of the original vector with insert (pDNR-LIB-ANKRD1 
and CMV-YAP1) were digested overnight (ON), and separately also the target vectors (10 
µg plasmid), with the restriction enzymes at the corresponding temperature. Afterwards, the 
fragments were purified by preparative gel electrophoresis (1% gel) using the gel extraction 
kit from Macherey- Nagel.  
 
To clone the promoter of ANKRD1, a 606 bp region before the transcription start site was 
amplified by PCR (see appendix 1). The primers used for this propose are listed in Table 6. 
The primers created HindIII and XmaI restriction sites in the amplified fragment, which 
were used for the cloning into the cloning vector (pJet) and later in the renilla luciferase 
vector (pRL-null). The amplified fragment and digested pRL vector were purified with 
preparative gel electrophoresis and gel extraction kit from Macherey- Nagel.  
 
2.2.1.2 Ligation and transformation 
 
Following restriction digestion and purification, the purified fragments were ligated. For 
that, the vector background and the isolated insert at a ratio of 1:5 were ligated ON at room 
temperature (RT) using the T4 ligase and the corresponding buffer from Fermentas. 
 
The amplification of the constructs was performed by transformation of competent 
Escherichia coli (E. coli) strains (DH5α, TAM I or XL10-Gold) (Table 3). 30 µl of 
competent cells on ice were mixed with 1 µl of plasmid. The mixture was incubated for 30 
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min on ice, before the heat shock at 42°C for 45 s. The transformed cells were incubated 
for 2 min on ice and mixed with 250 µl SOC medium. After 1 h incubation at 37°C, 100 µl 
of this aliquot was plated on LB-plates with the necessary antibiotics (ampicillin: 60 µg/ml; 
kanamycin: 50 µg/ml; chloramphenicol: 30 µg/ml final concentration) and incubated ON at 
37°C.  
 
2.2.1.3 Plasmid preparation and glycerol stock cultures 
 
To gain large amounts of the plasmids, midi and mini preparations had to be performed. 
The transformed E. coli cells were grown in LB liquid medium with the specific antibiotic 
at 37°C ON. Next day, the plasmids were purified according to the kits from Macherey-
Nagel GmbH & Co. KG. For the glycerol stocks, 750 µl of the E. coli suspension were 
supplemented with 250 µl sterile 80% glycerol, mixed thoroughly and stored at -80°C. The 
correctness of the plasmid sequences and orientation were verified by restriction digestion 
and by conventional sequencing. The sequences were further analysed using the BioEdit 
software. The functionality of the generated plasmid was controlled by fluorescent 
microscopy, qRT-PCR and at the protein level by western blotting.  
 
2.2.2 Mutagenesis 
 
During this work, mutagenesis steps were performed for various reasons e.g. to create 
specific restriction sites (BglII sites) in pDNR-LIB-ANKRD1, to create the YAP1 point 
mutants (YAP1-S127A, YAP1-S127E, YAP1-T119A, YAP1-S138A, YAP1-S127E), or to 
delete a nucleotide to bring the insert in frame, since the reading frame is essential for the 
correct expression of the fusion protein (mCherry-YAP1). The mutagenesis primers were 
created using the in silico tool of Stratagene and are listed Table 9. The mutagenesis PCR 
was performed with the Quick Change Lightning Site-Directed Mutagenesis Kit from 
Agilent Technologies with the settings indicated in Table 16. 
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2.2.3 Cell culture  
2.2.3.1 Cell lines and transfections 
 
This work is a cell culture based study. The cell lines used, their origin and respective 
growth medium are listed in Table 4. The cell lines were cultivated in DMEM or RPMI 
containing 10% FCS and PS at 37°C under 5% CO2 concentration. The cells were 
transfected at a confluence of 60-80% in serum free media (Opti-MEM from Gibco) with 4 
or 10 µg plasmid DNA in 6-well or 10 ml plates respectively. HEK293T and TREx293 
cells were transfected using PEI. LNCaP cells were transfected with Lipofectamine from 
Invitrogen. A549 and T47D were transfected using Turbofect from Fermentas. A427 cells 
were transfected using X-tremGENE HP from Roche according with the instructions of the 
manufacturers. The transfected cells were further used for expression analyses, promoter 
assays, colony formation, growth curves, as well as for protein, RNA and DNA isolation.  
 
2.2.3.2 Promoter assays 
 
The promoter assays performed in this study were used to corroborate the effect of the 
putative transcription factor or activators on the promoters of target genes. The activation 
of the cloned promoter is linked experimentally to the luciferase activity. The 
measurements of reporter activity were performed using the Dual-Luciferase Reporter 
Assay System, which also contains the catalytic enzyme to oxidate luciferin. The generated 
light intensity was measured by the microplate illuminometer ORION L. The obtained data 
were normalized to the corresponding control vectors. 
 
The promoters of p53, p21, MDM2 and BAX were cloned into pGL-vectors (firefly 
luciferase) and were obtained from the AG Schmitz (Department of Biochemistry, 
University of Giessen). The p53 vector is an artificial construct with 13 binding sites of 
TP53 in a pGl luciferase vector. A fragment of 606 bp of the ANKRD1 promoter was 
cloned into pRL-null vector as previously indicated in 2.2.1.1. The luciferase vector pRL-
RASSF1A (length promoter: 0.5 kb) was created by Dr. Kiehl in the AG Dammann.  
 
For the promoter assays, HEK293T or the YAP1-inducible TREx293 cells were co-
transfected with 2 µg of the luciferase vector (RASSF1A, ANKRD1, TP53, p21, MDM2 or 
BAX) together with 1.7 µg of the transcription factor or activator. The transfection 
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efficiency was controlled using 0.3 µg of the corresponding control empty vector (pGL2 or 
pGL3 for the renilla luciferase vectors or pRL-null for the firefly luciferase vectors). For 
the respective normalization, mock transfections were performed by co-transfection of the 
respective empty vector together with the transcription factors or activator. 24 h post 
transfection, the cells were lysed with 200 µl of the 1x passive lysis buffer from the Dual-
Luciferase Reporter Assay kit. The cell lysate was spun down for 1 min at 10000 rpm. 20 
µl of the lysate were analysed in the illuminometer ORION L. 
 
The firefly luciferase activity was measured by adding 33 µl Lar II buffer (provided in the 
Dual-Luciferase Reporter Assay kit). To stop the firefly luciferase activity and to measure 
the renilla luciferase activity, 33 µl of Stop&Glo buffer with the diluted substrate 
Stop&Glo 50X (1:50) was added (provided in the Dual-Luciferase Reporter Assay kit). The 
obtained measurements were normalized in three steps: first to the corresponding vector for 
the transfection efficiency, secondly, the values were normalized to the sample transfected 
with the luciferase reporter vectors and overexpression empty vectors; finally, each sample 
was normalized to the corresponding sample co-transfected with the luciferase empty 
vector and with the overexpression vector of the transcription factor. 
 
2.2.3.3 Colony formation and growth curves 
 
In order to investigate the effect of ANKRD1 on cell growth, colony formation assays and 
growth curves were performed. For the colony formation assay HEK293T, A427, LNCaP 
and T47D cells were seeded in 6-well plates. The following day, the cells were transfected 
in triplicates with 4 µg plasmid. A427, LNCaP and T47D cells were transfected with 
pCMV-ANKRD1 or with the pCMV-empty vector as control. The H293T cells were 
transfected as previously described either with pcDNA4TO-ANKRD1 or with pcDNA4TO-
empty vector. The overexpression of ANKRD1 was proved by semiquantitative PCR as 
indicated in figure 17. 24h after transfection, the culture medium was supplemented with 
geneticin (G418) or zeocin for the selection as indicated in Table 10. After approximately 
three weeks, the colonies were stained with GIEMSA in a dilution of 1:10 with water. 
 
For the statistical analysis, the number of the colonies in the technical triplicates was 
counted, the mean value was determinated and normalized relative to the cells transfected 
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with the empty control vector. For the standard deviation, the mean values of the biological 
triplicates were used and plotted in figure 17. 
 
Table 10. Antibiotic concentration for colony formation. 
Cell line Antibiotic Concentration 
A427 G418 (30.000 U/ml) 5 µl/ml 
A549 G418 50 µl/ml 
HEK293T Zeocin (100 mg/ml) 7 µl/ml 
LNCaP G418 33.34 µl/ml 
T47D G418 100 µl/ml 
 
The growth curves of LNCaP and A549 cells were generated after ectopic expression of 
ANKRD1. For this proposes, the cells were transfected either with 4 µg pCMV empty 
vector or with 4 µg pCMV-ANKRD1 vector. After 48 h selection with G418, 2 x 105 cells 
were plated under antibiotic selection pressure in duplicates. Every 24 h the cell number of 
the duplicates was counted using the Neubauer chamber. The cell number of day one was 
used as start point to quantify the fold change of the cell number over the experimental time 
period.  
 
2.2.3.4 Generation of stable cell line 
 
The stable cell lines were generated using the Tet-On inducible system from Invitrogen, 
which allows a site directed regulation or activacion of a specific gene. The TREx293 cells 
are stably transfected with a tetracycline response element (TRE) repressor and with a 
plasmid containing a TRE promoter and the gene of interest. The adding of tetracycline or 
its derivate doxycycline (Dox) produces the release of the repressor from TRE leading to 
the free promoter, which then allows the high transcription of the downstream gene of 
interest.  
 
For the generation of the ANKRD1 and YAP1 stable cell lines, cDNAs of YAP1 or 
ANKRD1 were cloned into pcDNA4TO Myc vector as indicated in Table 2. 10 µg of the 
vectors were transfected in the TREx293 cells in 10 cm plates. The cells were cultivated in 
DMEM with 10% tetracycline free serum and PS under the same conditions described 
above. The vector containing the Tet repressor is blasticidin resistant and the pcDNA4TO 
Myc vector is zeocin resistant. After three weeks of selection by blasticidin (5 µg/ml) and 
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zeocin (500 µg/ml), the individual clones were isolated and extended. The induction of 
YAP1 or ANKRD1 was performed using Dox in a final concentration of 2µg/ml. The 
individual clones and the pool of clones were further used for transfection, expression and 
protein analysis.  
 
2.2.3.5 Knockdown assays by small interfering RNA    
 
Small interfering RNA (siRNA) is a double stranded small non-coding RNA, which binds 
complementary to the mRNA sequence of its target genes to enhance its degradation (Fire 
et al., 1998). During the natural gene regulation by siRNA in cells, the precursor siRNA is 
cleaved into small 20-25 bp length RNA in the DICER protein complex. The siRNA duplex 
loads one strand on the RNA-induced silencing complex (RISC), in which the target 
mRNA is scanned and cleaved (Esteller, 2011). In this study, the ANKRD1 knockdown 
was performed with the commercial siRNA from Dharmacon.  
 5’- 3’ sequences 
Non-targeting pool 
(5 nmol) 
             
                UGGUUUACAUGUCGACUAA 
 UGGUUUACAUGUUGUGUGA 
 UGGUUUACAUGUUUUCUGA 
 UGGUUUACAUGUUUUCCUA 
Human ANKRD1 siRNA SMARTpool 
(5 nmol) 
 
CUACAAGACCUCUCGCAUA 
 GAACCAAAGCAAUAUUCGA 
 CGAAUUCCGUGAUAUGCUU 
 GCUAUAAGAUGAUCCGACU 
 
HEK293T cells were transfected at a confluence of 80% either with 50 pmol of a non-
targeting siRNA control pool or with 50 pmol of the siRNA for ANKRD1 using the 
Lipofectamine® RNAiMAX from Invitrogen. For the transfection, 50 pmol siRNA were 
diluted in 100 µl Opti-MEM; 10 µl Lipofectamine were prepared also in 100 µl Opti-MEM 
and mixed with the corresponding siRNA dilution. Before the transfection, 800 µl of Opti-
MEM was added to the cells. Both siRNA/Lipofectamine mixes were incubated for 20 min 
at room temperature (RT) and added to the cells with Opti-MEM. After 6 h, the medium 
was changed to DMEM and the transfected cells were incubated for 4 days under the same 
conditions described in 2.2.3.1. The cells were then harvested for RNA isolation and 
expression analysis. 
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2.2.4 DNA isolation 
 
The isolation of DNA was perfomed at RT. Before DNA isolation, the cells were washed 
twice with 1x PBS and harvested by scraping. The cells were centrifuged at 13000 rpm for 
30 s. The cell pellet was resuspended in 400 µl Proteinase K buffer. 15 µl of Proteinase K 
(20 mg/ml) was added to the cells and incubated ON at 55°C. The following day, DNA was 
isolated by phenol/chloroform extraction. To this effect, 500 µl of phenol were added to the 
cell lysate and mixed vigorously. The phase separation was performed by centrifugation at 
13000 rpm for 3 min. The upper aqueous layer containing the nucleic acids was transferred 
into a new tube. 500 µl phenol/chloroform/isoamyl alcohol mix were added to the sample 
and mixed for 1 min. After a centrifugation step of 13000 rpm for 3 min, the upper aqueous 
layer was isolated and mixed with 500 µl chloroform. The DNA/chloroform mix was 
centrifuged for 3 min at 13000 rpm. The supernatant was transferred into a new reaction 
tube. The DNA was precipitated by adding 1/10 volume of 3 M NaAc and 1 volume of 
isopropyl alcohol. The sample was centrifuged for 3 min at 13000 rpm. The DNA pellet 
was washed in 150 µl 70% ethanol (EtOH) and after a further centrifugation step for 5 min 
at 13000 rpm, the pellet was dried for 10 min at RT. The DNA was resuspended in TE-
buffer. Subsequently, a RNaseA digestion was performed by adding 2 µl RNaseA and an 
incubation step at 37°C for 10 min. The DNA concentration was determinated using the 
TECAN apparatus.  
 
2.2.5 RNA isolation 
  
The cells used for RNA isolation were washed once with 1x PBS and lysed with 1 ml 
TRIzol. To the lysates 200 µl chloroform were added and mixed thoroughly. After an 
incubation for 3 min at RT, the samples were centrifuged at 12000 rpm for 10 min at 4°C. 
The upper aqueous layer was transferred into a new reaction tube and mixed with 500 µl 
isopropyl alcohol. After thoroughly mixing the sample, another centrifugation step at 12000 
rpm for 10 min at 4°C was performed. The RNA pellet was washed with 150 µl of 70% 
EtOH diluted in DEPC water and centrifugated for 5 min. The supernatant was discarded 
and the pellet was dried at RT for maximal 3 min. Depending on the size of the pellet 20 – 
50 µl DEPC water were added. Before the measurement of the concentration, the RNA 
samples were incubated for 10 min at 65°C and subsequently for 30 min at 37°C. The 
integrity of the isolated RNA was verified by agarose gel electrophoseresis in a 1% agarose 
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gel. The isolated RNAs were subsequently used for the reverse transcriptase PCR and for 
the expression analyses by quantitative real time PCR. 
 
2.2.6 Methylation analysis 
 
The methylation of the ANKRD1 and RASSF1A promoter was analysed using bisulfite PCR 
followed by restriction analysis. 
 
2.2.6.1 In vitro methylation (ivm) 
 
In vitro methylated DNA (ivm DNA) was used as positive control for the methylation 
analyses. 2 µg genomic DNA in 164 µl ddH2O were supplemented with 20 µl Buffer 2, 1 µl 
SAM (200x), 15 µl SssI (4 U/µl) and incubated ON at 37°C. After the first 2-3 h of 
incubation, another 1 µl SAM was added. Following the incubation the sample was diluted 
with 100 µl TE-buffer. Subsequently, the ivm DNA was purified with phenol/chloroform 
extraction as indicated in 2.2.4. 
 
2.2.6.2 DNA bisulfite conversion 
 
During the DNA bisulfite conversion all unmethylated cytosines (Cs) are converted into 
uracil by desulphonation, while all methylated Cs are maintained as Cs, since the methyl 
group protects the cytosine from the hydrolytic deamination thus avoiding its conversion to 
uracil. For this purpose, 2 µg of genomic DNA (cell line DNA, tumor and matched normal 
tissue DNA) were diluted in 18 µl of ddH2O and supplemented with 2 µl of 3 M NaOH. 
The samples were incubated for 15 min at 37°C. Thereafter, 12 µl of 0.1 M hydroquinone 
and 208 µl of 1.9 M sodium metabisulfite were added. The sample mix was incubated at 
50°C ON. The following day, the DNAs were purified using the MSB®Spin PCRapace kit. 
The purified bisufite DNA was supplemented with 5 µl 3M NaOH to remove the sulfur 
group. Afterwards, the DNA was precipitated by EtOH and the DNA pellet was 
resuspended in 30 µl TE buffer. Thereafter, a PCR with the bisulfite treated DNA was 
performed. The region of interest from each cell line or tissue was amplified by PCR using 
the specific primers for bisulfite DNA indicated in Table 7. The ivm DNA was also 
bisulfite treated and further used for the PCR. 
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2.2.6.3 Combined bisulfite restriction analysis (CoBRA) 
 
The CoBRA method allows the qualitative determination of the methylation status of the 
promoter region of a gene. The generated PCR product was subsequently digested with a 
restriction enzyme, which recognizes a palindromic sequence within a CG context. In this 
work, the restriction enzyme TaqI was used for the digestion both for ANKRD1 as well as 
for RASSF1A. The restriction site of this enzyme is TCGA. Thus the digestion can only 
take place if the CG of interest was methylated before the bisulfite treatment.  
 
For the CoBRA analysis, the PCR from the ivm DNA was used as positive control and as 
negative control, a mock digestion without enzyme was performed. In this study, 8.5 µl of 
the PCR product were used for the restriction digestion with TaqI and 8.5 µl of the PCR 
product was used for the mock digestion. The samples were digested at 65°C for 60 min. 
Thereafter, the CoBRA digest was analysed by gel electrophoresis on a 2% agarose gel. 
 
2.2.7 Agarose gel electrophoresis (AGE) 
 
Agarose gel electrophoresis is a molecular method for separating DNA fragments 
according to their molecular size. For the study, 1% and 2% agarose gels in Tris-Borate-
EDTA (TBE) buffer containing ethidium bromide for were used for the visualization of 
DNA and RNA fragments. Ethidium bromide intercalates with the nucleic acids and 
fluoresces under UV-light.  
 
1% gels were employed for RNA, genomic DNA, vector digests and preparative digests. 
2% gels served to analyse PCR products and the CoBRA fragments. The gels were run at 
200 volts for approx. 12-20 min. As molecular size standards, DNA ladders of 1 kb or 100 
bp ladder from Fermentas were used. 
 
2.2.8 Polymerase chain reaction (PCR) 
 
The polymerase chain reaction is a biochemical method to amplify a particular DNA 
sequence using specific primers, which are short DNA fragments complementary to the 
target region. PCR consists of three steps: denaturation, annealing and extension. During 
the denaturation, the double DNA strand melts open at 94°C to single stranded DNA to 
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initiate a new PCR cycle and to stop all enzymatic reactions from the previous cycle. In the 
second (annealing) step, the primers bind to the single stranded DNA template at the target 
region, thus the polymerase can attach to the template. The temperature of annealing is 
variable (50 to 62°C) and depends on the melting temperature of the primer set. The last 
step (extension) occurs at 72°C; this is the ideal working temperature for the polymerase at 
which it copies that part of the DNA template defined by the position of the forward and 
reverse primer.  
 
2.2.8.1 Reverse transcriptase PCR (RT-PCR) 
 
To analyse the expression of genes at the transcriptional level, the RNA isolated from the 
cells (as described in 2.2.5), was reverse transcribed into cDNA. For this purpose, 2 µg of 
RNA was digested with DNAse I to remove the remaining DNA and plasmid from a 
sample. For the digestion, the RNA samples were supplied with 1 µl DNaseI, 2 µl DNaseI 
buffer and 0.5 µl Ribolock and filled to a final volume of 20 µl with DEPC water. The 
digestion was performed at 37°C for 30 min, afterwards, the enzyme was inactivated at 
65°C for 10 min. 
 
For the subsequent RT-PCR, 1 µg of RNA was mixed with 5 µl MMLV buffer (5x), 8 µl 
dNTPs (2.5 mM), 1 µl oligodT (10 pmol/µl) and 1 µl hexamers (10 ng/µl). The conditions 
for the RT-PCR are described in Table 11. After 10 min incubation at 62°C, 0.5 µl MMLV 
reverse transcriptase was added to the samples, and further incubated at 42°C as indicated 
in Table 11. 
 
Table 11. Settings for RT-PCR. 
Temperature Time   
62°C 10 min  
Cool samples on ice 
  
Adding of 0.5 µl MMLV Reverse transcriptase and 
0.5 µl Ribolock 
42°C 60 min  
90°C 5 min  
4°C Pause  
 
Following the reverse transcription the cDNA was diluted 1:5. The generated cDNA was 
used as template for the semi- and quantitative real time PCR. 
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2.2.8.2 Semiquantitative PCR 
  
The semiquantitative PCR serves to determinate the expression of a gene in a qualitative 
form. In this study, the semiquatitative PCR was used to control the reverse transcription of 
RNA into cDNA, overexpressions and gene inductions. Furthermore, it was used to 
visualize the endogenous level of target genes and GAPDH. The expression level of the 
housekeeping gene GADPH was used as control and for the normalization of the gene 
expression of the target genes. The semiquantitative PCR products were analysed by 
agarose gel electrophoresis in a 2% TBE gel using a DNA ladder marker of 100 bp as size 
marker. 
 
The primers used here are the same as for the quantitative real time PCR. The annealing 
temperatures, the concentration of MgCl2, the number of cycles for the optimal 
visualization as well as the addition of formamide were determined and displayed in Table 
8 and in Table 12. The cycler conditions are annotated in Table 13. 
 
Table 12. Parameters for semiquantitative PCR (fill up with ddH2O for a final reaction volume of 25 µl). 
 
Gene 
 
Cycles 
 
10x NH4 
buffer  
in µl 
 
MgCl2 
(50mM) 
in µl 
 
Primer 
(10nM) mix 
in µl 
 
dNTPs 
(2.5mM) 
in µl 
 
Taq  
in µl 
 
Formamide 
in µl 
ANKRD1 34 2.5 1 2 2 0.5 0 
BAX 32 2.5 1.25 2 2 0.5 0 
CDKN1A 32 2.5 1.25 2 2 0.5 0 
CTGF 36 2.5 1 2 2 0.5 1 
GAPDH 23 2.5 0.75 2 2 0.5 0 
MDM2 30 2.5 1 2 2 0.5 0 
PUMA 29 2.5 1.5 2 2 0.5 1 
TP53 36 2.5 1.5 2 2 0.5 0 
TP73 39 2.5 1.5 2 2 0.5 1 
RASSF1A 34 2.5 0.75 2 2 0.5 1 
RASSF2 35 2.5 0.75 2 2 0.5 0 
RASSF3 30 2.5 0.75 2 2 0.5 0 
RASSF4 34 2.5 0.75 2 2 0.5 0 
RASSF5 33 2.5 0.75 2 2 0.5 0 
RASSF6 33 2.5 0.75 2 2 0.5 0 
YAP1 35 2.5 0.75 2 2 0.5 1 
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Table 13. Settings for semiquantitative PCR.  
Step Time Temperature 
Initial denaturation 5 min 95°C 
Denaturation 30 s 94°C  
Cycles: 
variable 
Annealing 30 s 60°C / 62°C 
Extension 30 s 72°C 
 4 min 72°C 
 
2.2.8.3 Quantitative real time PCR (qRT-PCR) 
 
Quantitative real time PCR (qRT-PCR) is a technique that is used to amplify and 
simultaneously quantify a target DNA molecule. The quantity can be either an absolute 
number of copies or a relative amount when normalized to DNA input or additional 
normalizing genes. For this study, the SYBR green from Life Technologies was used. The 
SYBR green intercalates with the DNA. After each cycle, the light emission of the SYBR 
green is measured, detected and obtained in the raw data.  
 
One qRT-PCR reaction sample consists of 5 µl SYBR, 2 µl ddH2O, 1 µl of 4 nM primer 
mix and 2 µl cDNA.  The primers used and the respective optimal temperatures are listed in 
Table 8. The qRT-PCR data were measured in triplicates in Rotor Gene 3000 from Corbett 
Research. The raw data were processed with the corresponding program using the 
comparative quantification between the samples. The calibrator for this quantification was 
the control sample transfected with empty vector. The raw data were normalized to the 
respective GAPDH expression and relative to the respective control sample (set to 1). The 
settings used for the qRT-PCR are described in Table 14. 
 
Table 14. Settings for qRT-PCR. 
Step Time Temperature 
Initial denaturation 5 min 95°C 
Denaturation 20 s 94°C  
Cycles: 
40 X 
Annealing 20 s 60°C / 62°C 
Extension 30 s 72°C 
 4 min 72°C 
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2.2.8.4 PCR for CoBRA  
 
For the methylation analysis by CoBRA, the promoter region of ANKRD1 and RASSF1A 
were amplified by PCR using the specific primers indicated in Table 7 and bisulfite 
converted DNA. The selectivity of PCR relies on the specificity of the primers. The primer-
design technique is important for improving the PCR product yield and for avoiding the 
formation of unspecific products. The primers used for CoBRA PCR were tested at 
different temperatures to define the optimal annealing conditions (Table 7). Their 
specificity for bisulfite DNA and not for genomic DNA was also verified.  
 
The CoBRA PCR reaction for ANKRD1 consist of 2.5 µl 10X NH4 buffer, 2 µl dNTPs (2.5 
mM), 1.75 µl of 50 mM MgCl2, 0.5 µl Taq DNA-Polymerase, 5 µl bisulfite DNA (300 ng), 
2 µl of 10 nM primer mix and 11.25 µl ddH2O. For RASSF1A, a seminested PCR was 
perfomed adding formamide to the reaction samples. The settings used for the thermocycler 
are described in Table 15. The amplifications were checked by agarose gel electrophoresis 
loading 5 µl of the PCR products onto a 2% TBE gel. Subsequently, the PCR products can 
be digested enzymatically as described in 2.2.6.3. After the TaqI digestion, the PCR 
fragments were analysed by agarose gel electrophoresis in a 2% TBE gel using a 100 bp 
DNA ladder as size marker. 
 
Table 15. Settings for CoBRA PCR. 
Step Time Temperature 
Initial denaturation 2 min 95°C 
Denaturation 20 s 95°C  
Cycles: 
45 X 
Annealing 20 s variable 
Extension 30 s 72°C 
Final extension 4 min 72°C 
 ∞ 4°C 
 
2.2.8.5 Mutagenesis PCR  
 
As previously described in 2.2.2, the vector mutagenesis was performed using the Quick 
Change Lightning Site-Directed Mutagenesis Kit and the mutagenesis PCR. Here the whole 
vector is amplified using the complementary mutagenic primers listed in Table 9 and the 
thermocycler settings from Table 16. 
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Table 16. Settings for mutagenesis PCR. 
Step Time Temperature 
Initial denaturation 2 min 95°C 
Denaturation 20 s 95°C  
Cycles: 
17 X 
Annealing 10 s 60°C 
Extension variable 68°C 
Final extension 5 min 68°C 
 ∞ 4°C 
 
 
2.2.9 Protein extraction 
 
For protein preparation, the cell lines were transfected beforehand in 10 cm plates at a 
confluence of 60-80% and incubated in as described in 2.2.3.1. Prior to the isolation, the 
cells were washed once with 1x PBS. For the whole cell lysis 0.5 - 1 ml (depending on the 
finally density and further uses) of cold lysis buffer with protease inhibitor mix was added 
to the cells. The cells were scraped off and transferred to a pre-cooled reaction tube. The 
cell lysates were incubated at 4°C in a rotation device for 30 min. To remove the cell 
debris, the lysates were centrifuged at 10000 rpm for 10 min at 4°C. Afterwards, the 
cleared cell lysates were used for the co-immunoprecipitation assays or denatured by 
adding of 2x Laemmli buffer and boiling at 95°C for 5 min. The rest of the lysate was 
stored at -80°C. 
 
Before freezing, the protein concentration was determined by Bradford assay using a 
standard curve with different dilutions of bovine serum albumin. 10 µg of denatured protein 
lysate was loaded per lane in a 10% SDS gel and further analysed by gel electrophoresis 
and western blotting. By protein denaturation, the SDS in the Laemmli buffer provides the 
samples with a negative charge and the β-mercaptoethanol disturbs the hydrogen bonds and 
disulphide bridges. 
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2.2.10 Co-Immunoprecipitation (Co-IP) 
 
The Co-Immunoprecipitation assays (Co-IPs) performed during this study were used to 
determine the protein-protein interaction between ANKRD1 and TP53 and MDM2. This 
method is based on immunoprecipitation to capture and purify a primary target (or antigen) 
as well as other secondary targets, which are bound to the primary target by native 
interactions.  
 
For this purpose, HEK293T cells were transiently transfected either with Flag-/GFP-empty 
vector or with Flag-/GFP-ANKRD1 (primary target). 72 h after transfection, the cells were 
lysed with 1 ml Flag lysis buffer for the Flag Co-IPs or with 200 µl RIPA lysis buffer 
(included in the GFP-Trap® kit) for the GFP Co-IPs. The lysate preparation was performed 
as previously mentioned by 30 min rotation at 4°C and a centrifugation step of 10 min at 
4°C. An aliquot of the cell lysate taken before the Co-IP was used as input to control the 
overexpression and the protein level of GAPDH, TP53 and MDM2. The enrichment of 
ANKRD1 with a Flag tag and the Co-IP of the interacting proteins were performed using 
agarose beads coupled with an anti-FLAG antibody. The immunoprecipitated GFP-
ANKRD1 and its interacting proteins were enriched using the GFP-Trap® system from 
ChromoTek. 
 
The anti-Flag and anti-GFP beads were equilibrated before adding to the protein lysates. 50 
µl of anti-Flag beads were washed twice with 1 ml cold 1x TBS and spun down at 4°C for 5 
s. The suspension with anti-GFP beads (25 µl) was equilibrated by washing three times in 
500 µl dilution buffer (included in the GFP-Trap® kit) and spun down at 2500 x g for 2 
min at 4°C as indicated in the manufacturer’s instructions. After equilibration, the beads 
were added to the pre-cleared cell lysates and incubated ON under constant rotation at 4°C. 
The following day, the anti-Flag beads were centrifuged and washed twice with cold 1x 
TBS as previously described. The anti-GFP beads were washed twice with 500 µl wash 
buffer (included in the GFP-Trap® kit) and centrifuged at 2500 x g for 2 min at 4°C. After 
the final wash step, the supernatant was completely removed and 30 µl Laemmli buffer 
were added to the beads. The input samples and the Co-IPs samples were denatured at 95°C 
for 5 min and further analysed by SDS-polyacrylamide-gel-electrophoresis and western 
blotting. 
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2.2.11 SDS-Polyacrylamide-Gel-Electrophoresis (SDS-PAGE) 
 
The SDS-Polyacrylamide-gel-electrophoresis (SDS-PAGE) technique serves to separate 
proteins according to their molecular weight. In this work, the SDS-PAGE together with 
western blotting were widely used, for example to determinate protein overexpression, 
endogenous protein levels, fusion proteins and to analyse the Co-IPs.  
 
The used SDS-Polyacrylamide gels consisted of a 4% stacking gel and of a 10% separation 
gel. The exact composition of the gels is indicated in Table 17. N, N, N', N'-
tetramethylethylenediamine (TEMED) and 10% ammonium persulfate (APS) were used for 
the polymerisation. For the electrophoresis, the chamber containing the gels was filled with 
1x SDS running buffer. Pre lane, 10 µg of denatured protein lysates were loaded in three 
technical triplicates. The electrophoresis was performed at a constant voltage of 120 V for 
80 min. Afterwards, the SDS gels containing the proteins were used for the western blot. 
 
Table 17. SDS-Polyacrylamide gel composition (for 2 gels). 
Components Stacking gel (4%) Separating gel (10%) 
ddH2O 6.1 ml 4.1 ml 
Acrylamide 1.3 ml 3.3 ml 
Stacking gel buffer 
0.5M Tris HCl pH 6.8 
2.5 ml - 
Separating gel buffer 
1.5M Tris HCl pH 8.8 
- 2.5 ml 
10% SDS 100 µl 100 µl 
10% APS 50 µl 50 µl 
TEMED 5 µl 10 µl 
 
2.2.12 Western blot 
 
The separated proteins were transferred by wet blotting onto a PVDF membrane from 
Amersham for the subsequent immunodetection with antibodies. Before the transfer, the 
membrane was activated with methanol for 10 s and equilibrated in transfer buffer (1x) for 
20 min. The western blot chambers were filled with transfer buffer (1x). The transfer was 
performed by 350 mA for 2 h at 4°C.  
 
The proteins on the PDVF membrane were detected with specific antibodies (see Table 1). 
The non-specific binding of antibodies was avoided by prior blocking with 3% skimmed 
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milk powder in 1x TBS-T for 1 h. The blocked membrane was cut according to the 
molecular weight of the proteins to be investigated using the prestained page rule size 
markers of Fermentas as reference. The membrane fragments were incubated ON with the 
respective antibody dilution (in 3% skimmed milk powder in 1x TBS-T, see Table 1) at 
4°C under constant rotation.  
 
Next day, the membranes were washed three times with 1x TBS-T for 5 min at 4°C. 
Thereafter, the membranes were incubated for 1 h at 4°C with the corresponding HRP-
labeled secondary antibody. The membranes were then washed three times for 5 min with 
1x TBS-T. The individual membrane fragments were scanned in the Versadoc scan system 
of BioRad using the ECL kit from Immobilon Western for the detection of HRP activity 
from the secondary antibody. The imaging data of the three technical samples were further 
analysed for the statistical analysis. The protein amount detected on the membranes was 
quantified using the ImageJ software. For this propose, the intensity of each individual 
protein band was measured taking into account areas of identical size and the light 
intensity. The background of the membrane fragment was also determined and subtracted 
from the total measured protein intensity. Thus, the values (after background substraction) 
were normalized to the respective GAPDH level and protein level on the control sample. 
The mean and standard deviation were obtained from the biological replicates as indicated 
in figure 19 and figure 26. 
 
2.2.13 Fluorescence-activated cell sorting (FACS) 
 
In this study, cell cycle analysis and the cell sorting by FACS was performed in 
cooperation with the FACS core facility of the Institute of Clinical Immunology of the 
University of Giessen. 
 
The flow cytometry technique allows the fluorescence measurement of individual cells. In 
this method, a beam of monochromatic light is directed onto a hydrodynamically focused 
stream of fluid. Each suspended particle or cell passing through the beam scatters the ray 
and produces a fluorescent mark (in this case GFP). The emitted light has a longer 
wavelength than the light source. The detectors use the combination of scattered and 
fluorescent light for the analysis of fluctuations in brightness, which deliver information 
about the physical and chemical structure of each individual particle. The fluorescence-
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activated cell sorting or FACS is an advanced technique that combines the flow cytometry 
analysis and cell sorting, in which the single cells are detected and separated according to 
their specific fluorescence signal. 
 
2.2.13.1 Flow cytometry 
 
 
To analyse the cell cycle distribution, the YAP1-inducible TREx293 cells were transfected 
in 10 cm plates (density of 70-80%) as described in 2.2.3.1 with one of the following 
vectors:  GFP-empty vector, YFP-empty vector, YFP-RASSF1A, GFP-RASSF1A, YFP-
RASSF2, YFP-RASSF3, YFP-RASSF4, YFP-RASSF5, YFP-RASSF6, or with YFP-MST1 
and YFP-MST2 (2 x 10 cm plates for each transfection). Eight hours post transfection, the 
cell medium was changed to DMEM. The following day, the YAP1 induction with Dox 
(2µg/ml) was started in one set of the samples and after 72 h induction, the cells were fixed 
and prepared for flow cytometry.  
 
To avoid the loss of dead cells, the detached dead cells and the living cells from the plate 
were transferred to a 15 ml tube and pelleted at 1500 rpm for 3 min. Thereafter, the cells 
were washed twice in 5 ml 1x PBS. The cells were resuspended in 1.5 ml 1x PBS to obtain 
single cells. Using a vortexer (lowest level), 3.5 ml ice-cold 100% EtOH were added 
dropwise. The cell fixation with EtOH was performed with an ON incubation at -20°C. 
 
The following day, the fixed cells were pelleted at 1500 rpm for 3 min and washed twice in 
1x PBS. To avoid the intercalation of propidium iodide with the dsRNA, RNaseA (5 µg/ml) 
was added to the samples and incubated at 37°C for 30 min. After the RNAseA digestion, 
the cells were analysed. For this purpose, 100 µl cells were transferred to a FACS tube and 
supplemented with 5 µl propidium iodide. Depending on the amount of cells, this mix was 
diluted with 1x PBS; the volume of propidium iodide was also adjusted accordingly. The 
red fluorescence emitted by propidium iodide possesses a different wavelength than YFP, 
therefore allowing the differentiation of both. The transfected cells are gated according to 
their DNA content (sub G1, G0/G1, S, M phase). The measurements were performed using 
the BD FACSCanto with the following settings: to measure the diffraction at a flat angle, 
forward scatter was adjusted at FCS = 220 mV.  To determine the granularity of the cells, 
the size and structure of the nucleus, the side scatter was adjusted at SSC = 319 mV. The 
detection of the transfected cells occurred via the FITC channel (= 280 mV). For the 
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measurement of the DNA content the PE channel was set at 330 mV. The gates were 
selected to enclose the transfected cells. Afterwards the data were processed using the 
software: BDFacsDivaTM Version 6.1.3. 
 
2.2.13.2 Fluorescence-activated cell sorting  
 
The RNA used for the microarrays was isolated from the YAP1-inducible TREx293 cells, 
which were sorted beforehand for GFP transfected cells. For this purpose, the YAP1-
inducible TREx293 cells were seeded in 10 cm plates. Next day, the cells were transfected 
at a density of 70% either with 10 µg GFP-empty vector or GFP-RASSF1A (2 x 10 cm 
plates for each transfection). Six hours after transfection, the cell medium was changed to 
DMEM. The following day (24h after transfection), the YAP1 induction with Dox (2µg/ml) 
was started in one plate transfected with GFP-empty and in one plate transfected with GFP-
RASSF1A. The other two plates were treated with water as mock induction. After 72 h 
induction of YAP1, the four transfected cell plates were prepared for sorting. For that, the 
cells were washed twice with 1x PBS and trypsinized. Afterwards, the cells were 
resuspended in DMEM medium to inactivate the trypsin and were transferred to a 15 ml 
dark tube. The cells are pelleted at 1500 rpm for 3 min and washed twice in 10 ml 1x PBS, 
since the phenol red color of the DMEM media can disturb the sorting. Thereafter, the cells 
were resuspended in 10 ml sorting medium, which contains cold 1x PBS with 1mM EDTA 
and 25mM HEPES. In this condition, the dark tubes with the samples were transported on 
ice to the FACS core facility. Before sorting, the cells were sterile filtered in the sorting 
medium using cell filters with pores of 40 µm.  
 
The living cells were sorted at 4°C in the BD Biosciences FACS Aria III flow cytometer. 
The optimization of the experiment was performed together with the personal of the core 
facility. The settings used for the sorting are listed in Table 18. 
 
One million living cells with a positive GFP signal were sorted and collected in a new 15 
ml tube containing DMEM media. The purity of the GFP signal from the sorted cells was 
analysed after sorting as shown in appendix 2. Immediately after the verification of the 
GFP purity, the cells were pelleted at 1500 rpm for 3 min at 4°C. The supernatant medium 
was discarded and the cells were lysed with 1 ml TRIzol and stored at -20°C for the further 
RNA isolation next day. 
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   Table 18. Settings for cell sorting. 
Parameter Setting Parameter Setting 
Frequency 47.1 Phase mask 0 
Amplitude 24.8 Single cell Off 
Phase 0 Sweet spot On 
Drop delay 27.65 Frist drop 207 
Attenuation off Plates voltage 5,000 
Precision 0-16-0 Voltage centering 85 
Yield mask 0 Sheath pressure 45.00 
Purity mask 16   
 
 
2.2.14 Microarrays 
 
The microarray analyses were performed in collaboration with the AG Boettger of the Max 
Planck Institute in Bad Nauheim.   
 
The microarrays were used to find those genes with differential expression after YAP1 
induction and RASSF1A overexpression compared to corresponding control and uninduced 
cells. The microarrays used for this propose were the HuGene version 2.0 ST arrays from 
Affymetrix, which cover the whole transcriptome and include probes to measure both 
messenger RNAs and long intergenic non-coding RNA transcripts. 
 
For the microarrays, 250 ng of RNA from the sorted cells with a GFP signal (described in 
2.2.13.2) was isolated as described in 2.2.5. The sample labelling and hybridisation were 
performed by the AG Boettger using the Affymetrix® GeneChip WT terminal labeling and 
controls reagent kit according to the manufacturer’s instructions. Colleagues of AG 
Boettger also performed the data extraxtion and normalization using the software and the 
probes library from Affymetrix. 
 
To find the potential target genes, which are differently expressed after YAP1 induction 
and RASSF1A expression, the obtained relative gene expression levels were normalized to 
the expression of microarray internal controls. The differentially expressed up- and 
downregulated genes were found by normalization of the samples with YAP1 induction 
and RASSF1A expression in relationship to the control cells. Thus, the relative gene 
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expression from the samples: GFP/YAP1 ind.; RASSF1A/unind. and RASSF1A/YAP1 
ind., were normalized relative to the control sample, which are the cells transfected with 
GFP empty and without induction of YAP1 (GFP/ unind. cells). After the normalization, 
the samples were sorted by descending differential expression of the cells with a YAP1 
induction and RASSF1A expression relative to the control cells without YAP1 induction 
and without RASSF1A (GFP/ unind. cells). The top 10 differential up- and downregulated 
genes (without miRNAs and pseudogenes) are listed in Table 19. The unbiased analysis of 
the top differential up- and down-regulated genes is listed in Table 21 and Table 22 
(appendix 5 and 6). 
 
2.2.15 Fluorescence microscopy  
 
In this study, the localization of YAP1 in the presence of RASSF1A was analysed by 
fluorescence microscopy using overexpression constructs both for GFP-RASSF1A and 
mCherry-YAP1 or mCherry-YAP1 point mutations. HEK293T cells were seeded on sterile 
coverslips on 6-well plates. The following day, the cells were co-transfected at a density of 
20% with the corresponding mCherry and GFP constructs. Six hours after transfection, the 
media were changed to DMEM and the cells were incubated for another 2 days. The third 
day, the cells were washed twice with 1x PBS and fixed for 15 min by cold 3.7 % 
formaldehyde. The cells were washed three times with 1x PBS and subsequently 
permeabilized with cold 0.2% Triton X followed by three wash steps with 1x PBS. 
Afterwards, the nuclear staining was performed with freshly prepared DAPI (1 mg/ml) by 
an incubation for 5 min. The cells were briefly washed three times with 1x PBS. For the 
mounting, the coverslips are flipped onto a slide with a drop of Mowiol. The images were 
captured using the 63X zoom lens of Axio Observer.Z1 microscope from ZEISS with a 
camera Orca-ER HAMAMATSU and Volocity software. In addition, n =100 co-transfected 
cells were analysed in more detail and counted for the corresponding statistical analysis.  
 
From each co-transfection, the nuclear morphology of 100 cells was analysed using the 
DAPI staining and sorted in these three categories: entire nucleus, deformed or apoptotic. 
The localization of the mCherry signal was also analysed using the function “navigation” 
from the Volocity software, in which the individual channels can be set on or off and the 
light intensity can be changed, without affecting the original picture. The localization of the 
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mCherry signal was determinated in the same 100 cells as for the nuclear morphology and 
it was sorted in the following two categories: “mCherry signal in the cytosol and nucleus”, 
and “mCherry signal in nucleus”. The GFP signal was characterised by the localization 
either in the whole cell or at the microtubules as fusion protein with RASSF1A.   
 
2.2.16 Statistical analysis 
 
The statistical and correlation analyses were performed using R (version 6.3), a 
programming language for creating graphics including linear and nonlinear modeling, 
classic statistical tests, time-series analysis, classification and clustering.  
 
The bar graphs showed in this work were produced in Excel. Unless otherwise indicated, 
the graphs present the means of biological triplicates ± standard deviation. The p-values 
were quantified using R by Student’s unpaired t-test, with the assumption that the data are 
distributed normal and the zero hypothesis is true. The differences were considered 
significant if p < 0.05. The correlation data were performed by simple linear regression 
analysis in R. The p-values were calculated with the corresponding t-test for the regression 
coefficients and were considered as significant if p < 0.05. The Chi square test was used to 
analyse the significance of the observed differences from the flow cytometry data. The 
statistical test was performed assuming that the data are chi-squared distributed and the 
zero hypothesis is true. 
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3. RESULTS 
 
The Hippo pathway regulates the organ size and plays an important role in both 
proliferation and apoptosis (Edgar, 2006; Harvey et al., 2013). The function of the Hippo 
signalling in cancer is still controversial, since it is regulated by the tumor suppressor 
RASSF1A but the main downstream co-activator is YAP1, which is an oncogenic protein 
(Kang et al., 2011). In addition, YAP1 regulates the expression of both pro-proliferative 
genes as well as of tumor suppressor genes by binding e.g. to the TEADs or TP73 
transcription factors (Basu et al., 2003; Wang et al., 2016; Wang et al., 2010).  
 
According to various studies, RASSF1A is known to be epigenetically inactivated in several 
types of cancers (Dammann et al., 2000; Richter et al., 2009; Schagdarsurengin et al., 
2003). The genomic amplification of YAP1 in cancer cells and the further silencing of 
RASSF1A by promoter hypermethylation might contribute to cellular instability and 
tumorigenesis. The main focus of this study was to dissect the role of RASSF1A in the 
cellular function of the YAP1 signalling and its deregulation in cancer. 
 
3.1 Role of RASSF1A in the Hippo pathway 	  
3.1.1 RASSF1A regulates the expression of YAP1 target genes  
 
In order to investigate the effect of RASSF1A on the regulation of the Hippo pathway, the 
expression of the potential YAP1 target genes, namely ANKRD1, CTGF, BBC3, CDKN1A 
and BAX (Fig. 5) were analysed by qRT-PCR 72h after transfection of YAP1 and 
RASSF1A in HEK293T cells. YAP1 is well known to induce the expression of CTGF 
(Zhao et al., 2008); for this reason, the upregulation of CTGF was used as control for the 
functional activity of YAP1.  
 
The potential target genes such as BAX, CDKN1A, and BBC3, which were previously 
reported to be involved in the pro-apoptotic signalling of the Hippo Pathway, did not 
exhibit an obvious deregulation after the co-transfection of RASSF1A and YAP1 as 
checked by semiquantitative PCR (Fig. 5A). YAP1 significantly increased the expression 
of CTGF and ANKRD1 (Fig. 5B-5C). However, compared to YAP1 overexpression, the 
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expression of ANKRD1 increased further after the co-transfection of RASSF1A and YAP1 
(Fig. 5A-5C). ANKRD1 is known to be a target gene of YAP1 (Li et al., 2013). The 
increase in ANKRD1 expression after co-transfection of both RASSF1A and YAP1 was up 
to 4-fold compared to the control (p-value 0.007) and up to 2-fold more than the 
upregulation with YAP1 alone (p-value 0.04) (Fig. 5C). 
                             A) 
 
B)               C) 
Figure 5: Induction of ANKRD1 and CTGF in HEK293T cells. A) Semi-quantitative PCR of YAP1 target 
genes (CTGF, ANKRD1, BAX, CDKN1A, BBC3) and controls (RASSF1A, YAP1 and GAPDH) 48h and 72h 
after transfection in HEK293T cells. Ctrl: Flag-empty vector; RASSF1A: Flag-RASSF1A; YAP1: Flag-YAP1 
B) Quantitative analysis of CTGF expression level in HEK293T cells transfected with Ctrl empty plasmid, 
YAP1 and/or RASSF1A plasmid. Expression was analysed by qRT-PCR, normalized to GAPDH and control 
transfection was set to 1. C) Quantitative analysis of ANKRD1 level by qRT-PCR. p-values: * p<0.05, ** and 
p<0.01 (t-test). 
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3.1.2 Characterisation of the YAP1-inducible cell line 
 
The transient transfection of YAP1 and the co-transfection with RASSF1A resulted in a 
significant induction of ANKRD1 expression. In order to validate the previous findings and 
to obtain a more precise idea on the regulation events, YAP1 was stably transfected into a 
tetracycline inducible TREx293 cell line, also known as Tet-On inducible system. The 
TREx293 cells were cultivated in DMEM medium containg 10% tetracycline-free serum. 
The expression of YAP1 was activated by adding doxycycline (Dox). Control cells were 
also created, in which the empty vector was stably transfected and used to analyse the 
expression of the YAP1 target genes in a system with endogenous YAP1 expression (Fig. 
6A). Here, the expression of YAP1, ANKRD1, BAX, CDKN1A and BBC3 was unaffected in 
the Dox-treated TREx293 control cells (Fig. 6A). In addition, 12 individual clones and a 
pool of YAP1 clones were generated and further characterised. The pool of YAP1-
inducible TREx293 cells displayed a high sensitivity to Dox, which allowed the induction 
of YAP1 and its target gene ANKRD1 even with a low concentration of Dox (Fig. 6B). 
A)       
 
B) 
                          
Figure 6: Analyses of expression of YAP1 and target genes in the control TREx293 cells and in the 
YAP1-inducible TREx293 cell line pool after induction with Dox. A) Expression of YAP1, ANKRD1, 
BAX, CDKN1A and BBC3 in control TREx293 cells transfected with control plasmid (pcDNA4TO) 24h after 
transfection and Dox induction (2 µg/ml). B) Induction of YAP1 and upregulation of target genes after YAP1 
induction by indicated Dox dilutions in the YAP1-inducible TREx293 pool of clones. 
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The expression of YAP1 in the 12 individual clones varied between 5- up to 40-fold after 
the YAP1 induction with Dox relative to the samples without induction and after 
normalization to GAPDH (Fig. 7A).  
 
A) 
	  
B) 
 
C) 
 
 
Figure 7: Expression of YAP1 target genes in the individual YAP1-inducible clones. A) Relative YAP1 
level was analysed by qRT-PCR in YAP1-inducible TREx293 individual clones 24h after induction with Dox 
(2 µg/ml) compared to uninduced cells (Ctrls: set at 1) B) Relative expression of CTGF and ANKRD1 after 
24h induction of YAP1 compared to uninduced cells. C) Relative expression of BAX, CDKN1A and BBC3 
24h after induction of YAP1 compared to uninduced cells. All values are relative to GAPDH expression and 
to the control cells without YAP1 induction (Ctrls=1). D) Correlation analysis of the relative YAP1 expression 
with ANKRD1, CTGF, BAX, BBC3 and CDKN1A expression of the 12 different YAP1-inducible TREx293 
clones and their respective p-values. Analyses performed using the software “R”. 
0	  
5	  
10	  
15	  
20	  
25	  
30	  
35	  
40	  
45	  
Ctrls	   Y25	   Y14	   Y27	   Y29	   Y16	   Y21	   Y6	   Y18	   Y4	   Y26	   Y22	   Y11	  
re
la
*v
e	  
ex
pr
es
sio
n	  
	  o
f	  	  
YA
P1
	  	  
0	  
5	  
10	  
15	  
20	  
25	  
Ctrls	   Y25	   Y14	   Y27	   Y29	   Y16	   Y21	   Y6	   Y18	   Y4	   Y26	   Y22	   Y11	  
re
la
*v
e	  
ex
pr
es
sio
n	  
	  
CTGF	  
ANKRD1	  
0	  
1	  
2	  
3	  
Ctrls	   Y25	   Y14	   Y27	   Y29	   Y16	   Y21	   Y6	   Y18	   Y4	   Y26	   Y22	   Y11	  
re
la
*v
e	  
ex
pr
es
sio
n	  
BAX	  
CDKN1A	  
BBC3	  
 
D) 
 
 
 
 
 
	   	   Results	  
62	  	  
All induced clones showed an increase in the expression of ANKRD1 and CTGF after YAP1 
induction (Fig. 7B); furthermore, the expression levels of BAX, CDKN1A and BBC3 
correlated with YAP1 expression (Fig. 7C-D). The clones with higher YAP1 expression 
showed an increase in BAX, CDKN1A and BBC3 expression, while, the clones with a 5- to 
10-fold YAP1 induction showed a reduction in the expression of BAX, CDKN1A and BBC3. 
The correlation data in figure 7D indicate a significant correlation between YAP1 
expression and ANKRD1 (p-value 0.02), CTGF (p-value 0.01), BAX (p-value 0.001), and 
BBC3 expression (p-value 0.002). The correlation between YAP1 and CDKN1A is not 
significant but the expression of CDKN1A showed the same tendency as BAX and BBC3 
with exception of clone Y25 (Fig. 7C).  
 
The protein level of YAP1 at the individual clones was analysed by western blotting using 
the lysates from the same cells used for the expression analyses in figure 7. A lysate of the 
pool of clones was used as control, to compare the protein level of the individual clones 
(see Fig. 8).  
 
 
Figure 8: YAP1 protein level in the individual YAP1-inducible TREx293 clones after induction with 
Dox. Western blot analysis of YAP1 and GAPDH level in the cell lysates from the individual clones and pool 
of clones (YPool). The expression of YAP1 was induced with Dox (2 µg/ml) (+) for 24h. 10 µg of protein 
was loaded per lane in a 10% SDS gel, separated by SDS-PAGE and analysed by western blot on PVDF 
membrane. Experiment performed together with M.Sc. A. Traum. 
	   	   Results	  
63	  	  
Figure 8 indicates that the pool of clones expressed the highest protein level of YAP1 
compared to the individual clones; interestingly, all four western blots displayed this result. 
The YAP1 protein level of the individual clones in figure 8 did no correlate with the 
expression data indicated in figure 7; therefore the subsequent experiments were performed 
using the pool of clones. The level of endogenous ANKRD1 protein could not be analysed 
due to the lack of an adequate antibody. 
 
3.1.3 YAP1 downregulates the expression of tumor suppressor genes 
 
To achieve a homogenous effect of YAP1 induction and to avoid clonal differences, the 
pool of clones was used for the further characterisation. Dox treatment of the YAP1-
inducible cells resulted in a 12-fold increase YAP1 mRNA level (Fig. 9A); furthermore, a 
significant increase in CTGF and ANKRD1 expression was observed (Fig. 9B; 3.2-fold and 
3.3-fold, respectively). Interestingly, the induction of YAP1 also resulted in a significant 
decrease in the expression of tumor suppressor genes: RASSF1A (decreased by 48%), TP53 
(29%), BAX (24%), CDKN1A (33%) and BBC3 (27%), as indicated in figure 9B. 
 
A)                B) 
 
Figure 9: YAP1 induction reduced the expression of tumor suppressor genes. A. Relative expression of 
YAP1 in TREx293 pool of clones 24h after induction with Dox (2 µg/ml) (YAP1 ind.) compared to uninduced 
cells (unind.) B. Relative expression of ANKRD1, CTGF, RASSF1A, TP53, BAX, CDKN1A and BBC3 after 
24h induction of YAP1 with Dox (YAP1 ind.) compared to uninduced cells (unind.). The data were 
normalized to GAPDH expression. The value for the uninduced cells was set 1. p-values: * p<0.05, ** p<0.01 
and *** p<0.001 (t-test). 
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3.1.4 RASSF1A neutralizes the oncogenic potential of YAP1 and induces cell cycle 
arrest  
 
To further analyse the effect of RASSF1A on the function of YAP1, the inducible YAP1 
TREx293 pool of cells was transfected with GFP or GFP-RASSF1A. The expression of 
RASSF1A and the induction of YAP1 were confirmed on protein level by western blotting 
as indicated in figure 10A; in addition, the cell cycle distribution was analysed by flow 
cytometry 72h after transfection of RASSF1A and induction of YAP1 (Fig. 10B).  
 
The flow cytometry analysis revealed that after 72h, YAP1 (GFP/YAP1 ind.) produces a 
cell accumulation in the S-phase compared to the uninduced cells (GFP/unind.; p-value< 
0.00001) (Fig. 10B). In contrast, RASSF1A (RASSF1A/unind.) produced a cell 
accumulation in the G0-G1 phase compared to the control uninduced cells (GFP/unind.) 
(Fig. 10B). Moreover, RASSF1A (RASSF1A/YAP1 ind.) abolishes the S-phase induction of 
YAP1 (GFP/YAP1 ind.) and increases the cell number in the G0-G1 phase (Chi-square test 
p<0.001) (Fig. 10B). 
   A)               B) 
     
                         	  
 
Figure 10: Cell cycle distribution after induction of YAP1 and RASSF1A transfection. A) Western blot 
of YAP1 in TREx293 cells 72h after transfection of GFP-empty or GFP-RASSF1A with and without 
induction of YAP1 with Dox (2 µg/ml). 10 µg of protein were loaded per lane and separeted on a 10% SDS 
gel and afterwards blotted onto PVDF membrane. B) Flow cytometry analysis of YAP1-inducible TREx293 
cells transfected with GFP-empty or GFP-RASSF1A (104 transfected cells) after 72h with or without 
induction of YAP1. The cell cycle distribution was analysed by flow cytometry using propidium iodide 
staining.  
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As previously indicated, YAP1 displays its oncogenic potential by repression of the TP53 
target genes and of RASSF1A (Fig. 9B) and by induction of the S-phase (Fig. 10B). The 
suppressive effect of YAP1 on these genes was subsequently validated by promoter assays 
in HEK293T cells as shown in figure 11. The luciferase constructs with the individual 
promoter regions of CDKN1A, BAX, MDM2, RASSF1A and a synthetic vector with 13 
TP53 target sites were sequenced and their activity verified after expression of TP53,	  TP73 
and ∆Np73 (Fig. 11A). The activity of the RASSF1A promoter was verified after 
transfection of Myc and Max (Fig. 11C), since both transcription factors bind to the 
RASSF1A promoter (Charlet et al., 2014). 
 
In the YAP1-inducible TREx293 cells, the induction of YAP1 resulted in a decrease in the 
promoter activity of TP53 target site (28%; p-value < 0.001), CDKN1A (18%; p-value 
<0.0001), BAX (7%; p-value 0.02) and MDM2 (28%; p-value 0.03) (Fig. 11B). The activity 
of the RASSF1A promoter was also significantly reduced (25%; p-value 0.01) after YAP1 
transfection in HEK293T cells (Fig. 11C). To characterise the effect of RASSF1A on the 
YAP1 target genes, further promoter assays were performed in the YAP1-inducible 
TREx293 cells after expression of RASSF1A with and without induction of YAP1 (Fig. 
11B). Here, RASSF1A neutralized the inhibitory effect of YAP1 on the promoters and 
activated the promoter activity of TP53 target site (28% increase; p-value 0.01), BAX 
(23%; p-value 0.005) and CDKN1A (34%; p-value 0.002) compared to the YAP1 induction 
(Fig. 11B).  
 
To date there is no published indication for the regulation of RASSF1A by YAP1. Since 
YAP1 activates tumor suppressor genes (BBC3) together with TP73 (Matallanas et al., 
2007), the effect of YAP1 and TP73 on the RASSF1A promoter was further analysed by 
promoter assays both in HEK293T cells as well as in the YAP1-inducible TREx293 cells 
(Fig. 11C). As previously mentioned, the expression of YAP1 significantly repressed the 
promoter activity of RASSF1A in HEK293T cells by 25% (p-value 0.01). The induction of 
YAP1 in the TREx293 cells also resulted in a decrease of 16% (p-value 0.06) on the 
promoter activity of RASSF1A (Fig. 11C). In contrast to YAP1, TP73 significantly 
enhanced the promoter activity of RASSF1A (1.9-fold; p-value 0.05). The RASSF1A 
repression by YAP1 was also observed after co-expression of YAP1 with RASSF1A (45%; 
p-value 0.03) as well as after co-expression of YAP1 with TP73 (67%; p-value 0.04). The 
∆Np73 isoform did not affect the promoter activity of RASSF1A (Fig. 11C). 
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 A) 
 
B)	  	  
 
 
C)  
 
 
Figure 11: Promoter assays of YAP1 and TP53 target genes. A) Control promoter assays of BAX, 
CDKN1A, MDM2 and synthetic TP53 target sites after transfection of TP53, TP73 and ∆Np73 in HEK293T 
cells. B) Firefly luciferase activity at the BAX, CDKN1A, MDM2 and TP53 target sites promoters in the 
YAP1-inducible TREx293 cells after expression of CMV empty vector or RASSF1A and YAP1 induction 
(YAP1 ind.) or without induction (unind.). Control vector pGL2 empty. C) Renilla luciferase activity of 
RASSF1A promoter after transfection of control vector pRL-null empty, RASSF1A, YAP1, TP73 or ∆Np73 
and the corresponding co-transfection with YAP1 in HEK293T cells or in TREx293 cells with or without 
YAP1 induction. Myc and Max were used as positive control (1:1). The data were normalized to the renilla 
luciferase (B) or firefly luciferase activity (C) and to the empty vector (set to 1). p-values: * p<0.05, ** 
p<0.01 and *** p<0.001 (t-test). 
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3.1.5 RASSF1A triggers the translocation of YAP1 into the nucleus 
 
The effect of RASSF1A on the intracellular YAP1 localization is still controversial in the 
literature. RASSF1A activates the MST/LATS kinase cascade to phosphorylate YAP1 at 
five serine sites (Zhao et al., 2010a). Few reports have demonstrated that the 
phosphorylation of YAP1S127 is involved in nuclear translocation (Matallanas et al., 2007). 
Other authors reported this phosphorylation site as essential for the cytoplasmatic retention 
and the further degradation of YAP1 (Zhao et al., 2007). To further investigate the cellular 
localization of YAP1 and the effect of RASSF1A on this localization, mCherrry-YAP1 
constructs with point mutations at serine 127 (S127A and S127E) were created and 
compared to YAP1 wild type. For this purpose, the mCherry-YAP1 constructs (wild type 
or YAP1S127 mutants) were co-transfected with GFP-RASSF1A in HEK293T cells and 
analysed by microscopy after 72h (Fig. 12A). These data are also represented in figure 
12B-C after quantification of the YAP1 localization and the nuclear morphology of 100 
transfected cells. 
 
Figure 12A indicates that the expression of GFP empty and mCherry empty is distributed 
all over the cell, both in the nucleus and in the cytosol. RASSF1A was located at the 
cytoskeleton binding to the microtubules (Fig. 12A). In 74% of the cells, wild type YAP1 
was predominantly located in the cytosol. In 26% of the cells, YAP1 was located in both 
the nucleus and the cytosol (Fig. 12A-B). In contrast to the wild type, both YAP1 mutants 
were predominantly located in the nucleus, namely in 67% of the cells transfected with the 
YAP1S127A, and 78% of the cells transfected with the YAP1S127E mutant (Fig. 12A-B). The 
most important observation in this part was that RASSF1A increased the translocation of 
YAP1 wild type into the nucleus by 37% compared to control cells without RASSF1A 
(Fig. 12A-B). Moreover, RASSF1A increased the nuclear localization of the YAP1 
mutants: 18% increase in translocation in YAP1S127A mutant and 14% increase in 
YAP1S127E mutant compared to the control cells without RASSF1A. The morphology of the 
nucleus was also analysed and quantified (Fig. 12C). Here it was observed that the nuclear 
morphology of the cells with YAP1 wild type was comparable to the mCherry empty 
control. The YAP1 mutants showed an increased number of deformed nuclei compared to 
the mCherry control. Also an increase of 5.6% of the mitotic cells was observed in cells 
with YAP1 wild type and of 4.4% in the cells with YAP1S127A. Furthermore, figure 12C 
indicates that the expression of RASSF1A produced an increase of deformed nuclei and 
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inhibition of mitosis, especially after co-transfection with YAP1 wild type. In summary, we 
observed that RASSF1A increased the nuclear translocation of YAP1, repressed mitosis 
and increased the number of deformed nuclei (Fig. 12A-C). The localization of the 
phosphorylation mutant YAP1S127A  and mimicking mutant YAP1S127E was predominantly 
nuclear. RASSF1A increased the nuclear localization of both YAP1 mutants and inhibited 
mitosis (Fig. 12A-C).  
A) 
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B)   
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Figure 12: Cellular localization of YAP1 and RASSF1A mediated nuclear translocation. HEK293T cells 
were co-transfected with mCherry-YAP1 wild type or YAP1S127 mutants with GFP-RASSF1A or with the 
corresponding control plasmids. 72h after transfection, the cells were fixed by formaldehyde and 
permeabilized using Triton X; the cell nucleus was stained with DAPI and analysed by fluorescence 
microscopy (magnification of 63X and oil immersion). Via microscopy images, the mCherry localization and 
nuclear morphology of 100 cells were analysed and quantified using the software Volocity and the inverse 
microscope Axio Observer.Z1. A) Microscopy images of HEK293T cells after co-expression of GFP-empty 
or GFP-RASSF1A together with mCherry-empty or mCherry-YAP1 wild type or YAP1S127 mutants. B) 
Quantification of the cellular localization of mCherry-empty and mCherry-YAP1 wild type or YAP1S127 
mutants after RASSF1A co-transfection. C) Quantification of nuclear morphology after GFP-RASSF1A co-
transfection with mCherry-YAP1 wild type or YAP1S127 mutants (n=100 cells).  
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3.1.6 Microarray data confirm the upregulation of ANKRD1 by YAP1 and RASSF1A 
and reveal novel target genes 
 
In order to identify novel YAP1 targets, which are regulated by RASSF1A and are involved 
in the cell cycle arrest or the apoptosis described above, we performed expression analyses 
by microarrays using the YAP1-inducible TREx293 pool of clones. Therefore, the cells 
were transfected with GFP or GFP-RASSF1A and with or without YAP1 induction and 
sorted for GFP positive cells. The RNA from 106 million sorted cells was analysed by 
microarrays (appendix 2). The protein level and expression of YAP1 and RASSF1A in 
these cells are plotted in figure 13.  
                      A) GFP	   +	   +	   -­‐	   -­‐	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   -­‐	   -­‐	   +	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Figure 13: Microarray analysis. The YAP1-inducible TREx293 cells were transfected with GFP-RASSF1A 
or GFP control plasmid. After 72h, with or without induction of YAP1 by Dox (2 µg/ml), the cells were 
sorted for GFP positive cells; 250 ng RNA were analysed by microarrays. A) Western blot analysis of 
MDM2, BAX, TP53, YAP1 and GAPDH in the YAP1-inducible TREx293 cells used for the microarrays 
before sorting by FACS. 10 µg of protein were loaded and separated on a 10% SDS gel and afterwards 
blotted onto PVDF membrane. B) Relative expression of YAP1 and RASSF1A in TREx293 cells obtained by 
microarrays after normalization to GAPDH. The expression levels in control cells (GFP/unind.) were set 1. 
GFP/unind.: GFP without YAP1 induction; GFP/YAP1 ind.: GFP with YAP1 induction; RASSF1A/unind.: 
GFP-RASSF1A without YAP1 induction; RASSF1A/YAP1 ind.: GFP-RASSF1A with YAP1 induction.  
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The protein levels of RASSF1A, YAP1, TP53, BAX and MDM2 in the cells used for the 
sorting and microarrays were confirmed by western blotting (Fig. 13A). Here, a diminution 
of the MDM2 level was observed in the cells transfected with RASSF1A and YAP1 
induction. Figure 13B shows the expression of RASSF1A and YAP1 in the microarrays on 
RNA level and the reduction by 50% of RASSF1A expression after YAP1 induction. 
 
Subsequently, the results of the microarrays were analysed in further detail and the top up- 
and downregulated candidate genes were determined (appendix 5 and appendix 6). Table 
19 summarizes these top 10 up- and downregulated candidate genes, which were detected 
in the microarrays to be regulated by RASSF1A and YAP1. The expression levels were 
normalized to control cells (GFP/unind.) and to the internal microarray controls.  
 
Table 19. Expression of top 10 up- and downregulated genes and selected target genes (bold) after YAP1 
induction (YAP1 ind.) and RASSF1A transfection in the YAP1-inducible TREx293 cells.  
Gene GFP/unind. GFP/YAP1 ind. RASSF1A/unind. 
RASSF1A/YAP1 
ind. 
 
HIF1A-AS2 1,00 7,70 1,16 10,90 T
op 10 up-regulated 
 genes 
ACTBL2 1,00 2,72 1,16 4,85 
COL12A1 1,00 4,60 1,11 4,41 
CTGF 1,00 2,26 1,34 3,97 
MT-TW 1,00 2,90 2,58 3,64 
ANKRD1 1,00 2,88 1,24 3,40 
CYR61 1,00 2,66 1,43 3,26 
CPA4 1,00 2,74 1,24 3,22 
AJUBA 1,00 2,25 1,20 2,77 
SPANXC 1,00 1,69 1,55 2,67 
CDKN1A 1,00 0,64 0,84 0,91 
 TP53 1,00 0,79 0,95 0,95 
BAX 1,00 0,63 0,83 1,00 
MDM2 1,00 0,83 1,11 0,61 
FOS 1,00 0,92 0,97 0,73 T
op 10 dow
n-regulated 
genes 
MAP2K6 1,00 1,15 0,91 0,59 
PINK1 
TP53I13 
1,00 0,86 0,71 0,56 
1,00 0,81 0,84 0,51 
GDF15 1,00 0,60 0,72 0,46 
FOXD3 1,00 0,74 0,48 0,46 
FGF21 1,00 0,59 0,46 0,45 
ANAPC1P1 1,00 0,65 0,54 0,45 
GH1 1,00 0,57 0,65 0,41 
MAP3K8 1,00 0,40 0,89 0,39 
 
Table 19 indicates the top ten YAP1 upregulated target genes. The activation of these genes 
increased further after expression of RASSF1A and YAP1 induction (Table 19). Several 
candidate genes are already associated with the Hippo pathway and some of them also play 
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a role in hypoxia, such as HIF1A-AS2 and AJUBA. The Lim domain protein AJUBA has 
been linked to the Hippo pathway (Das Thakur et al., 2010). Other candidates such as 
CYR61, ANKRD1 and CTGF were previously identified as YAP1 target genes (Li et al., 
2013; Zhou et al., 2016). Other genes like the actin isofom ACTBL2, COL12A1, which 
codes for an extracellular matrix protein (Januchowski et al., 2014), and the HIF1A 
antisense 2, are not described yet as related to the Hippo pathway and there are only few 
reports about their functions (Bertozzi et al., 2011; Mineo et al., 2016).  
 
The expression of the top 10 downregulated genes is repressed by YAP1 alone (see Table 
19), but RASSF1A intensified this repression, especially in the genes: MDM2, FOS, 
MAP2K6, GDF15, FOXD3 and FGF21 (Table 19). Other novel candidate genes were also 
detected; among those genes are regulatory elements such as zinc fingers, microRNAs and 
other non-coding RNA genes (see Table 21 and Table 22 in appendix 5 and 6). 
 
Additionally, Table 19 shows the expression levels of ANKRD1, TP53, BAX and CDKN1A 
according to the microarrays (in bold). The expression of these genes is interesting because 
ANKRD1 is a YAP1 target gene, whereas TP53, BAX and CDKN1A are tumor suppressor 
genes, which were detected to be repressed by YAP1 as shown in figure 9B. Here, the 
YAP1 and RASSF1A-induced upregulation of ANKRD1 (3.4-fold) was verified (Fig. 5C); 
also the downregulation of TP53 (0.79-fold), BAX (0.63-fold) and CDKN1A (0.63-fold) 
after YAP1 induction was confirmed (Fig. 9B). In addition, the microarrays also suggested 
that RASSF1A neutralizes the repressive effect of YAP1 on TP53, BAX and CDKN1A 
expression (see Table 19).  
 
The microarray data were further validated in three independent biological replicates by 
qRT-PCR using the YAP1-inducible TREx293 cells (Fig. 14, appendix 7). For this 
purpose, GFP and GFP-RASSF1A were overexpressed for 72h in the TREx293 cells with 
and without YAP1 induction. Figure 14 indicates the relative expression of CTGF, 
ANKRD1, AJUBA, TP53, BAX and CDKN1A in one representative experiment (Fig. 14). 
The overexpression of RASSF1A and the induction of YAP1 were controlled by 
semiquantitative PCR as indicated in appendix 7. 
 
Figure 14 indicates that the expression of CTGF, ANKRD1 and AJUBA was significantly 
enhanced by YAP1: expression increase for CTGF: 4.8-fold (p-value< 0.00001); ANKRD1: 
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3.2-fold (p-value< 0.0001) and 2-fold for AJUBA (p-value< 0.004). In contrast, the 
induction of YAP1 repressed the expression of TP53 by up to 17%; the expression of BAX 
was also reduced by 41% (p-value 0.001), and the expression of CDKN1A was repressed by 
21% (p-value 0.0004) in comparison to the uninduced cells (Fig 14). The expression of 
RASSF1A alone did not affect the expression of the candidate genes, but together with 
YAP1 activated the expression of ANKRD1 by 70% (p-value 0.02) and the expression of 
AJUBA by 83% (p-value 0.004) (Fig. 14). Moreover, RASSF1A reactivated the expression 
of the tumor suppressor genes despite of the induction of YAP1. Compared to the YAP1 
induced cells, the RASSF1A/YAP1 induced cells showed a significant increase of 17% (p-
value 0.01) in TP53 expression, of 30% in BAX expression (p-value 0.007) and of 21% in 
CDKN1A expression (p-value 0.03) (Fig. 14). 
        
 
 
Figure 14: RASSF1A effect on YAP1 target genes. Expression analysis using qRT-PCR of a representative 
experiment of TREx293 cells after 72h transfection with GFP-RASSF1A or GFP without or with YAP1 
induction. Relative expression level of CTGF, ANKRD1, AJUBA, TP53, BAX and CDKN1A compared to the 
uninduced control cells (GFP/unind.) and after normalization to GAPDH.	   The standard deviations and p-
values were calculated using the technical replicates of the experiment. p-values: * p<0.05, ** p<0.01 and 
*** p<0.001 (t-test). 
 
The promoter assays plotted in figure 11B-C and the expression data from figure 14 
confirmed the data obtained by the microarrays; such as the downregulation by YAP1 of 
the tumor suppressor genes (TP53, BAX and CDKN1A) and their reactivation after 
RASSF1A expression. In addition, figure 5C and figure 14 validated the co-regulation of 
ANKRD1 expression by YAP1 and RASSF1A.  
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3.1.7 The Hippo pathway regulates the expression of ANKRD1  
 
As previously indicated, the expression of ANKRD1 is regulated by YAP1 and RASSF1A. 
The Hippo pathway is activated by RASSF1A through the SARAH (Sav/Rassf/Hpo) 
domain, which interacts with MST2 to phosphorylate LATSs and YAP1 (Dittfeld et al., 
2012). The focus of this part of our work was to determine if the regulation of ANKRD1 
occurs via the Hippo signalling. For this purpose, expression analyses were performed 
using HEK293T cells with overexpression of YAP1, RASSF1A wild type and RASSF1A 
mutant with depletion of the SARAH domain (RASSF1A-ΔSARAH) (Fig. 15A). The 
obtained results were further validated by promoter assays using the YAP1-inducible 
TREx293 cells and the promoter of ANKRD1 in a renilla luciferase vector. The promoter 
activity was measured after overexpression of RASSF1A wild type or RASSF1A-
ΔSARAH mutant and YAP1 induction (Fig. 15B).  
 
A)                            B) 
     
Figure 15: ANKRD1 expression is regulated via the Hippo pathway. A) Representative figure of the 
relative ANKRD1 expression in HEK293T cells 72h after transfection of RASSF1A, RASSF1A-ΔSARAH 
and/or co-transfected with YAP1. The values were normalized to GAPDH expression and to the normalized 
values for the control cells (empty vector) were set to 1. B) Representative figure of the relative ANKRD1 
promoter activity after RASSF1A (wild type or ΔSARAH mutant) and control vector (Ctrl) transfection with 
and without induction of YAP1 in the YAP1-inducible TREx293 cells. The promoter activity was normalized 
to the firefly luciferase activity (pGL2) and the control cells (Ctrl/unind.) was set to 1. The standard 
deviations and p-values were calculated using the technical replicates of the experiment. p-values: * p<0.05, 
** p<0.01 and *** p<0.001 (t-test).  
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Figure 15A shows the relative expression of ANKRD1 after overexpression of RASSF1A-
ΔSARAH mutant in comparison to RASSF1A wild type. As previously demonstrated, 
YAP1 alone induced the expression of ANKRD1, and the co-expression of YAP1 with 
RASSF1A wild type further increased the expression of ANKRD1 (Fig. 5, Fig. 14 and Fig. 
15A). The RASSF1A-ΔSARAH mutant alone induced the expression of ANKRD1. In 
contrast, RASSF1A-ΔSARAH mutant co-expressed with YAP1 did not increase the 
expression of ANKRD1 compared to the co-transfection of YAP1 with the RASSF1A wild 
type (Fig. 15A). 
 
The data indicated in figure 15A were further validated by promoter assays. For this 
purpose, 606 bp of the ANKRD1 promoter region was cloned into a renilla luciferase vector 
(appendix 1) and analysed in the YAP1-inducible TREx293 cells after YAP1 induction and 
expression of RASSF1A or RASSF1A-ΔSARAH mutant (Fig. 15B). The induction of 
YAP1 significantly induced the promoter activity of ANKRD1 (p-value 0.001). The 
induction of the ANKRD1 promoter activity by YAP1 and RASSF1A (p-value 0.01) was 
also observed (Fig. 15B). RASSF1A-ΔSARAH mutant and the wild type RASSF1A 
activated the promoter activity of ANKRD1; but interestingly, the RASSF1A-ΔSARAH 
mutant in combination with YAP1 did not affect the promoter activity of ANKRD1 (Fig. 
15B). In comparison to the YAP1/RASSF1A wild type, the RASSF1A-ΔSARAH was 
unable to further increase the promoter activity of ANKRD1 (p-value 0.01) (Fig. 15B). 
 
3.1.8 ANKRD1 is epigenetically silenced in human cancer and represents a potential 
tumor suppressor gene 
 
To date, ANKRD1 is described as a cardiac protein (Ishiguro et al., 2002; Torrado et al., 
2005). To further characterise the cellular function of ANKRD1, its expression level was 
analysed using RNA from normal tissues samples and from different human cancer cell 
lines (Fig. 16). 
 
ANKRD1 is highly expressed in heart, 9-fold more than in liver and 5-fold more than in 
lung, but it is absent in breast tissue (Fig. 16A). The expression of ANKRD1 and YAP1 was 
analysed by qRT-PCR in different human cancer cell lines, including lung cancer (H322, 
A549 and A427), prostate cancer (LNCaP and PC-3), breast cancer (MCF7 and T47D) and 
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skin cancer (MeWo and Sk-Mel-28); the expression levels of YAP1 and ANKRD1 in the 
cell lines were plotted relative to those in HEK293T (Fig. 16B). Endogenous YAP1 
expression was observed in all analysed cell lines. In A427 and T47D cells, the expression 
of YAP1 was 6-fold and 15-fold higher than in HEK293T cells, respectively (Fig. 16B). 
This figure also indicated the expression of ANKRD1 in the cell lines. Interestingly 
ANKRD1 was not expressed in LNCaP, MCF7 and in MeWo cells; whereas in T47D it was 
expressed up to 4-fold higher than in HEK293T cells (Fig. 16B). 
 
A)          B) 
         
 
 
 
Figure 16: Expression of ANKRD1 in normal tissue and cancer cell lines. A) Expression of ANKRD1 was 
analysed by qRT-PCR in heart, breast, liver and lung tissues. The expression levels were normalized to 
GAPDH. The normalized expression of ANKRD1 in heart was set to 1. B) Expression of ANKRD1 and YAP1 
in cell lines. The expression analysis was performed by qRT-PCR and normalized to GAPDH expression; the 
normalized expression in HEK293T cells was set to 1. C) CoBRA analysis of the methylation status of 
ANKRD1 promoter in LNCaP, MeWo, MCF7, A427 and HEK293T cells. A fragment of 139 bp was 
amplified by PCR using bisulfite converted DNA and subsequently digested with TaqI enzyme (+) or without 
enzyme as control (-). ivm: in vitro methylated DNA. m: methylated. u: unmethylated. Arrow: digested 
fragments. D) Semiquantitative PCR of GAPDH and ANKRD1 expression in LNCaP, MeWo, MCF7, A427 
and HEK293T cells after 4d of 5-Aza-2’-deoxycytidine (Aza) (0,5,10 µM) treatment.  
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The inactivation of ANKRD1 in LNCaP, MeWo, MCF7 and A427 cells was further 
investigated. For this purpose, the methylation status of the promoter region of ANKRD1 
was analysed by CoBRA in these cell lines (Fig. 16C). The CoBRA analysis in figure 16C 
indicated that the ANKRD1 promoter was methylated in LNCaP, MeWo, A427 and MCF7 
cells, whereas it was unmethylated in HEK293T (Fig. 16C). The expression analysis shown 
in figure 16D verified that ANKRD1 was downregulated in these cell lines, and a 
reexpression of ANKRD1 was observed after cell treatment with 5 or 10 µM Aza (Fig. 
16D), which indicated that ANKRD1 was epigenetically silenced in LNCaP, MeWo, A427 
and MCF7 cells (Jiménez et al. 2017). 
 
To further characterise the function of ANKRD1, colony formation assays were performed 
by overexpressing ANKRD1 or the respective empty control vector in LNCaP, A427, 
HEK293T and in T47D cells (Fig. 17A-C). In addition, growth curves of A549 and LNCaP 
cells were generated to determine the cellular proliferation after expression of ectopic 
ANKRD1 (Fig. 17D). 
 
Figure 17A and 17C indicate that ANKRD1 expression significantly reduced the number of 
colonies in LNCaP (42% reduction; p<0.001), in A427 (80%; p<0.001) and in HEK293T 
cells (87%; p<0.0001) compared to transfected control cells. In contrast, ANKRD1 
increased the colony number in T47D cells (p-value< 0.0001) in comparison to the control 
cells (Fig. 17A-C). The overexpression of ANKRD1 was controlled by semiquantitative 
PCR as indicated in figure 17B. 
 
In figure 17D, A549 and LNCaP cells were transfected either with ANKRD1 or with the 
empty control vector and selected for 1 week with G418. Afterwards, 105 cells were plated 
and after 16h the exact number of cells was quantified (day 0 (0d)). Every 24h the cell 
number was quantified and the growth ratio was determined by normalization to the cell 
number at 0d. After two and three days, we observed a significant decrease in the growth 
ratio of the cells transfected with ANKRD1, whereas in cells transfected with the control 
plasmid, we observed exponential growth in A549 or duplication after 48h in LNCaP cells 
(Fig. 17D). In A549 cells, the growth ratio of the cells with ANKRD1 decreased 
significantly after 2d (p-value 0.01) and after 3d (p-value 0.02) compared to the control 
cells; the cells with ANKRD1 showed a 2-fold reduction of proliferation compared to the 
control cells (Fig. 17D). In LNCaP cells, the overexpression of ANKRD1 produced 
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apoptosis. After three days, the control cells triplicated their cell number, whereas in the 
cells transfected with ANKRD1, the cell number was similar to that of the initial day 0 (0d) 
(p-value 0.05) (Fig. 17D). 
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C)                D) 
       
 
Figure 17: ANKRD1 reduced colony formation and proliferation of cancer cells. A) Colony formation 
assay. LNCaP, A427 and T47D cells were transfected either with Flag-empty vector (Ctrl) or with Flag-
ANKRD1 and further selected with G418 for three weeks. HEK293T cells were transfected with either 
pCDNA4TO empty vector (Ctrl) or with pCDNA4TO-ANKRD1 and selected with Zeocin for three weeks. 
The colonies were stained with Giemsa. B) Overexpression controls by semiquantitative PCR for ANKRD1 
overexpression and GAPDH. C) Percentage of colony number of the different cell lines. D) Growth curve of 
A549 und LNCaP pool of cells after stable transfection of Flag-empty vector (Control) or Flag-ANKRD1. 105 
cells were plated on 0d and after 1d, 2d and 3d the cell growth ratios of three technical triplicates were 
measured using the Neubauer counting chamber. The measured growth ratio is given relative to day 0 (0d).  
p-values: * p<0.05 and *** p<0.001 (t-test).  
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3.1.9 ANKRD1 activates the expression of CDKN1A, BAX and TP53 
 
ANKRD1 was demostrated to inhibit colony formation and cell growth (Fig. 18). In 2010 
Kojic et al. have suggested a role of ANKRD1 as a co-activator of TP53 (Kojic et al., 
2010). In this part of the study, the effect of ANKRD1 on the expression of the TP53 target 
genes was further investigated (Fig. 18). For this purpose, expression analysis and promoter 
assays were performed in HEK293T cells after transfection of either ANKRD1 or of the 
control vector (Fig. 18A-B). Furthermore, an inducible ANKRD1 TREx293 cell line was 
created and the expression of the TP53 target genes was analysed after induction of 
ANKRD1 with Dox (Fig. 18C).  
      A)                        B) 
                         
           
 C) 
         
 
Figure 18: ANKRD1 mediates the activation of CDKN1A, BAX and TP53. A) Relative expression of 
TP53, BAX and CDKN1A in HEK293T cells 72h after expression of Flag-empty vector (Ctrl) or Flag-
ANKRD1. The expression was measured by qRT-PCR and normalized to GAPDH and to the control cells 
(set to 1). B) ANKRD1 activates the promoter activity of BAX. HEK293T cells were transfected for 24h with 
Flag-empty vector (Ctrl) or Flag-ANKRD1 and either with pGL2 empty or pGL-BAX vector. pRL-null was 
used as control for transfection efficiency. The promoter activity was normalized to the renilla luciferase 
(pRL-null) and the pGL2 empty vector was set to 1. C) Relative expression of TP53, BAX and CDKN1A in 
ANKRD1-inducible TREx293 cells with and without induction with Dox (2 µg/ml). The expression was 
measured by qRT-PCR and normalized to GAPDH and to the uninduced cells (set to 1). p-values: * p<0.05, 
** p<0.01 and *** p<0.001 (t-test). 
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Figure 18A indicates that in HEK293T cells, the ectopic expression of ANKRD1 
upregulated the mRNA levels of TP53 (1.5-fold; p-value 0.003), of BAX (1.2-fold; p-value 
0.04) and of CDKN1A (1.2-fold; p-value 0.002). Furthermore, the promoter assays in figure 
18B revealed the significant activation of the BAX promoter by ANKRD1 (1.8-fold, 
p<0.001) in comparison to the control cells (Fig. 18B). In the ANKRD1-inducible 
TREx293 cell line, the induction of ANKRD1 also resulted in the upregulation of TP53 
(1.4-fold), BAX (1.3-fold), MDM2 (1.7-fold) and CDKN1A (1.3-fold, Fig. 18C). The 
overexpression and induction of ANKRD1 were validated by qRT-PCR and western 
blotting as indicated in appendix 8. 
 
In summary, our data show that ANKRD1 is silenced by promoter methylation in various 
cancer cell lines. In addition, ANKRD1 is capable of inhibiting colony formation and cell 
growth. Further analyses revealed that it significantly activates the expression of TP53, 
BAX, MDM2 and CDKN1A. 
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3.1.10 RASSF1A-YAP1-ANKRD1 regulates TP53 via MDM2   	  	  
The previous experiments demonstrated that YAP1/RASSF1A and ANKRD1 modulate the 
expression of the TP53 target genes BAX and CDKN1A. The tumor suppressor gene TP53 
is known to be regulated by posttranslational modifications, and its major regulator is 
MDM2 (Kussie et al., 1996; Momand et al., 1992; Oliner et al., 1993). Interestingly, our 
microarray data displayed a downregulation of MDM2 mRNA levels (0.61-fold) by 
RASSF1A expression and YAP1 induction (Table 19). The transcriptional repression of 
MDM2 by RASSF1A and YAP1 could not be validated, neither by qRT-PCR nor by 
promoter assay (Fig. 11B). However, at the protein level, a decrease in MDM2 expression 
was observed in the cell lysates from the YAP1-inducible TREx293 cells, which were 
sorted and used for the microarrays (Fig. 13A).   
 
In this part of the study, the protein level of YAP1, TP53, BAX and MDM2 were further 
analysed (Fig. 19). For this purpose, HEK293T cells were co-transfected either with 
RASSF1A and YAP1 or with ANKRD1 for 72h. Afterwards, the cell lysates were 
separated by SDS-PAGE and transferred to a PVDF membrane by western blotting (Fig. 
19A). The endogenous protein amounts of TP53, BAX, MDM2 and the overexpression of 
YAP1 were quantified using the ImageJ software and plotted in figure 19B-C. 
 
Figure 19A indicates one representative western blot from five independent biological 
replicates. After 72h co-transfection of RASSF1A with YAP1, a significant decrease of 
MDM2 (40% reduction; p-value 0.05) compared to the controls was observed. In addition, 
an increase in TP53 and BAX (1.4-fold) levels was detected. Interestingly, the 
overexpression of ANKRD1 also resulted in a decrease of the MDM2 level (0.6-fold, 
p<0.001) and in an increase of TP53 (1.3-fold; p-value 0.03) and BAX level (1.8-fold) (Fig. 
19A-B). These results correlated with the measured decrease of MDM2 level detected in 
the YAP1-inducible TREx293 cells from figure 13A, in which RASSF1A expression and 
YAP1 induction resulted in a decrease of MDM2 protein level by 30%. Additionally, figure 
19C indicates the YAP1 level in the analysed blots. An increase of YAP1 protein level was 
measured after overexpression of RASSF1A (Fig. 10A and 19C), which suggests that 
RASSF1A stabilises YAP1 on the protein level and induces its translocation into the 
nucleus according to the results presented in figure 12.  
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Figure 19: Decrease of MDM2 through the Hippo pathway. A) Representative western blot of 
overexpression of Flag-empty, Flag-RASSF1A, Flag-YAP1, Flag-ANKRD1 and co-transfection of Flag-
RASSF1A with Flag-YAP1 after 72h in HEK293T cells. B) Quantification of protein levels of MDM2, TP53, 
GAPDH and BAX from 5 experiments after overexpression in HEK293T cells. C) Quantification of the 
protein level of YAP1. The protein levels were quantified by ImageJ and normalized to GAPDH and to the 
control lysates (set to1). p-values: * p<0.05, ** p<0.01 and *** p<0.001 (t-test). 
 
 
In summary, the co-expression of RASSF1A and YAP1, as well as the expression of 
ANKRD1 resulted in a decrease of MDM2 at the protein level, whereas the TP53 and BAX 
levels increased. 
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3.1.11 ANKRD1 interacts with TP53 and MDM2  
 
To verify the interaction of ANKRD1 with TP53 reported by Kojic et al. (2010) and to 
further investigate a possible protein-protein interaction of ANKRD1 with MDM2, Co-IPs 
of ectopic ANKRD1 with endogenous TP53 and MDM2 were performed. HEK293T cells 
were transfected for 72h either with the control empty vector or with a vector containing 
Flag- or YFP-ANKRD1 (Fig. 20). The Co-IPs were performed using anti Flag-tag- or anti 
GFP-agarose beads respectively and analysed by western blotting as indicated in figure 20. 
A)                                                              B) 
 
Figure 20: ANKRD1 interacts with TP53 and MDM2. A-B) Co-immunoprecipitation of ANKRD1 with 
endogenous TP53 and MDM2 from HEK293T cell lysates after 72h transfection of Flag-/YFP-empty vector 
or Flag-/YFP-ANKRD1. 10 µg of protein lysate before IP were used as input. The IPs were performed using 
Flag-tag- or anti GFP-agarose beads after ON incubation with the protein lysates. The input and IPs were 
loaded on a 10% SDS gel and separated by SDS-PAGE and afterwards blotted onto PVDF membrane. The 
co-immunoprecipitated proteins and the respective controls in the input were detected using the antibodies as 
indicated in Table 1. 
 
In figure 20, the signal of the input lysates indicates the overexpression of ANKRD1 as 
demonstrated both with the Flag antibody (Fig. 20A) as well as with the fusion protein with 
GFP (Fig. 20B). GAPDH was used as loading control. Furthermore, endogenous TP53 and 
MDM2 were detected both in the cells transfected with the empty vectors as well in the 
cells with the ANKRD1 overexpression (Fig. 20A-B). It is important to emphasize that the 
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decrease of MDM2 level was observed in the input after overexpression of Flag-ANKRD1 
(Fig. 20A); in the cells with GFP-ANKRD1, we did not directly observe such a decreased 
MDM2 expression; however, since the GAPDH level between the two samples was 
apparently different, this effect on MDM2 expression may be occluded by the varying 
GAPDH level (Fig. 20B).  
 
The interaction of ANKRD1 with TP53 was confirmed both with Flag-ANKRD1 as well as 
with GFP-ANKRD1 (Fig. 20A-B). Moreover, an interaction of ANKRD1 with endogenous 
MDM2 was detected with the Flag-ANKRD1 co-IP (Fig. 20A) and further validated with 
the GFP-ANKRD1 (Fig. 20B). These results suggest that ANKRD1 can interact with 
MDM2 and with TP53.  	  
3.1.12 ANKRD1 knockdown results in a decreased TP53, BAX, CDKN1A and MDM2 
expression 
 
To verify the involvement of ANKRD1 in the regulation of the TP53 target genes obtained 
previously, gene-silencing experiments using siRNA against ANKRD1 were performed 
and analysed by qRT-PCR (Fig. 21). HEK293T cells were transfected with control siRNAs 
or with siRNAs against human ANKRD1. After 4d transfection, the cells were harvested 
and the gene expression was further analysed by qRT-PCR as indicated in figure 21. 
 
 
 
Figure 21: ANKRD1 knockdown represses gene expression of TP53 target genes. HEK293T cells were 
transfected with a pool of siRNA controls or with a pool of siRNA against ANKRD1. Gene expression of 
ANKRD1 and target genes were analysed by qRT-PCR. The expression levels were normalized to GAPDH 
and to the control siRNA (set to 1). p-values: * p<0.05, ** p<0.01 and *** p<0.001 (t-test). 
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The expression of ANKRD1 was significantly reduced by 80% (p-value<0.001) after the 
gene-specific knockdown compared to the control siRNA (Fig. 21); furthermore the 
knockdown of ANKRD1 caused a decrease in the expression of TP53 (reduction of 28%; 
p-value 0.03), BAX (24%; p-value 0.1), CDKN1A (44%; p-value<0.001) and MDM2 (44%; 
p-value 0.02), which confirmed the hypothesis that ANKRD1 acts a potential tumor 
suppressor gene by co-regulation of the TP53 target genes (Fig. 21).  
 
In this part of the study it was demonstrated that RASSF1A and YAP1 co-regulates the 
expression of ANKRD1 through the Hippo pathway. In addition, ANKRD1 inhibits colony 
formation and cell growth by significant activation of TP53, BAX and CDKN1A and 
induces the destabilisation of MDM2 levels. Moreover, ANKRD1 interacts with TP53 and 
MDM2. In addition, the silencing of ANKRD1 by promoter methylation or its knockdown 
by siRNA produced a significant decrease in the expression of TP53 target genes. 
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3.2 Role of the C-terminal members of the RASSF in the Hippo pathway 
 
The RAS association domain family (RASSF) encodes for 10 highly conserved tumor 
suppressor genes. Six members of the RASSF gene family (RASSF1 to RASSF6) encode a 
SARAH domain suggesting a possible role in the regulation of the Hippo pathway (Dittfeld 
et al., 2012; Richter et al., 2009). To date, there is not much information available on the 
cellular function of these genes; however, few reports have demonstrated an inactivation of 
these genes by promoter hypermethylation in some cancer types e.g. RASSF2 and RASSF5 
are hypermethylated in merkel cell carcinoma and in pheochromocytoma (Richter et al., 
2013; Richter et al., 2015). The aim of this part of the study was the comparative analysis 
of the effect of the C-terminal RASSF members on the regulation of YAP1 target genes.  
3.2.1 Aberrant promoter methylation of C-terminal RASSFs in liver tumors 	  
As indicated in appendix 3 and in Jiménez et al. (2017), the promoter methylation status of 
the Hippo core components (RASSF1A, MST1, MST2, WW45, LATS1, LATS2 and YAP1) 
was analysed by CoBRA in DNA samples from five primary liver tumors compared to the 
corresponding matched normal tissues. Here, only RASSF1A presented a specific tumor 
methylation (Jiménez et al. 2017, appendix 3). Subsequently, the promoter methylation of 
the other C-terminal RASSFs was analysed and compared to the methylation status of 
RASSF1A using the same liver cancer and normal samples (Fig. 22). 
 
 
Figure 22: Methylation analysis of the promoter region of C-terminal RASSFs in liver tumors. 
Combined bisulfite restriction analysis of the promoter region of RASSF1A, RASSF2, RASSF3, RASSF4, both 
isoforms of RASSF5 (A and C) and RASSF6 in liver tumors (T) compared to matched normal samples (N). 
Positive control: in vitro methylated DNA (ivm). Mock digest (-); PCR product digested with enzyme (+). 
Experiment performed by B.Sc. S. Kürschner. 
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In figure 22, the promotor methylation of RASSF2, RASSF3, RASSF4, RASSF5A, RASSF5C 
and RASSF6 were analysed by CoBRA and compared to the methylation of RASSF1A. 
RASSF1A was found to be methylated in 3 out of 5 liver tumors (patients: 1(2800), 3(3084) 
and 4(974)). The promoter of RASSF2 was methylated only in the tumor sample of patient 
1(2800). The promoter region of RASSF3 was tumor-specifically methylated in the sample 
of patient 2(2844) and patient 3(3084). The promoter of RASSF5A was detected as 
methylated in four DNA tumor samples compared to DNA of the corresponding matched 
normal tissues (patiente 1(2800), 2 (2844), 3(3084) and 4(974)) (Fig. 22).  
 
In contrast, the promoter region of RASSF4 was found to be methylated in one normal 
tissue (patient 3(3084)). RASSF5C is methylated both in tumor as well in normal tissue in 
the patients 1(2800), 2(2844) and 3(3084); the DNA of the other patients was found to be 
unmethylated, both in tumor as well in normal tissue (Fig. 22). The promoter of RASSF6 
was found to be unmethylated in all patients (Fig. 22). In summary, our data indicated that 
the methylation status of the C-terminal RASSFs was heterogeneous in the analysed DNA 
samples, nevertheless RASSF1A, RASSF2, RASSF3 and RASSF5 presented a tumor-
specific promoter methylation. This result needs to be confirmed in a larger set of samples.  
 
3.2.2 C-terminal RASSFs affect the cell cycle  
 
The C-terminal RASSF family members encode a SARAH interaction domain, which e.g. 
interacts with MST2 to activate the Hippo pathway (Cooper et al., 2009; Schagdarsurengin 
et al., 2010; Song et al., 2010). To further analyse the function of the C-terminal RASSFs 
regarding the regulation of the Hippo signalling, the YAP1-inducible TREx293 cells were 
transfected with the respective C-terminal GFP-RASSFs or GFP-MSTs constructs and the 
cell cycle distribution was analysed by flow cytometry 72h after induction of YAP1 as 
described in 3.1.4 (Fig. 23). 
 
Figure 23 indicates the cell cycle distribution of the YAP1-inducible TREx293 cells after 
transfection of the GFP-RASSF1A, GFP-RASSF2, GFP-RASSF3, GFP-RASSF4, GFP-
RASSF5, GFP-RASSF6 and GFP-MST1/MST2 with and without induction of YAP1. The 
overexpression of GFP-RASSF1A and GFP-empty vector were used as controls. As 
described in figure 10, YAP1 leads the cells into the S-phase and RASSF1A arrests the 
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cells in the G0-G1 phase and inhibits the proliferative effect of YAP1 (Fig. 10B). In this 
additional experiment, the YAP1 and RASSF1A transfected cells exhibited the same 
pattern as in figure 10B (Fig. 23). Interestingly, the co-expression of MST1 and MST2 
showed the same effect as that of YAP1, namely a significant increase of cells in the S-
phase (chi-square test; p-value< 0.0001) (Fig. 23). In contrast, the C-terminal RASSFs, 
with exception of RASSF2, counteract the S-phase induction by YAP1 thus accumulating 
the cells in the G0-G1 phase (p-values< 0.0001) as compared to the control cells and to the 
cells transfected with RASSF1A (Fig. 23). In contrast, the expression of RASSF2 alone and 
together with YAP1 resulted in a cell accumulation in the G2-M phase (p-value< 0.0001, 
Fig. 23).  
 
 
Figure 23: Cell cycle distribution of YAP1-inducible TREx293 cells after transfection of the C-terminal 
RASSFs or co-transfection of MST1 and MST2. Flow cytometry analysis of YAP1-inducible TREx293 
cells transfected with GFP-empty,	   GFP-RASSF1A, GFP-RASSF2, GFP-RASSF3, GFP-RASSF4, GFP-
RASSF5, GFP-RASSF6 or GFP-MST1 and GFP-MST2 (1:1) with or without induction of YAP1 (72h). The 
cell cycle of 104 transfected cells was analysed by flow cytometry using propidium iodide staining.  
 
The induction of YAP1 and the co-expression of MST1 and MST2 resulted in an increase 
in cell proliferation (S-phase). Every C-terminal RASSF family member affected the 
progression of the cell cycle.  RASSF2 lead to the accumulation of the cells in the G2-M 
phase, whereas RASSF1A, RASSF3, RASSF4, RASSF5 and RASSF6 counteracted the 
proliferative effect of YAP1 arresting the cells in the G0-G1 phase. 
3.2.3 Effect of RASSFs on YAP1 target genes 
 
The SARAH domain of the C-terminal RASSFs mediates the activation the Hippo pathway 
(Cooper et al., 2009; Song et al., 2010). To understand the role of the C-terminal RASSFs 
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in the regulation of the YAP1 target genes, the YAP1-inducible TREx293 cells were 
transfected with the respective Flag-RASSFs or with the corresponding empty vector and, 
after 72h induction of YAP1, were further analysed by qRT-PCR. Also HEK293T cells 
were co-transfected with the Flag-RASSFs and YAP1 and further analysed by qRT-PCR 
(Fig. 24 and Fig. 25). In addition, TP73 and ∆Np73 were overexpressed in both cell lines 
and used as positive control for the expression of BAX, CDKN1A and BAX. Since the C-
terminal RASSFs affected the cell cycle (Fig. 23), the expression of p16 (CDKN2A) was 
determined and used as indicator for cell cycle arrest. The overexpression was controlled 
by semiquantitative PCR as shown in appendix 9. The expression of ANKRD1 is plotted in 
figure 24; the expression levels of BAX, BBC3, CDKN1A, TP53 and p16 are plotted in 
figure 25. 
A) 
    
B) 
    
 
Figure 24: C-terminal RASSFs regulate the expression of ANKRD1. Representative graph of ANKRD1 
expression analysed by qRT-PCR 72h after transfection of Flag-empty, -RASSF1A, -RASSF2, -RASSF3, -
RASSF4, -RASSF5, -RASSF6, -TP73, -∆Np73 and the respective induction or co-transfection of YAP1 in: 
A) YAP1-inducible TREx293 cells with or without induction B) HEK293T cells. The expression levels were 
normalized to GAPDH and to the controls cells (set to1). SD from technical replicates. 
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Figure 24 indicates that C-terminal RASSFs and the TP73 isoforms together with YAP1 
were able to regulate the expression of ANKRD1 both in the TREx293 cells after induction 
of YAP1 (Fig. 24A) as well as after co-transfection with YAP1 in the HEK293T cells (Fig. 
24B). The co-expression of the RASSFs with YAP1 resulted in a significant increase of 
ANKRD1 expression in a range of 13- to 45-fold compared to the controls cells and of 4- to 
5-fold compared to YAP1-overexpressing cells (Fig. 24). The observed expression changes 
were significant relative to the control cells and to the cells with an overexpression of 
YAP1 and even to the cells with the co-expression of RASSF1A and YAP1 (the p-values 
are listed in Table 23 in appendix 10). The regulation of ANKRD1 expression by RASSF4 
and TP73 could not be reproduced (Fig. 24). 
 
Figure 25 indicates the expression of BAX, BBC3, CDKN1A, TP53 and p16 after 
transfection of the C-terminal RASSFs both in the TREx293 cells after induction of YAP1 
(Fig. 25A) as well as in the HEK293T cells (Fig. 25B). In the YAP1-inducible TREx293 
cells (Fig. 25A), the induction of YAP1 repressed the expression of BAX, BBC3 and 
CDKN1A as previously observed in figure 9. Ectopic RASSF1A expression significantly 
increased the expression of BAX and TP53 whereas the expression of BBC3, CDKN1A 
returned almost to the normal level (Fig. 25A). The other C-terminal RASSFs together with 
YAP1 caused a significant increase of up to 2-fold in the expression of TP53, BAX and p16 
expression compared to the uninduced cells and control cells. Moreover, both TP73 
isoforms together with YAP1 showed an additional increase in the gene expression of the 
target genes, except for p16 (Fig. 25A; the p-values are listed in Table 23 in appendix 10).  
 
The data presented in figure 25A were further validated in a biological replicate in 
HEK293T cells (Fig. 25B). Here, the transfection of the C-terminal RASSFs, TP73 and 
∆Np73 also resulted in a significant increase of the TP53 expression (Fig. 25B). The 
increase of the BAX expression was observed after transfection of RASSF1A and RASSF5 
compared to the control cells. The co-transfection of RASSFs with YAP1, with exception 
of RASSF4, resulted in an increase in the expression of all analysed genes compared to the 
controls without YAP1. (Fig. 25B, the p-values are listed in Table 23 in appendix 10).  
 
The C-terminal RASSFs and YAP1 alone induced the expression levels of p16 in a range 
between 10% up to 60% (Fig. 25). The co-transfection of RASSFs with YAP1 or the 
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induction of YAP1 in the TREx293 cells significantly increased the expression of p16 by 
up to 72% compared to the respective controls cells (Fig. 25A). Moreover, TP73 and 
∆Np73 affected the p16 expression independent of YAP1. These preliminary data suggest 
that the C-terminal RASSFs together with YAP1 could be involved in the regulation of p16 
expression levels, which in turn might explain the cell cycle arrest observed in 3.2.2. 
 
A) 
 
B)  
 
Figure 25: C-terminal RASSFs regulate the expression of YAP1 target genes and of p16. Representative 
graph of the expression of TP53, BAX, CDKN1A, BBC3 and p16 after 72h transfection of Flag-empty, -
RASSF1A, -RASSF2, -RASSF3, -RASSF4, -RASSF5, -RASSF6, -TP73, -∆Np73 and the respective co-
transfection with YAP1 in: A) YAP1-inducible TREx293 cells with or without induction of YAP1. B) 
HEK293T cells. The expression levels were normalized to GAPDH and to the control cells (set to 1). SD from 
technical replicates. 
 
0	  0.5	  
1	  1.5	  
2	  2.5	  
unind.	   YAP1	  i
nd.	   unind.	   YAP1	  i
nd.	   unind.	   YAP1	  i
nd.	   unind.	   YAP1	  i
nd.	   unind.	   YAP1	  i
nd.	   unind.	   YAP1	  i
nd.	   unind.	   YAP1	  i
nd.	   unind.	   YAP1	  i
nd.	   unind.	   YAP1	  i
nd.	  
Ctrl	   RASSF1A	   RASSF2	   RASSF3	   RASSF4	   RASSF5	   RASSF6	   TP73	   ∆Np73	  
relative
	  expres
sion	  
TP53	   BAX	   CDKN1A	   BBC3	   p16	  
0	  
1	  
2	  
3	  
4	  
5	  
6	  
Ctrl	   YAP1	   Ctrl	   YAP1	   Ctrl	   YAP1	   Ctrl	   YAP1	   Ctrl	   YAP1	   Ctrl	   YAP1	   Ctrl	   YAP1	   Ctrl	   YAP1	   Ctrl	   YAP1	  Ctrl	   RASSF1A	   RASSF2	   RASSF3	   RASSF4	   RASSF5	   RASSF6	   TP73	   ∆Np73	  	  
relative
	  expres
sion	  
TP53	   BAX	   CDKN1A	   BBC3	   p16	  
	   	   Results	  
92	  	  
3.2.4 Effects of RASSFs on MDM2 level 
 
RASSF1A, RASSF2 and RASSF5 are the best characterised C-terminal RASSF members. 
In our study, RASSF1A, RASSF2, RASSF3 and RASSF5 showed tumor-specific 
methylation (Fig. 22) and activated the expression of ANKRD1 (Fig. 24). RASSF1A and 
RASSF5 arrested the cells in the G0-G1 phase, whereas RASSF2 is the only C-terminal 
RASSF members that arrested the cells in the G2-M phase (Fig. 23). Kudo et al. (2012) and 
Iwasa et al. (2013) reported the inhibitory effect of RASSF3 and RASSF6 on MDM2 level 
independent of the Hippo pathway; therefore, the effect of RASSF2 and RASSF5 on 
MDM2 was further investigated. The protein levels of MDM2 after 72h expression of 
RASSF1A, RASSF2 and RASSF5 were further analysed by western blotting using the 
YAP1-inducible TREx293 cells with and without YAP1 induction (Fig.  26). 
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Figure 26: Destabilisation of MDM2 by the C-terminal RASSFs. A) Representative western blot of 72h 
overexpression of Flag-empty, Flag-RASSF1A, Flag-RASSF2 and Flag-RASSF5A in TREx293 cells with 
and without induction of YAP1. B) Quantification of protein levels of MDM2 from three biological 
replicates. The protein levels were quantified by ImageJ and normalized to GAPDH and to the control lysates 
(unind.). p-values: * p<0.05, ** p<0.01 and *** p<0.001 (t-test). 
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Figure 26A indicates a representative western blot of the YAP1-inducible TREx293 cells 
transfected with RASSF1A, RASSF2 and RASSF5 with and without YAP1 induction. The 
control blot for the overexpression is shown in appendix 11. The respective quantification 
of three biological replicates is plotted in figure 26B. Here we observed, that the expression 
of RASSF1A and RASSF2 alone significantly reduced the level of MDM2 by up to 37% 
(p-value 0.005) and up to 53% (p-value<0.001), respectively, in comparison to the control 
cells without the RASSFs and YAP1. In combination with YAP1, only RASSF1A resulted 
in a significant decrease of MDM2 (reduction of 25%; p-value 0.05) in comparison to the 
uninduced cells transfected with RASSF1A (Fig. 26). Compared to the control uninduced 
cells, RASSF1A and YAP1 reduced the protein level of MDM2 by up to 62% (p-
value<0.001) (Fig. 26B). RASSF2 and RASSF5A in combination with the induction of 
YAP1 did not reduce the MDM2 level.  
 
Table 20 summarizes the obtained data of the potential role of the C-terminal RASSFs in 
the regulation of the Hippo pathway. The promoter methylation of C-terminal RASSFs is 
described in this work using DNA from liver tumors compared to DNA from matched 
normal tissues. In comparison to YAP1 and to the control cells, the expression of the C-
terminal RASSFs resulted in cell cycle arrest in the G0-G1 phase or G2-M phase. The 
expression the YAP1 target genes and of p16 is regulated by the C-terminal RASSFs. From 
the literature, and from this work, it is known that C-terminal RASSFs diminish the protein 
level of MDM2. RASSF1A in association with YAP1 also reduced the MDM2 level.  
 
Table 20. Summary of the potential function of C-terminal RASSFs  
 
Factor 
Tumor-
specific 
promoter 
methylation 
 
cell cycle 
accumulation 
 
transcriptional co-regulation 
together with YAP1 
decrease of 
MDM2 level 
ANKRD1 TP53 P16 BAX alone 
with 
YAP1 
YAP1 um S + - + - - - 
RASSF1A m G0-G1 + + + + + + 
RASSF2 m G2-M + + + + + - 
RASSF3 m G0-G1 + + + + + NA 
RASSF4 um G0-G1 + + + + NA NA 
RASSF5A m G0-G1 + + + + +	   - 
RASSF6 um G0-G1 + + + + +	   NA 
   Not analysed (NA). Unmethylated (um). Methylated (m).  No regulation (-).  Significant regulation (+).
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4. DISCUSSION  
 
4.1 The Hippo pathway and cancer 
 
The precise balance between cell growth and death is essential for the maintenance of 
tissues, and the deregulation of this homeostasis results in cancer. Cancer cells inactivate 
the function of tumor suppressor genes by several mechanisms, e.g. by deletion of genomic 
loci, mutations or gene silencing via promoter methylation (Feinberg et al., 2016; Risch 
and Plass, 2008). In contrast, oncogenes like MDM2 or MYC are activated in the genome 
e.g. by amplification (Hanahan and Weinberg, 2011) 
 
The Hippo pathway is a kinase cascade that plays a crucial role in organ size regulation, 
carcinogenesis and apoptosis (Edgar, 2006; Harvey et al., 2013). The cellular localization 
of the Hippo components can be divided into two groups, a junctional localization group 
and a cytoskeleton interaction group (Yu and Guan, 2013). RASSF1A is an important 
regulator of the Hippo kinases MST1/2 and the large tumor suppressor kinases LATS1/2 
(Dittfeld et al., 2012; O'Neill et al., 2004; Praskova et al., 2004). RASSF1A disrupts the 
Raf1-MST2 complex and interacts with MST2 via the SARAH domain hereby activating 
the kinase cascade (Hwang et al., 2007; Matallanas et al., 2007). In turn, MST1/2 
phosphorylate LATS1/2. The active LATS1/2 phosphorylate YAP1, but the function of the 
phosphorylation is still discussed controversially in the literature. Various authors have 
reported that the phosphorylation is necessary for the cytoplasmic retention and subsequent 
degradation of YAP1 (Basu et al., 2003), but other authors have suggested that 
phosphorylated YAP1 translocates into the nucleus and acts as a co-activator (Matallanas et 
al., 2007; Strano et al., 2001; Wang et al., 2016). 
 
The downstream transcriptional activator of the Hippo pathway is YAP1, which is mostly 
described as an oncogenic factor (Kang et al., 2011; Mizuno et al., 2012; Steinhardt et al., 
2008). YAP1 is highly expressed in cancer cells and involved in tumorigenesis, cell 
proliferation and metastasis interacting as co-factor with TEADs, SMADs and ß-catenin 
(Kim et al., 2015; Silvis et al., 2011). However, YAP1 can also interact with the tumor 
suppressor TP73 and regulates the transcription of pro-apoptotic genes (Levy et al., 2008b; 
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Strano et al., 2001). These reports suggest that YAP1 acts as an oncogenic factor and as a 
co-regulator of the tumor suppressor activity of the Hippo pathway as well.  
 
Matallanas et al. (2007) have shown that RASSF1A induces apoptosis through the Hippo 
pathway and YAP1 by activating the transcription of the pro-apoptotic gene BBC3 and the 
stabilisation of the tumor suppressor protein TP73 (Matallanas et al., 2007). In A549 lung 
cancer cells, our group has observed the upregulation of CDKN1A and BAX after 
overexpression of RASSF1A confirming the apoptotic functions of RASSF1A (Richter et 
al., 2010). However, several reports have shown that RASSF1A is one of the most 
frequently epigenetically inactivated genes in different types of human cancer and acts as a 
prominent tumor suppressor (Dammann et al., 2000; Richter et al., 2009; Schagdarsurengin 
et al., 2003).  As indicated in Jiménez et al. (2017), the promoter methylation status of the 
Hippo core components (RASSF1A, MST1, MST2, WW45, LATS1, LATS2 and YAP1) was 
analysed using liver tumor samples compared to the matched normal tissues (see appendix 
3). Only RASSF1A showed a tumor-specific methylation in primary liver cancer (Jiménez 
et al. 2017). The inactivation of the key regulator RASSF1A produces an imbalance in the 
pathway, which may alter the pro-apoptotic effect of the Hippo pathway switching into the 
oncogenic function (Yu and Guan, 2013). 
 
From the literature we know that the cellular function of YAP1 depends on its 
phosphorylation status (Basu et al., 2003; Zhao et al., 2010b) and on the binding of YAP1 
to transcription factors (Strano et al., 2001; Sudol et al., 2012), but the mechanism 
underlying the regulation of the YAP1 activity is still unclear. Furthermore, the Hippo 
cascade is activated by RASSF1A; however, RASSF1A is frequently silenced in cancer 
cells (Dammann et al., 2000). For this reason, the aim of this study was to analyse the 
effect of RASSF1A on the regulation of YAP1 and on the expression of the YAP1 target 
genes. 
 
4.2 The oncogenic function of YAP1 
 
The amplification of YAP1 is commonly observed in tumors e.g. in oral squamous 
carcinoma, medulloblastoma and in glioblastoma (Fernandez et al., 2009; Modena et al., 
2006; Orr et al., 2011). The increased level of YAP1 drives oncogenesis in human HCC 
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and ovarian cancer (Moran-Jones et al., 2015; Xu et al., 2013). In murine HCC, the Yap 
gene locus is mutated and amplified; Yap1 cooperates with Myc favoring tumor 
transformation (Zender et al., 2006). To understand the role of the amplification of YAP1 in 
cancer cells, a YAP1-inducible system was created using the TREx293 cells and it was 
further characterised as individual clones and as a pool of clones. Compared to the control 
cell line (Fig. 6A) and to the uninduced cells, the mRNA and protein levels of YAP1 vary 
between the individual clones (Fig. 7, Fig. 8); nevertheless, there is a significant correlation 
between the expression of YAP1 and the expression of BAX, BBC3, CTGF and ANKRD1 
(Fig. 7D). To avoid this clonal variability and to obtain a homogeneous expression of 
YAP1, a pool of clones was used for the further analysis.  
 
The induction of YAP1 with Dox (Doxycycline) in the pool of clones was very sensitive 
(Fig. 6B) and resulted in a 12-fold expression increase compared to the uninduced cells 
(Fig. 9A). The induction of YAP1 occurred even with a low concentration of Dox and 
resulted in the upregulation of the YAP1 target genes ankyrin repeat domain 1 (ANKRD1) 
(Fig. 6B, Fig. 7B) and connective tissue growth factor (CTGF) (Fig. 7B). YAP1 together 
with TEAD regulate the expression of Cyr61, CTGF and AREG (Li et al., 2013; Zhou et 
al., 2016). CTGF is a growth factor, which is associated with the oncogenic properties of 
YAP1 e.g. in non-small cell lung cancer (Hsu et al., 2016; Zhao et al., 2008). In ovarian 
cancer, YAP1 and CTGF are overexpressed and associated with poor prognosis and 
metastasis (Moran-Jones et al., 2015). The function of ANKRD1 will be explained below in 
more detail in a RASSF1A and TP53 context. 
 
In this study, YAP1 also displays its oncogenic potential by transcriptional repression of 
following tumor suppressor genes: RASSF1A, TP53, BAX, BBC3 and CDKN1A (Fig. 9B). 
The transcriptional downregulation of these tumor suppressor genes by YAP1 was 
observed in the microarrays (Table 19) and further validated by qRT-PCR (Fig. 14) and by 
promoter assays (Fig. 11B). In normal cells, TP53 is the major regulator of the cell cycle, 
senescence and apoptosis (Levine, 1997). Since CDKN1A, BBC3 and BAX are target genes 
of both TP73 and TP53 (Levine, 1997), their downregulation by YAP1 resulted in a shift in 
the cell cycle distribution of the cells into the S-phase (Fig. 10B). These results together 
with the correlation data from the YAP1 individual clones (Fig. 7D) suggest a modulation 
of the expression of RASSF1A and TP53 target genes by YAP1 and by the Hippo pathway 
(see Fig. 27).   
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CDKN1A is an important regulator of the cell cycle progression in G1/S and G2/M 
transition by inhibiting CDKs and the phosphorylation of RB (Harper et al., 1993; Xiong et 
al., 1993). The down-regulation of CDKN1A by YAP1 observed in this study correlates 
with the findings in the literature. Hsueh et al. (2015) demonstrated the proliferative effect 
of YAP1 in human corneal endothelial cells through reduction of CDKN1A levels and the 
transition of the cells into the G1/S phase (Hsueh et al., 2015). Also, Muramatsu et al. 
(2011) suggested YAP1 as putative oncogene in esophageal squamous cell carcinoma 
(Muramatsu et al., 2011). This group indicated that the knockdown for YAP1 by siRNA 
reactivates the expression of CDKN1A and inhibits the expression of survivin in KYSE170 
cells (Muramatsu et al., 2011). BAX, in association with voltage-dependent anion channels, 
induces the mitochondrial dependent apoptosis by formation of pores in the mitochondrial 
outer membrane, which allows the release of cytochrome c (Shimizu et al., 1999). The 
transcriptional repression of BAX and BBC3 by YAP1 observed in this work has not been 
reported in the literature. The transcriptional regulation of BAX by YAP1 was previously 
reported by Basu et al. (2003) and by Zagurovskaya et al. (2009), but only as co-factor 
together with TP73 or ERG1, respectively (Basu et al., 2003; Zagurovskaya et al., 2009). 
The regulation of BBC3 by YAP1 is linked to RASSF1A and TP73 (Matallanas et al., 
2007).  
 
Figure 27: Hippo pathway in cancer cells after silencing of RASSF1A.  YAP1 displays its oncogenic 
potential by repressing tumor suppressor genes and the activation of growth factors such as CTGF. 
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To date there is a big discrepancy about the connection of YAP1 with TP53. YAP1 can 
interact with the TP53 family members TP73 and TP63, but not with TP53 (Levy et al., 
2008a; Strano et al., 2001; Tomlinson et al., 2010). Recently, YAP1 was identified as a 
novel potential TP53 target gene by genome-wide analysis of TP53 response elements 
(Tebaldi et al., 2015). Bai et al. (2013) demonstrated that the YAP1/TEAD complex 
activates the expression of TP53 during chemotherapy in HCC; furthermore by ChIP 
assays, they detected that YAP1 could directly bind to the TP53 promoter suggesting a 
TP53-YAP1 feedback (Bai et al., 2013). However, in this work YAP1 induction represses 
the expression of TP53, which might also explain the repression of BAX, BBC3 and 
CDKN1A. Other reports also showed an association between amplification of YAP1 and 
TP53 deficiency e.g. in mice models of mammary carcinoma (Cheng et al., 2010). 
Sugawara et al. (2011) demonstrated a correlation of the TP53 missense mutation 
(TP53R273H) with the amplification of YAP1 in tumors from patients with Li-Fraumeni 
syndrome (Sugawara et al., 2011). Moreover, YAP1 can inhibit cellular senescence in a 
RB-TP53-p16 dependent manner by the regulation of CDK6 expression (Xie et al., 2013).  
 
RASSF1A is frequently silenced in cancer cells by promoter hypermethylation; however, 
there are few reports about the transcriptional regulation of RASSF1A. HDAC6 and MYC 
together with PRC2 and DNMT3B are involved in the epigenetic inactivation of RASSF1A 
(Charlet et al., 2014; Tao et al., 2016). Furthermore, Beckedorff et al. (2013) described a 
novel mechanism of inactivation by an antisense noncoding RNA (ANRASSF1) that also 
recruits PRC2 to the RASSF1A promoter region (Beckedorff et al., 2013). To date it is 
known that the transcription factors Sp1 and Sp3 bind to the GC-boxes and activate the 
RASSF1A promoter (Strunnikova et al., 2005). In the literature, there is no data that 
indicates a regulation of RASSF1A expression by TP73 or YAP1. In this study, we 
observed a possible novel mechanism of regulation in which TP73 activates the promoter 
activity of RASSF1A, while YAP1 represses it and abrogates the effect of TP73 (Fig. 11C). 
In addition, Tian et al. (2011) demonstrated that TP53 could regulate the expression of 
RASSF1A by direct binding to the promoter and create a negative autoregulatory feedback 
loop between RASSF1A and TP53 (Tian et al., 2011). However, the data obtained in this 
study suggest a positive feedback between RASSF1A with TP53 via YAP1, since the 
inactivation of RASSF1A results in transcriptional repression of TP53 and its target genes 
by YAP1 (Fig. 9B, Fig. 11B, see Fig. 27).  
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In summary, the induction of YAP1 results in the upregulation of the oncogenic CTGF and 
the repression of the expression of TP53, BAX, CDKN1A, BBC3 and RASSF1A. These 
results corroborate the data from the literature, which suggest YAP1 as an oncogenic factor. 
In addition, the literature and the results from this work suggest a regulatory loop between 
YAP1 and TP53 (Bai et al., 2013; Tebaldi et al., 2015) as well as between RASSF1A and 
TP53 (Tian et al., 2011). 
 
4.3 RASSF1A regulates the expression of the YAP1 target genes and counteracts the 
oncogenic function of YAP1 
 
RASSF1A is epigenetically silenced in cancer cells (Dammann et al., 2000). The tumor 
suppressive function of the Hippo pathway has been described in association with 
RASSF1A and TP73 (Levy et al., 2008a; Matallanas et al., 2007; Strano et al., 2001). 
RASSF1A is methylated in the YAP1-inducible TREx293 cells (appendix 4); therefore, to 
analyse both the effect of RASSF1A on the expression of the YAP1 target genes, as well as 
to identify novel potential target genes of the Hippo pathway, RASSF1A was 
overexpressed in HEK293T cells and in the YAP1-inducible TREx293 cells for further 
investigation.  
  
The obtained results from the microarrays and the further validation (Table 19, Fig. 14) 
demonstrated that RASSF1A promotes its tumor suppressive function through the 
activation of pro-apoptotic and anti-proliferative YAP1 target genes such as ANKRD1, BAX 
and CDKN1A (Table 19, Fig. 11B, Fig. 14). In addition, RASSF1A counteracts the 
oncogenic properties of YAP1 by neutralizing the YAP1-induced downregulation of BAX 
and CDKN1A (Table 19, Fig. 11B, Fig. 14, see Fig. 28). These data and the flow cytometry 
data suggest that RASSF1A and YAP1 regulate the cell cycle by the transcriptional 
regulation of CDKN1A and BAX, which results in accumulation or cell arrest either in the 
S-phase after induction of YAP1 or in the G0/G1 phase by co-expression of RASSF1A 
with YAP1 (Fig. 10B). RASSF1A regulates the cell cycle by several mechanisms, for 
example the G1/S transition by transcriptional repression of cyclin A2 and the inhibition of 
cyclin D1 (Ahmed-Choudhury et al., 2005; Shivakumar et al., 2002). RASSF1A interacts 
with and stabilises the microtubules, and its depletion affects the mitotic checkpoint 
(G2/M) and chromatid segregation (Dallol et al., 2004; Rong et al., 2004). Moreover, 
Discussion	  
100	  	  
Aurora A, together with RASSF1A, modulates the CDC20/anaphase-promoting complex 
and the anaphase phase progression (Song et al., 2009b). Aurora A and Aurora B kinases 
phosphorylate RASSF1A and induce mitotic arrest by modulating the ability of RASSF1A 
to bind to the microtubules (Rong et al., 2007; Song et al., 2009a). 
 
Interestingly, the microarrays revealed that the co-expression of RASSF1A and YAP1 
repressed the mRNA expression of MDM2 (Table 19). This finding could not be validated 
either by qRT-PCR or by promoter assays (Fig. 11). However, the western blots indicated 
that the co-expression of RASSF1A and YAP1 significantly reduces the protein level of 
MDM2, which produces an increase of TP53 and BAX level (Fig. 13A, Fig. 19A, see Fig. 
28). MDM2 is a TP53 target gene, which encodes for an E3 ubiquitin ligase (Momand et 
al., 1992). TP53 is negatively regulated by MDM2 via ubiquitination of the transactivation 
domain, which leads to the subsequent proteasomal degradation (Kussie et al., 1996; 
Momand et al., 1992; Oliner et al., 1993). Song et al. (2008) had reported that RASSF1A 
negatively regulates MDM2 by disrupting the MDM2-DAXX-HAUSP complex by 
inducing the self-ubiquitination of MDM2 (Song et al., 2008). Other reports have indicated 
the inhibitory effects of RASSF3 and RASSF6 on MDM2 independent of Hippo signalling 
(Iwasa et al., 2013; Kudo et al., 2012). Furthermore, it has also been reported that the 
LATS2 kinase binds MDM2 and thereby inhibits its E3 ligase function and activates TP53 
(Aylon et al., 2006).  
 
Figure 28: Effect of RASSF1A on the Hippo pathway. RASSF1A activates the expression of the YAP1 
target genes such as BAX, ANKRD1, CDKN1A and AJUBA. YAP1 and RASSF1A reduce the MDM2 level.   
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From the microarray data, it is also interesting to note that the co-expression RASSF1A and 
YAP1 repressed the expression of other growth-associated genes including transcription 
factors (FOS and FOXD3), mitogen-activated protein kinases (MAP2K6 and MAP3K8) and 
growth factors (FGF21, GH1 and GDF15) (Table 19, see Fig. 28, appendix 5 and 6). Of 
these genes, only FOS has been described in association with the oncogenic YAP1. Recent 
data have shown that YAP1 and FOS compensate the loss of K-Ras signalling by activating 
the epithelial-mesenchymal transition (Shao et al., 2014). Zanconato et al. (2015) also 
demonstrated that YAP1 and TEAD could form a complex with the AP-1 proto-
oncoproteins JUN and FOS, to regulate the expression of CTGF, AJUBA and ANKRD1 in 
breast cancer cells (Zanconato et al., 2015). There is no data in the literature on the 
transcriptional repression of FOS, FOXD3, MAP2K6, MAP3K8, FGF21, GH1 and GDF15 
by RASSF1A and YAP1; hence they could represent novel potential target genes of the 
Hippo pathway.  
 
Additionally, it was observed that RASSF1A induced the expression of the YAP1 target 
genes such as ANKRD1, CYR61, AJUBA (Fig. 5, Fig. 14, see Fig. 28) and the expression of 
other novel target genes like HIF1A-antisense 2, ACTBL2, CPA4 and COL12A1 (see Table 
19 and appendix 5). The gene regulation of the remaining novel target genes by YAP1 and 
RASSF1A needs to be further validated, since this work is focused on the regulation and 
function of ANKRD1. The precise tumor-related function of some YAP1 targets is still 
under investigation and may depend on expression level, cell origin or the genetic and 
epigenetic background. For example, in this study the expression of AJUBA is activated by 
YAP1 and RASSF1A, but the function of the gene in this context needs to be investigated 
(Fig. 14). Some authors have proposed AJUBA as a potential tumor suppressor gene 
(Foxler et al., 2012; Tanaka et al., 2015). In 2012, Foxler et al. demonstrated that AJUBA, 
in complex with PHD and VHL, regulates HIF-1α degradation and thus its oncogenic 
activity (Foxler et al., 2012). Further, AJUBA has been shown to suppress the proliferation 
of malignant mesothelioma, and its expression is reduced in lung cancer by promoter 
hypermethylation and genomic instability (Sharp et al., 2008; Tanaka et al., 2015). 
However, AJUBA has also been described as a negative regulator of the Hippo signalling 
and as the link for the regulation of YAP1 by other cellular pathways, since AJUBA can 
interact with LATS1/2 and inhibit the phosphorylation of YAP1S127 (Das Thakur et al., 
2010). The JNK signalling promotes the activity of YAP1 by regulating the 
phosphorylation of AJUBA and the binding to LATS1/2 or SAV1, respectively (Reddy and 
Discussion	  
102	  	  
Irvine, 2013; Sun and Irvine, 2013). Similar to RASSF1A, AJUBA is located at the 
microtubules and can interact with Aurora A and Aurora B (Ferrand et al., 2009). The 
interactions of AJUBA with Aurora and with LATS proteins are essential for the mitotic 
spindle formation and the centrosomal localization of Aurora-A and γ-tubulin (Abe et al., 
2006; Ferrand et al., 2009; Hirota et al., 2003). To understand the regulatory function of 
RASSF1A on YAP1, it may be important to analyse the expression changes of ANKRD1, 
AJUBA and HIF-1AS by different stimuli such as UV stress, hypoxia or serum starvation. 
Since RASSF1A controls the cell cycle by microtubule stabilisation, it would be interesting 
to also analyse the effect of nocodazole on the expression of ANKRD1 or AJUBA and on 
the cell cycle in the YAP1-inducible system.   
 
In summary, in this work it was observed that RASSF1A activates the expression of YAP1 
target genes (ANKRD1, BAX and CDKN1A). Moreover, RASSF1A and YAP1 cause a 
decrease of the MDM2 level, which in turn results in an increase in TP53 and BAX (Fig. 
28). These data suggest a mechanism of RASSF1A together with YAP1 in regulating TP53 
and the G1/S transition of the cell cycle. The microarray data suggest that RASSF1A 
restrains the cell proliferation and cancer stemness by direct transcriptional repression of 
growth factors (MDM2, CTGF, FOS and GH1) and of factors involved in stem cell 
maintenance (FOXD3 and FGF21). RASSF1A induced the expression of the YAP1 target 
genes CYR61, ANKRD1 and AJUBA, which are regulated by the binding of YAP1 to TEAD 
(Li et al., 2013; Zanconato et al., 2015; Zhou et al., 2016). These data suggest that 
RASSF1A regulates the binding of YAP1 to TP73 (Matallanas et al., 2007) and the binding 
of YAP1 to the TEAD transcription factors; thus it will be interesting to further dissect the 
exact mechanism in more detail.  
 
4.3 RASSF1A triggers the nuclear localization of YAP1  
 
The post-transcriptional modifications of YAP1 are under investigation and their function 
is not fully understood. In part, the phosphorylation of YAP1 is responsible for its protein 
stability, cellular localization and enhances the interactions with binding partners (Basu et 
al., 2003; Oka et al., 2010; Sudol et al., 1995). YAP1 has over 20 different sites that could 
be phosphorylated by several kinases such as: LATS1/2, MAPK9, MAPK8, CK1 and 
ABL1 (Levy et al., 2008a; Tomlinson et al., 2010; Zhao et al., 2010b; Zhao et al., 2007). 
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The nuclear translocation of YAP1 and its regulation is controversial in the literature. It has 
been demonstrated that the phosphorylation of YAP1S127 is involved in both the nuclear 
translocation and as well as in the binding of YAP1 to 14-3-3 for cytoplasmatic retention 
and degradation (Matallanas et al., 2007; Zhao et al., 2007). LATS1/2 can phosphorylate 
YAP1 on five HXRXXS consensus motifs (S61, S109, S127, S164 and S381) (Zhao et al., 
2010a; Zhao et al., 2007). The deletion of all five LATS1/2 phosphorylation sites promoted 
the oncogenic potential of YAP1, but after restoration of S127 and S381 the transformation 
potential of YAP1 was suppressed (Zhao et al., 2010a). Moreover, YAP1 is phosphorylated 
by c-Abl on Y357 in response to DNA damage thereby increasing the affinity of YAP1 to 
TP73 (Keshet et al., 2015; Levy et al., 2008a).  
 
In this study, RASSF1A triggered the protein stabilisation (Fig. 10A, Fig. 19A and 19C) 
and the nuclear translocation of YAP1 (Fig. 12A-B). The translocation of YAP1 induced 
nucleus deformation and apoptosis (Fig. 12C). These data corroborated the hypothesis that 
RASSF1A regulates the translocation of YAP1 into the nucleus, which is necessary for 
inducing transcription of YAP1 target genes and cell death (Fig. 12) (Matallanas et al., 
2007; Wang et al., 2016). In this work YAP1S127A/E mutants were also created. Both YAP1 
mutants showed a nuclear and cytoplasmic localization and an increase in the nuclear 
localization after expression of RASSF1A (Fig. 12B). The results did not reveal a possible 
regulatory mechanism for how RASSF1A induces the nuclear translocation of YAP1. In 
contrast, they suggested that the regulation of YAP1 depends on several factors and not 
only on one phosphorylation site (YAP1S127). Further experiments should focus on the 
mutation of the five LATS phosphorylation sites and the location of these mutants after 
RASSF1, LATSs and MSTs expression or in response to cellular stress.  
 
4.4 ANKRD1 is a potential tumor suppressor gene 
 
ANKRD1 has been described as a cardiac protein, which is involved in heart development 
and failure (Ishiguro et al., 2002; Torrado et al., 2005). However, in this study it was 
demonstrated that ANKRD1 is also expressed in liver and lung tissue but is silenced in 
breast tissue (Almodovar-Garcia et al., 2014). The function of ANKRD1 in cardiac cells 
varies according to its localization; in the cytosol, in complex with titin, ANKRD1 plays a 
role in sarcomere stability, whereas in the nucleus it can act as transcriptional co-regulator 
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with YB1 and nucleolin e.g. by repression of MMP13 expression (Almodovar-Garcia et al., 
2014; Mikhailov and Torrado, 2008). Recent reports indicated the potential role of 
ANKRD1 in cancer, for example by interaction with TP53 and its involvement in the 
Hippo, Wnt and TGF-β pathways (Kojic et al., 2010; Labbe et al., 2007).  
 
An important observation in this study was the significant co-regulation of ANKRD1 
expression by YAP1 and RASSF1A via activation of the Hippo pathway (Fig. 5, Fig. 14, 
Fig. 15). The transcriptional activation of ANKRD1 by YAP1 and RASSF1A was measured 
by qRT-PCR in HEK293T cells (Fig. 5C) and in the YAP1-inducible TREx293 cells (see 
Fig. 14); it was also detected by microarrays (Table 19) and validated e.g. by promoter 
assays (Fig. 15B). In this work, the expression changes were observed after 72h expression 
of RASSF1A and induction of YAP1. It will be interesting to elucidate if cell density or 
hypoxic condition also play a role in this regulation. To date, there is no data in the 
literature that support the hypothesis of regulation of ANKRD1 by RASSF1A. The YAP1-
dependent regulation of ANKRD1 has been described previously in association with 
proliferation or apoptosis depending on the cellular context, e.g. as oncogene in the arsenic-
induced carcinogenesis in skin (Li et al., 2013), in glioblastoma by amplification of the 
YAP1 locus (Stein et al., 2015) and in ovarian cancer (Scurr et al., 2008). In contrast, 
ANKRD1 is described as a potential tumor supressor gene in HCC (Park et al., 2005), in 
cardiomyocytes (Shen et al., 2015) and in rhabdomyosarcomas (Ishiguro et al., 2002). 
However, it is still unclear if the anti-proliferative function of ANKRD1 is due to a dosage 
dependent effect or only functional in association with the regulation by RASSF1A and 
YAP1. Additionally, this work confirmed that the regulation of the expression of ANKRD1 
occurs via the Hippo pathway, since the truncation of the SARAH domain of RASSF1A 
abolished the induction of ANKRD1 expression compared to the effect of RASSF1A wild 
type (Fig. 15). As previously described, YAP1 and TEAD are responsible for the 
transcription of ANKRD1 (Li et al., 2013; Stein et al., 2015; Zanconato et al., 2015). 
However, according to the results presented in this study, TP73 and ∆Np73 also induced 
the expression of ANKRD1 (Fig. 24). There is no evidence in the literature for an 
interaction of YAP1 with ∆Np73 and therefore it needs to be investigated in further detail.  
 
The promoter region of ANKRD1 contains only few CpGs sites and therefore they are not 
defined as a CpG island. Breitling et al. (2011) demonstrated the effect of methylation of a 
single CpG site on the gene expression (Breitling et al., 2011). An important finding in this 
Discussion	  
105	  	  
work was the epigenetic inactivation of ANKRD1 by methylation of a CpG site 
(cg01262952) at the promoter region (Fig. 16C, appendix 1). The silencing of ANKRD1 
was observed in several cancer cells including lung (A427) and prostate cancer cells 
(LNCaP) (Fig. 16B). The obtained methylation data correlated with the expression analysis 
(Fig. 16B-C). Additionally a re-expression of ANKRD1 was observed after 4d Aza 
treatment of the cells, which confirmed the epigenetic regulation of ANKRD1 expression 
(Fig. 16D). The ectopic expression of ANKRD1 results in a significant reduction of the 
colony formation and cell proliferation in lung and prostate cancer cells by inducing e.g. 
the expression of TP53, CDKN1A and BAX (Fig. 17A-C, Fig. 18, see Fig. 29). These results 
are consistent with the observation of Park et al. (2005), which demonstrated the apoptotic 
function of ANKRD1 in human hepatic cancer cells (Hep3B and SK-HEP-1 cells) (Park et 
al., 2005). In contrast, in breast cells (T47D), the expression of ANKRD1 showed a 
proliferative effect (Fig. 17A-C), supporting the hypothesis that ANKRD1 could have a 
tissue-specific oncogenic or tumor suppressive role (Kojic et al., 2010; Lei et al., 2015; 
Shen et al., 2015). Here, it was demonstrated that ANKRD1 is expressed in a cell type-
dependent manner and its function should be analysed in other cell lines and in response to 
cellular and chemical stress.  
 
Figure 29: Model of RASSF1A-YAP1-ANKRD1 regulatory loop. RASSF1A induces cell cycle arrest and 
apoptosis through activation of specific YAP1 target genes (e.g. ANKRD1). RASSF1A and YAP1 as well as 
ANKRD1 increase TP53 and BAX levels by destabilisation or reduction of MDM2 protein level.  
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Interestingly, it has been suggested that ANKRD1 is a co-activator of TP53 (Kojic et al., 
2010). Recently it has been reported that ANKRD1 contributes to apoptosis in 
cardiomyocytes by mitochondrial translocation of BAX and TP53 phosphorylation (Shen et 
al., 2015). In addition, the interaction of ANKRD1 with TP53 and the transcriptional 
activation of CDKN1A and MDM2 by ANKRD1 were demonstrated in vitro and in vivo 
(Kojic et al., 2010). In our study, the interaction of ANKRD1 with TP53 was confirmed 
and it was extended by the detection of the interaction between ANKRD1 and MDM2 (Fig. 
20). Moreover, it was found that ANKRD1 induces the expression of TP53, BAX, MDM2 
and CDKN1A (Fig. 18), which supports the hypothesis and data of Kojic et al. (2010) that 
suggested ANKRD1 as a possible co-activator of TP53 (Kojic et al., 2010). The 
knockdown of ANKRD1 by siRNA also corroborated these findings, since the silencing of 
ANKRD1 resulted in a transcriptional repression of TP53 target genes (Fig. 21). Similar to 
the effect observed by the co-expression of YAP1 and RASSF1A (Fig. 13A, Fig. 19), 
ANKRD1 overexpression reduced the protein level of MDM2, which allows the 
stabilisation of TP53 and an increase of BAX level (see Fig. 29, Fig. 19A-B). In this study, 
it was observed that the transcriptional regulation of MDM2 depends on ANKRD1 and 
TP53; however, the reduction of the protein level of MDM2 by ANKRD1 overexpression 
or by co-expression of RASSF1A and YAP1 needs to be further investigated.  
 
There is no data on a possible kinase activity of ANKRD1, but somehow the level of TP53 
is stabilised after expression of ANKRD1 and after expression of RASSF1A and YAP1. 
This effect on TP53 might occur by direct phosphorylation of TP53 or indirectly e.g. by 
binding competition of ANKRD1 with MDM2 or TP53, which prevents the interaction of 
TP53 with MDM2 and the subsequent ubiquitinylation of TP53 (Fig. 19A-B, Fig. 20). The 
regulation of MDM2 and TP53 by ANKRD1 should be characterised in further detail, for 
example by competition assays or by using ANKRD1 depletion mutants. In the future, it 
also needs to be elucidated which ANKRD1 domain is responsible for the interaction with 
MDM2 and with TP53. The ankyrin repeat domains of ANKRD1 are among the most 
abundant motifs for protein-protein interactions, e.g. the INK4 tumor suppressors and the 
TP53 binding protein 2 contain several ankyrin repeats (Mosavi et al., 2004). Furthermore, 
ANKRD1 has been described as a potential transcription factor and as co-activator of TP53 
(Kojic et al., 2010; Liu et al., 2015), but there is no information on putative binding sites or 
novel potential target genes beside TP53, BAX and CDKN1A. It would be interesting to do 
microarrays or RNA-seq and ChIP analysis of ANKRD1 to further investigate its function 
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at the transcriptional level. ANKRD1 silencing by CRISPR-Cas should also be performed to 
confirm the findings of this work. 
 
Figure 29 summarizes the obtained data of this project and suggests a hypothetical model 
of the pro-apoptotic signalling of the Hippo pathway. In this study, RASSF1A, ANKRD1, 
MDM2 are the key players involved in the pro-apoptotic function of the Hippo pathway.  
RASSF1A stabilises YAP1 thereby increasing its translocation into the nucleus; once there, 
YAP1 induces a higher expression of ANKRD1, whereas MDM2 is destabilised, and TP53 
and BAX protein levels increase (Fig. 29). ANKRD1 showed a tumor suppressive function 
by interaction and activation of TP53, which induces BAX, CDKN1A and TP53 expression. 
Furthermore, ANKRD1 can interact and decrease the protein level of MDM2, suggesting 
that ANKRD1 could be responsible for the MDM2 destabilisation and the subsequent TP53 
stabilisation and BAX induction (see Fig. 29). Since RASSF1A and ANKRD1 show an 
aberrant promoter methylation and the resulting gene silencing, the pro-apoptotic signal of 
the Hippo pathway is disturbed and the oncogenic function of YAP1 cannot be 
counteracted. Subsequently, YAP1 represses the expression of the tumor suppressor genes 
and promotes cell proliferation.   
 
4.5 Effect of the other C-terminal RASSFs on the Hippo pathway 
 
Six members of the RAS association domain family (RASSF1 to RASSF6) have a SARAH 
interaction domain, which suggests a role in the regulation of the Hippo pathway. Through 
the SARAH domain, they are capable to interact with the MSTs, WW45 and with each 
other (Schagdarsurengin et al., 2010). In the literature RASSF1A, RASSF2 and RASSF5 
are directly associated with the regulation of both MSTs and the Hippo pathway (Cooper et 
al., 2009; Ni et al., 2013; Praskova et al., 2004; Song et al., 2010). Therefore in this study, 
the function of the other C-terminal RASSFs on the regulation of the YAP1 target genes 
was further characterised and compared to the previous results for RASSF1A.  
 
In contrast to RASSF1A, there are only few data available concerning the cellular function 
of the other RASSF genes. Few reports have demonstrated that they are also inactivated by 
promoter hypermethylation for example in thyroid cancer, Merkel cell carcinoma, and in 
pheochromocytoma (Richter et al., 2013; Richter et al., 2015; Schagdarsurengin et al., 
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2010). Also in this work we observed a tumor-specific methylation of RASSF2, RASSF3 
and RASSF5A isoform in HCC (Fig. 22). To date, there is no data on the methylation status 
of RASSF2, RASSF3 and RASSF6 in liver tumors. However, previous reports demonstrated 
that the RASSF5A and RASSF5B isoforms are inactivated by promoter methylation and 
their expression is reduced in HCC, which corroborated with our findings on RASSF5A 
(Liu et al., 2014; Macheiner et al., 2006).  
 
The data displayed in this study demonstrated that all C-terminal RASSFs induce the 
expression of the YAP1 target genes: ANKRD1, TP53 and BAX (Fig. 24, Fig. 25). 
Moreover, it was observed that YAP1 together with the C-terminal RASSFs, with 
exception of RASSF1A, induced the expression of p16 (Fig. 25), which resulted in cell 
cycle arrest in the G0-G1 phase (Fig. 23). p16 is the inhibitor of CDK4/CDK6 in 
association with the RB-E2F pathway inducing cellular senescence and cell cycle arrest in 
the G0-G1 phase (Ragione et al., 1996). There are two possible explanations for these 
observations; the first one is that YAP1 and the RASSFs could directly regulate the 
expression of p16, but there is no data in the literature supporting this hypothesis. The other 
explanation could be that the increase of p16 expression is a response to a pro-proliferative 
factor or a response to a highly expressed interaction partner like CDK6, which is 
interestingly also a YAP1 target gene (Xie et al., 2013). In the future, both hypotheses 
should be further analysed in further detail. It would also be important to analyse the 
expression of the other INK4 tumor suppressors after expression of YAP1 and the C-
terminal RASSFs, since p14 and p15 are located in the same genomic locus as p16. 
Moreover, it may be worthwhile to investigate a possible interaction of YAP1 with the 
transcription factors, which modulate the expression of p16. 
 
As previously indicated, the co-expression of RASSF1A with YAP1 and the 
overexpression of ANKRD1 reduce the MDM2 protein level (Fig. 19A-B). Since the other 
C-terminal RASSFs also induced the expression of ANKRD1 (Fig. 24), the protein level of 
MDM2 was further analysed after expression of RASSF2 and RASSF5 in the YAP1-
inducible cells. RASSF2 and RASSF5 are the best-characterised C-terminal RASSF 
members after RASSF1A. RASSF2 is located in the nucleus and its activation by p300 is 
associated with apoptosis (Liu et al., 2010; Schagdarsurengin et al., 2010). RASSF3 and 
RASSF6 regulate the MDM2 levels independent of the Hippo pathway (Iwasa et al., 2013; 
Kudo et al., 2012). In addition, RASSF5 and RASSF6 interact with MDM2 and regulate 
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TP53 expression (Donninger et al., 2015; Iwasa et al., 2013). In this study, it was observed 
that RASSF1A, RASSF2 and RASSF5 overexpression are capable to decrease the protein 
level of MDM2. At present, there is no data in the literature on RASSF2 regulation or 
interaction with MDM2 or TP53 regulation. The decrease of MDM2 by RASSF5 was 
recently published by Schmidt et al. (2016) in association with β-TrCP (Schmidt et al., 
2016). Only the expression of RASSF1A with YAP1 resulted in a significant decrease of 
MDM2 (Fig. 26), which may suggest that only RASSF1A is able to induce the repression 
of MDM2 via Hippo signalling. Here RASSF2 and RASSF5A did not reduce the MDM2 
level after induction of YAP1, suggesting that they may reduce MDM2 independently of 
the Hippo pathway, similar to RASSF3 and RASSF6.  
 
This study arises new questions involving the role of C-terminal RASSFs in the regulation 
of the Hippo pathway. For example; which are the regulatory upstream events that induce 
the apoptosis signalling through RASSF1A and YAP1. Another major point that needs to 
be investigated is how MDM2 is destabilised by RASSF1A and YAP1 or by ANKRD1. 
Other reports and this work demonstrated that the C-terminal RASSFs regulated the level 
of MDM2 and TP53. Here the mechanism needs to be elucidated, how RASSF1A together 
with YAP1 and RASSF2 modulate the protein level of MDM2.   
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Appendix 1: The promoter region of ANKRD1 (606 bp) was cloned into the pRL-NULL reporter vector for 
the subsequent promoter assays. For the methylation analysis, a region of 139 bp of the ANKRD1 promoter 
was amplified by PCR using bisulfite DNA and further analysed by CoBRA (panel). The blackvertical bars 
represent single CpG sites. The analysed CpG (cg01262952) site is represented with the dotted red line.  
 
APPENDIX 2 
 
 
 
 
 
Appendix 2: Experimental design for expression analysis by microarrays. A. Outline B. Sorted cells in 
green. C. Purity control of sorted cells; green spots: sorted cells with GFP signal.  
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APPENDIX 3 
 
 
 
Appendix 3: Methylation analysis of the promoter region of core components of the Hippo pathway. 
Combined bisulfite restriction analysis of the promoter region of RASSF1A, MST1, MST2, WW45, LATS1, 
LATS2, YAP1 and KIBRA in liver tumors (T) compared to matched normal samples (N). Positive control: in 
vitro methylated DNA (ivm). Mock digest (-); PCR product digested with respective enzyme (+), and further 
analysed by AGE in a 2% TBE gel. Experiment perfomed by Dr. Richter.  
 	  	  
APPENDIX 4 
 
 
 
 
 
Appendix 4: Methylation analysis of the promoter region of RASSF1A in TREx293 cells. Combined 
bisulfite restriction analysis of the promoter region of RASSF1A. A fragment of 205 bp of the promoter region 
of RASSF1A was amplified by seminested PCR using bisulfite converted DNA from TREx293 cells and A549 
cells as positive control. The PCR product was subsequently digested with TaqI (+) or with water (-) and 
further analysed by AGE in a 2% TBE gel.  
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Table 21. List of potential upregulated candidate genes (at least 2.5-fold) obtained after the unbiased analysis 
of the microarrays of the YAP1-inducible TREx293 cells. The genes were sorted in descending order by the 
relative measured expression of the samples with an overexpression of RASSF1A and YAP1 induction. The 
expression level is relative to the control uninduced cells (GFP/unind.).  
 
Gene name GFP/unind. GFP/YAP1 ind. RASSF1A/unind. RASSF1A/YAP1 ind. 
HIF1A-AS2 1.00 7.70 1.16 10.90 
MIR3665 1.00 0.52 1.68 5.39 
ACTBL2 1.00 2.72 1.16 4.85 
COL12A1 1.00 4.60 1.11 4.41 
RNU6-1284P 1.00 2.49 5.85 4.37 
RNU6-135P 1.00 3.09 1.90 4.02 
CTGF 1.00 2.26 1.34 3.97 
MT-TW 1.00 2.90 2.58 3.64 
YAP1 1.00 3.62 1.01 3.58 
RNA5SP253 1.00 7.42 5.05 3.44 
RNA5SP253 1.00 7.42 5.05 3.44 
RNA5SP253 1.00 7.42 5.05 3.44 
ANKRD1 1.00 2.88 1.24 3.40 
HIF1A-AS2 1.00 3.69 0.73 3.26 
CYR61 1.00 2.66 1.43 3.26 
CPA4 1.00 2.74 1.24 3.22 
RNU6-470P 1.00 1.62 1.55 3.09 
RNU6-96P 1.00 1.38 1.90 2.94 
RNU4ATAC16P 1.00 5.14 5.15 2.85 
MIR634 1.00 1.74 1.50 2.83 
MIR4441 1.00 2.37 1.80 2.80 
AJUBA 1.00 2.25 1.20 2.77 
MIR1321 1.00 3.17 2.04 2.76 
MIR329-1 1.00 1.55 1.62 2.74 
RNU6-1318P 1.00 4.05 4.05 2.69 
SNAPC1 1.00 2.02 1.20 2.69 
SPANXC 1.00 1.69 1.55 2.67 
RNA5SP222 1.00 1.05 1.24 2.67 
MIR378H 1.00 2.33 2.05 2.60 
SPATA31D4 1.00 1.56 0.83 2.56 
MYOF 1.00 1.81 1.34 2.55 
MIR4731 1.00 2.91 1.88 2.53 
RASSF1 1.00 0.46 2.30 2.52 
PRAMEF2 1.00 1.82 1.67 2.51 
RNU6-604P 1.00 2.41 1.32 2.50 
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Table 22. List of potential downregulated candidate genes (from 0.5-fold) obtained after the unbiased 
analysis of the microarrays of the YAP1-inducible TREx293 cells. The genes were sorted in descending order 
by the relative measured expression of the samples with an overexpression of RASSF1A and YAP1 
induction. The expression level is relative to the control uninduced cells (GFP/unind.).  
Gene name GFP/unind. GFP/YAP1 ind. RASSF1A/unind. RASSF1A/YAP1 ind. 
AC100802.3 1.00 0.48 0.56 0.50 
AF196970.3 1.00 0.65 0.75 0.50 
LINC00346 1.00 0.63 0.59 0.50 
AC073218.1 1.00 0.65 0.64 0.50 
TRIM48 1.00 0.51 0.78 0.50 
RP11-313D6.3 1.00 0.57 0.41 0.50 
RNA5SP207 1.00 0.85 0.78 0.50 
RP11-475I24.3 1.00 0.75 0.58 0.50 
ZNF280D 1.00 0.62 0.70 0.50 
RNU6-457P 1.00 0.84 0.55 0.50 
RNU6-487P 1.00 0.48 0.37 0.49 
SNORD115-32 1.00 1.09 0.75 0.49 
RNU6-646P 1.00 0.44 0.53 0.49 
SPRR2A 1.00 0.92 0.78 0.49 
HIST1H2BH 1.00 0.52 0.73 0.49 
PYDC2 1.00 0.99 0.64 0.49 
RNU6-271P 1.00 0.51 0.54 0.49 
OR2A14 1.00 0.88 0.61 0.48 
RNA5SP133 1.00 0.61 0.61 0.48 
SNORD23 1.00 0.79 0.77 0.48 
RNU6-971P 1.00 0.63 0.50 0.47 
CCL4 1.00 0.39 0.63 0.47 
RNA5SP230 1.00 0.72 0.54 0.47 
RNU6-218P 1.00 0.48 0.61 0.47 
RPLP0P2 1.00 0.51 0.55 0.47 
GDF15 1.00 0.60 0.72 0.46 
FOXD3 1.00 0.74 0.48 0.46 
MIR376B 1.00 0.69 0.64 0.46 
TREML5P 1.00 1.11 0.56 0.46 
IGHV3-15 1.00 0.67 0.72 0.46 
FGF21 1.00 0.59 0.46 0.45 
RNU6-659P 1.00 0.53 0.47 0.45 
ANAPC1P1 1.00 0.65 0.54 0.45 
RP11-166D18.1 1.00 0.50 0.48 0.45 
TRBJ2-4 1.00 0.83 0.76 0.45 
C6orf47 1.00 0.55 0.82 0.45 
MIR3189 1.00 0.72 0.44 0.45 
ARL14EPL 1.00 0.65 0.53 0.44 
ULBP2 1.00 0.49 0.46 0.44 
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RNA5SP302 1.00 0.42 0.92 0.44 
CLEC4M 1.00 0.34 0.35 0.44 
RPL23AP82 1.00 0.86 0.77 0.44 
MIR1184-1 1.00 0.44 0.54 0.43 
MIR1184-1 1.00 0.44 0.54 0.43 
MIR1184-1 1.00 0.44 0.54 0.43 
VTRNA2-2P 1.00 0.81 0.70 0.43 
LOC101927703 1.00 0.38 0.92 0.43 
RNU2-24P 1.00 1.64 1.28 0.42 
MIR548H3 1.00 1.08 0.72 0.42 
RNU1-92P 1.00 0.57 0.37 0.41 
ALPPL2 1.00 0.57 0.38 0.41 
MIR4710 1.00 0.72 0.76 0.41 
TRIM49 1.00 0.70 0.72 0.41 
GH1 1.00 0.57 0.65 0.41 
RNU2-71P 1.00 0.38 0.50 0.40 
RP11-203M5.8 1.00 0.43 0.49 0.40 
MIR601 1.00 0.51 0.71 0.40 
MAP3K8 1.00 0.40 0.89 0.39 
RNF216P1 1.00 0.49 0.85 0.39 
MIR4503 1.00 0.63 0.34 0.39 
RNA5SP241 1.00 1.05 0.56 0.39 
FAM66A 1.00 0.49 0.38 0.38 
RNU6-1295P 1.00 0.54 0.94 0.37 
MIR1324 1.00 0.99 0.49 0.35 
MIR3163 1.00 1.01 0.47 0.35 
KRT18P39 1.00 0.83 0.33 0.34 
RNY1P8 1.00 0.55 1.07 0.34 
RNU6-361P 1.00 0.96 0.41 0.33 
HIST1H3H 1.00 0.49 0.48 0.32 
RNU6ATAC25P 1.00 0.80 0.45 0.32 
RNU6-612P 1.00 0.81 0.26 0.31 
MIR501 1.00 0.63 0.47 0.15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix	  
115	  	  
APPENDIX 7 
 
 
 
 
Appendix 7: Semiquantitative PCR to control the overexpression of RASSF1A and YAP1 induction in 
the clones used for the validation of the microarrays. The individual YAP1-inducible TREx293 clones 
were tranfected with Flag-empty vector or with Flag-RASSF1A respectively. The PCR products were 
analysed by AGE. After 72h induction of YAP1 (- unind.; + YAP1 induced), the expressions of the 
candidates target genes were further analysed by qRT-PCR. The gene expression of the target genes of clone 
14 was displayed in figure 14. C: Overexpression of control empty vector. R: overexpression of RASSF1A. 
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Appendix 8: Controls corresponding to figure 18. A) Semiquantitative PCR to control the overexpression 
of ANKRD1 in HEK293T cells. The expressions of the target genes were further analysed by qRT-PCR and 
displayed in figure 18A. B) Western blot analysis and qRT-PCR to control the induction ANKRD1 in the 
ANKRD1-inducible TREx293 cells and the protein level of the target genes MDM2, GAPDH and BAX.  
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Appendix 9: Exemplary semiquantitative PCR to control the overexpression of the C-terminal 
RASSFs, TP73, ∆Np73 and the YAP1 induction in the YAP1-inducible TREx293 cells. The individual 
constructs were overexpressed in the YAP1-inducible TREx293 pool of clones. After 72h induction of YAP1 
(- unind.; + YAP1 induced), the expression of the candidates target genes were further analysed by qRT-PCR. 
R1A: overexpression of RASSF1A, R2: overexpression of RASSF2, R3: overexpression of RASSF3, R4: 
overexpression of RASSF4, R5: overexpression of RASSF5, R6: overexpression of RASSF6, TP73: 
overexpression of TP73, ΔNp73: overexpression of ΔNp73). The measured expression of the target genes was 
displayed in figures 24 and 25. 	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APPENDIX 10 
 
Table 23.  p-values corresponding to figure 24 and figure 25. 
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   Flag-­‐empty	   +	   +	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  Flag-­‐RASSF1A	   -­‐	   -­‐	   +	   +	   -­‐	   -­‐	   -­‐	   -­‐	  Flag-­‐RASSF2	   -­‐	   -­‐	   -­‐	   -­‐	   +	   +	   -­‐	   -­‐	  Flag-­‐RASSF5A	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   +	   +	  YAP1	  induction	   -­‐	   +	   -­‐	   +	   -­‐	   +	   -­‐	   +	  	  
	  	  	  	  	  AB:	  FLAG	  	   	  	  
Appendix 11: Control western blot for the overepression of Flag empty, Flag-RASSF1A, Flag-RASSF2 
and Flag-RASSF5. The induction of YAP1 and the protein level of GAPDH and MDM2 are indicated in 
figure 26. The anti-FLAG antibody showed the overexpression of RASSF2 (40 kDa). Since the FLAG and 
the RASSF1A antibodies do not showed the overepression as expected, the overexpressions of RASSF1A, 
RASSF2 and RASSF5 were confimed in the biological replicates by semiquantitative PCR as indicated in 
appendix 9.  	  	  
APPENDIX 12 
 
Additionally in this work, several potential binding partners of YAP1 were detected by 
mass spectrometry. In this appendix, the detected proteins with a mascot score higher than 
62 are listed in Table 24. Interestingly, it was found that YAP1 might interact with Lamin 
B1 and voltage-dependent anion channels. The interaction of YAP1 with Lamin B1 was 
further analysed but could not be validated. The possible interaction of YAP1 with voltage-
dependent anion channels may be associated with the apoptotic function of BAX and need 
to be analysed in more detail. With the exception of Lamin B1 and CENPF, the other 
identified proteins are cytoplasmic and related to cell-cell junctions, intermediate filaments 
or have been previously described with the Hippo pathway. In the future, it should be 
interesting to validate the interaction of those candidate interaction partners with YAP1 and 
the conditions that promote those interactions such as phosphorylation, conformational 
changes or localization. In addition, the mass spectrometry data should be repeated after 
cell fractionation, in order to find out novel YAP1 interaction partners in the nucleus.  
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 Table 24. Mass spectrometry results with the potential binding partners of YAP1 and the 
respective mascot score. 
Name  Mascot Score 
Angiomotin  403.0 
Heat shock 70 kDa protein 1A/1B  354.0 
Vimentin 252.0 
78 kDa glucose-regulated protein  227.0 
YAP1  208.0 
Pyrroline-5-carboxylate reductase 2  128.0 
Voltage-dependent anion-selective channel protein 1  116.0 
14-3-3 protein epsilon  108.0 
Heat shock 70 kDa protein 6  104.0 
Heat shock 70 kDa protein 1-like  100.0 
Heat shock cognate 71 kDa protein 96.6 
Polyadenylate-binding protein 1  96.0 
Voltage-dependent anion-selective channel protein 3  88.2 
60S ribosomal protein L5  88.0 
Voltage-dependent anion-selective channel protein 2 86.0 
A-kinase anchor protein 9  81.6 
WW domain-binding protein 2  81.3 
Actin, cytoplasmic 2 78.8 
Golgin subfamily A member 4  78.6 
40S ribosomal protein S4 78.4 
Golgin subfamily A member 4  74.6 
Heterogeneous nuclear ribonucleoproteins A2/B1  73.2 
Vinculin  69.4 
Tropomyosin beta chain 68.3 
Dystonin  68.0 
Lamin-B1  67.5 
Centromere protein F  67.4 
Plectin 65.8 
Hemoglobin subunit epsilon  64.4 
Uncharacterised protein  64.0 
Regulating synaptic membrane exocytosis protein 1  63.7 
Plectin  63.2 
Glutathione S-transferase Mu 1  62.9 
Prohibitin-2  62.8 
Spectrin alpha chain 62.0 
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